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A B S T R A C T
Background
Successful treatments for gestational diabetes mellitus (GDM) have the potential to improve health outcomes for women with GDM
and their babies.
Objectives
To provide a comprehensive synthesis of evidence from Cochrane systematic reviews of the benefits and harms associated with inter-
ventions for treating GDM on women and their babies.
Methods
We searched the Cochrane Database of Systematic Reviews (5 January 2018) for reviews of treatment/management for women with
GDM. Reviews of pregnant women with pre-existing diabetes were excluded.
Two overview authors independently assessed reviews for inclusion, quality (AMSTAR; ROBIS), quality of evidence (GRADE), and
extracted data.
Main results
We included 14 reviews. Of these, 10 provided relevant high-quality and low-risk of bias data (AMSTAR and ROBIS) from 128
randomised controlled trials (RCTs), 27 comparisons, 17,984 women, 16,305 babies, and 1441 children. Evidence ranged from high-
to very low-quality (GRADE). Only one effective intervention was found for treating women with GDM.
Effective
Lifestyle versus usual care
Lifestyle intervention versus usual care probably reduces large-for-gestational age (risk ratio (RR) 0.60, 95% confidence interval (CI)
0.50 to 0.71; 6 RCTs, N = 2994; GRADE moderate-quality).
Promising
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No evidence for any outcome for any comparison could be classified to this category.
Ineffective or possibly harmful
Lifestyle versus usual care
Lifestyle intervention versus usual care probably increases the risk of induction of labour (IOL) suggesting possible harm (average RR
1.20, 95% CI 0.99 to 1.46; 4 RCTs, N = 2699; GRADE moderate-quality).
Exercise versus control
Exercise intervention versus control for return to pre-pregnancy weight suggested ineffectiveness (body mass index, BMI) MD 0.11
kg/m², 95% CI -1.04 to 1.26; 3 RCTs, N = 254; GRADE moderate-quality).
Insulin versus oral therapy
Insulin intervention versus oral therapy probably increases the risk of IOL suggesting possible harm (RR 1.3, 95% CI 0.96 to 1.75; 3
RCTs, N = 348; GRADE moderate-quality).
Probably ineffective or harmful interventions
Insulin versus oral therapy
For insulin compared to oral therapy there is probably an increased risk of the hypertensive disorders of pregnancy (RR 1.89, 95% CI
1.14 to 3.12; 4 RCTs, N = 1214; GRADE moderate-quality).
Inconclusive
Lifestyle versus usual care
The evidence for childhood adiposity kg/m² (RR 0.91, 95% CI 0.75 to 1.11; 3 RCTs, N = 767; GRADE moderate-quality) and
hypoglycaemia was inconclusive (average RR 0.99, 95% CI 0.65 to 1.52; 6 RCTs, N = 3000; GRADE moderate-quality).
Exercise versus control
The evidence for caesarean section (RR 0.86, 95% CI 0.63 to 1.16; 5 RCTs, N = 316; GRADE moderate quality) and perinatal death
or serious morbidity composite was inconclusive (RR 0.56, 95% CI 0.12 to 2.61; 2 RCTs, N = 169; GRADE moderate-quality).
Insulin versus oral therapy
The evidence for the following outcomes was inconclusive: pre-eclampsia (RR 1.14, 95% CI 0.86 to 1.52; 10 RCTs, N = 2060),
caesarean section (RR 1.03, 95% CI 0.93 to 1.14; 17 RCTs, N = 1988), large-for-gestational age (average RR 1.01, 95% CI 0.76 to
1.35; 13 RCTs, N = 2352), and perinatal death or serious morbidity composite (RR 1.03; 95% CI 0.84 to 1.26; 2 RCTs, N = 760).
GRADE assessment was moderate-quality for these outcomes.
Insulin versus diet
The evidence for perinatal mortality was inconclusive (RR 0.74, 95% CI 0.41 to 1.33; 4 RCTs, N = 1137; GRADE moderate-quality).
Insulin versus insulin
The evidence for insulin aspart versus lispro for risk of caesarean section was inconclusive (RR 1.00, 95% CI 0.91 to 1.09; 3 RCTs, N
= 410; GRADE moderate quality).
No conclusions possible
No conclusions were possible for: lifestyle versus usual care (perineal trauma, postnatal depression, neonatal adiposity, number of ante-
natal visits/admissions); diet versus control (pre-eclampsia, caesarean section); myo-inositol versus placebo (hypoglycaemia); metformin
versus glibenclamide (hypertensive disorders of pregnancy, pregnancy-induced hypertension, death or serious morbidity composite,
insulin versus oral therapy (development of type 2 diabetes); intensive management versus routine care (IOL, large-for-gestational
age); post- versus pre-prandial glucose monitoring (large-for-gestational age). The evidence ranged from moderate-, low- and very low-
quality.
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Authors’ conclusions
Currently there is insufficient high-quality evidence about the effects on health outcomes of relevance for women with GDM and
their babies for many of the comparisons in this overview comparing treatment interventions for women with GDM. Lifestyle changes
(including as a minimum healthy eating, physical activity and self-monitoring of blood sugar levels) was the only intervention that
showed possible health improvements for women and their babies. Lifestyle interventions may result in fewer babies being large.
Conversely, in terms of harms, lifestyle interventions may also increase the number of inductions. Taking insulin was also associated
with an increase in hypertensive disorders, when compared to oral therapy. There was very limited information on long-term health
and health services costs. Further high-quality research is needed.
P L A I N L A N G U A G E S U M M A R Y
Treatments to improve pregnancy outcomes for women who develop diabetes during pregnancy: an overview of Cochrane
systematic reviews
What is the issue?
The aim of this Cochrane overview was to provide a summary of the effects of interventions for women who develop diabetes during
pregnancy (gestational diabetes mellitus, GDM) and the effects on women’s health and the health of their babies. We assessed all
relevant Cochrane Reviews (date of last search: January 2018).
Why is this important?
GDMcan occur inmid-to-late pregnancy. High blood glucose levels (hyperglycaemia) possibly have negative effects on both the woman
and her baby’s health in the short- and long-term.
For women, GDM can mean an increased risk of developing high blood pressure and protein in the urine (pre-eclampsia). Women
with GDM also have a higher chance of developing type 2 diabetes, heart disease, and stroke later in life. Babies born to mothers with
GDM are at increased risk of being large, having low blood glucose (hypoglycaemia) after birth, and yellowing of the skin and eyes
(jaundice). As these babies become children, they are at higher risk of being overweight and developing type 2 diabetes.
Several Cochrane Reviews have assessed different interventions for women with GDM. This overview brings these reviews together.
We looked at diet, exercise, drugs, supplements, lifestyle changes, and ways GDM is managed or responded to by the healthcare team.
What evidence did we find?
We found 14 Cochrane systematic reviews and included 10 reviews covering 128 studies in our analysis, which included a total of
17,984 women, and their babies. The quality of the evidence ranged from very low to high.
We looked at:
• Dietary interventions (including change to low or moderate glycaemic index (GI) diet, calorie restrictions, low carbohydrate diet,
high complex carbohydrate diet, high saturated fat diet, high fibre diet, soy-protein enriched diet, etc.)
We found there were not enough data on any one dietary intervention to be able to say whether it helped or not.
• Exercise programmes (including brisk walking, cycling, resistance circuit-type training, instruction on active lifestyle, home-based
exercise programme, 6-week or 10-week exercise programme, yoga, etc.)
Similarly, there were not enough data on any specific exercise regimen to say if it helped or not.
• Taking insulin or other drugs to control diabetes (including insulin and oral glucose lowering drugs).
Insulin probably increases the risk of high blood pressure and its problems in pregnancy (hypertensive disorders of pregnancy) when
compared to oral therapy (moderate-quality evidence).
• Supplements (myo-inositol given as a water-soluble powder or capsule).
We found there was not enough data to be able to say if myo-inositol was helpful or not.
• Lifestyle changes which combine two or more interventions such as: healthy eating, exercise, education, mindfulness eating (focusing
the mind on eating), yoga, relaxation, etc.
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Lifestyle interventions may be associated with fewer babies being born large (moderate-quality evidence) but may result in an increase
in inductions of labour (moderate-quality evidence).
•Management strategies (including early birth, methods of blood glucose monitoring).
We found little data for strategies which included planned induction of labour or planned birth by caesarean section, and there was no
clear difference in outcomes among these care plans. Similarly, we found no clear difference among outcomes for different methods of
blood glucose monitoring.
What does this mean?
There are limited data on the various interventions. Lifestyle changes (including as a minimum healthy eating, physical activity, and
self-monitoring of blood sugar levels) was the only intervention that showed possible health improvements for women and their babies.
Lifestyle interventions may result in fewer babies being large. Conversely, in terms of harms, lifestyle interventions may also increase the
number of inductions. Taking insulin was also associated with an increase in hypertensive disorders, when compared to oral therapy.
There was very limited information on long-term health and health services costs. Women may wish to discuss lifestyle changes around
their individual needs with their health professional. Further high-quality research is needed.
B A C K G R O U N D
Gestational diabetes mellitus (GDM) is a condition that may oc-
cur in the second half of pregnancy when blood glucose control is
more difficult to achieve, leading to hyperglycaemia (abnormally
high concentration of glucose in the blood) that may affect the
woman and her baby (ADA 2004; Holt 2013). TheWorld Health
Organization (WHO) defines GDM as “Carbohydrate intoler-
ance resulting in hyperglycaemia or any degree of glucose intoler-
ance with onset or first recognition during pregnancy usually from
24 weeks’ gestation onwards” and resolves following the birth of
the baby (WHO 2013). This definition clearly excludes women
who may have undiagnosed pre-existing type 1 or type 2 diabetes
mellitus first detected during screening in pregnancy (Nankervis
2013).
Recognised risk factors for developing GDM include obesity, ad-
vanced maternal age, weight gain in pregnancy, family history of
diabetes and previous history of GDM, macrosomia (large baby),
or unexplained stillbirth (Mokdad 2003; Yogev 2004; Boney 2005;
Rosenberg 2005; Zhang 2010; Teh 2011). Certain ethnicities,
such as Asian, African American, Native American, Hispanic, and
Pacific Island women have an increased risk of GDM (Rosenberg
2005; Schneider 2012).
The prevalence of GDM is increasing globally and has been docu-
mented with significant variation between 2% to 26% depending
on the ethnicity of the population screened and the diagnostic
criteria used (Cheung 2003; Ferrara 2007; Sacks 2012; Nankervis
2013; NZ Ministry of Health 2014; NICE 2015). The reported
global obesity epidemic is likely to increase the incidence of GDM
(Zhang 2010; Schneider 2012), and recurrent GDM diagnosis in
subsequent pregnancies for women who have had previously been
diagnosed with GDM (Bottalico 2007; England 2015; Poomalar
2015). Therefore, GDM is a serious public health issue.
Successful glycaemic treatments for GDM have the potential to
significantly impact on the short- and long-term health for the
woman and her baby. Treatments for GDM aim to keep glucose
levels within the recommended glycaemic reference range to pre-
vent maternal hyper- or hypoglycaemia. Treatments may include
dietary and exercise advice, subcutaneous insulin, oral hypogly-
caemic agents, such as pharmacological medications, dietary sup-
plements or nutraceuticals, antenatal breast milk expression, in-
duction of labour or caesarean section (Horvath 2010; Kavitha
2013; Bas-Lando 2014; Forster 2014; Ryu 2014; Kalra 2015).
Currently there are several Cochrane systematic reviews that assess
different treatment for women with GDM. This makes it difficult
for clinicians, consumers, and guideline developers to easily inter-
pret the available information. A Cochrane overview of systematic
reviews would provide summary evidence of the effectiveness for
each treatment for women with GDM and the effects on relevant
health outcomes as a one-stop resource for health professionals,
consumers and guideline developers to simplify clinical treatment
decision-making, and assist with the process of guideline develop-
ment.
Description of the condition
During pregnancy the continuous supply of appropriate and bal-
anced nutrients from the pregnant woman to her baby is essential
for optimal health and growth. Glucose is the primary source of
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energy for the fetus (Wilcox 2005; Hay 2006). Insulin is a peptide
hormone secreted by the β cells of the pancreatic islets of Langer-
hans and maintains normal glucose concentration by facilitating
cellular glucose uptake, regulating carbohydrate, lipid and pro-
tein metabolism and promoting cell division and growth (Wilcox
2005). Either inadequate insulin secretion (such as in type 1 dia-
betes) or insulin resistance (such as in type 2 diabetes or GDM)
(Devlieger 2008; Petry 2010), can result in hyperglycaemia. Dur-
ing the second half of pregnancy, insulin sensitivity falls by about
50% (Di Cianni 2003; Lain 2007). This is a normal physiologic
response ensuring that the growing fetus receives sufficient glucose
and other nutrients from the mother via the placenta (Buchanan
1991). In some pregnant women abnormal insulin resistance may
occur if they are unable to compensate for the increased demand
of insulin (Ragnarsdottir 2010; McCance 2011; Catalano 2014).
This results inGDM(ADA 2004;Holt 2013). It is known that the
maternal-fetal placental glucose transfer favours the fetus (Suman
Rao 2013; Sadovsky 2015).Women with GDM therefore transfer
higher amounts of glucose to the fetus when uncontrolled severe
and prolonged maternal hyperglycaemia is present (Wilcox 2005),
resulting in a baby born large-for-gestational age (Ornoy 2005;
Metzger 2008; Young 2013).
Lapolla 2005 suggests the two main contributors to insulin resis-
tance include increased maternal adiposity and the insulin desen-
sitising effects of hormones produced in the pregnancy, especially
in the placenta. As the placenta grows during the pregnancy, so
does the production of the placental hormones, leading to an in-
sulin-resistant state (Evans 2009). GDMusually resolves promptly
following the birth of the baby and the placenta, indicating in-
sulin resistance decreases rapidly after birth. The identified hor-
mones are tumour necrosis factor-alpha (TNF-α), placental lac-
togen, placental growth hormone human chorionic somatomam-
motropin (HCS), cortisol, oestrogen, and progesterone (Clapp
2006; Devlieger 2008). HCS stimulates pancreatic secretion of
insulin in the fetus and inhibits peripheral uptake of glucose in
the mother (Lapolla 2005). If the pregnant woman’s metabolism
cannot compensate adequately for this, maternal hyperglycaemia
results.
Maternal hyperglycaemia of varying degrees of severity has short-
and long-term health implications for the woman and her baby.
For the woman, these include a higher risk of developing ges-
tational hypertension and pre-eclampsia during her pregnancy,
having an increased risk of induction of labour, preterm birth,
caesarean section, perineal trauma, postpartum haemorrhage
(Crowther 2005; HAPO 2008; McCance 2011; NICE 2015),
and significant long-term risks of developing cardiovascular dis-
ease with half the women with GDM at risk of developing type 2
diabetes within five to 10 years (Bellamy 2009; Garrison 2015).
Health implications for the baby include an increased risk of be-
ing born macrosomic and large-for-gestational age (Ornoy 2005;
Young 2013), birth trauma (e.g. shoulder dystocia, bone frac-
tures, and nerve palsy) (Athukorala 2010), hyperbilirubinaemia
(Harris 1997; Hedderson 2006), respiratory distress syndrome
(Landon 2009), and neonatal hypoglycaemia (Devlieger 2008;
Harris 2013). Neonatal hypoglycaemia may be associated with de-
velopmental delay in childhood (Lucas 1988), and, if prolonged
or severe, may cause brain injury. Long-term health risks include
higher rates of obesity, development of type 2 diabetes in child-
hood (Page 2014), and late onset diabetes, hypertension and car-
diovascular disease in adulthood (Ornoy 2011).
Description of the interventions
Effective interventions for treatment of GDM aim to reduce the
risks of GDM for the mother and baby by normalising mater-
nal glycaemia through treating maternal hyperglycaemia (Farrar
2017). Glucose control is usually measured by monitoring capil-
lary blood glucose concentrations to ensure glucose concentrations
are maintained within pre-defined glycaemic thresholds (Garrison
2015). Thismay be achieved through interventions such as the use
of diet modifications (American Dietetic Association 2001; NZ
Ministry of Health 2014; NICE 2015), physical exercises (Harris
2005), pharmacological interventions such as oral hypoglycaemic
medications or subcutaneous insulin (ACOG 2013; NZMinistry
of Health 2014; NICE 2015), nutraceuticals (Thomas 2005; Hui
2009; Bagchi 2015) or other dietary supplements (D’Anna 2015;
Paivaa 2015).
Different types of diet
The main treatment recommended for women with GDM is di-
etarymodification (Bonomo 2005;Crowther 2005; Landon 2009;
NZ Ministry of Health 2014; NICE 2015). Dietary advice is
aimed at preventing maternal hyperglycaemia and ensuring the
woman’s diet provides sufficient energy and nutrients to enable
normal fetal growth while avoiding accelerated fetal growth pat-
terns, and minimising excessive maternal weight gain (Dornhorst
2002). The recommendation is that all women diagnosed with
GDM need to consult with a diabetic specialised dietitian or ex-
perienced nutritionist to determine the appropriate individualised
diet, taking cultural preferences into account (Cheung 2009; Serlin
2009).
Different types of diets recommended for treatment include low
or moderate glycaemic index (GI) diets, high fibre or high fibre-
enriched diets, energy restricted diets, low carbohydrate diet or
high complex carbohydrate diet and/or low monounsaturated fat
diets (Rae 2000; Zhang 2006; Radesky 2008;Wolff 2008; Cheung
2009; Moses 2009; Louie 2011; Moreno-Castilla 2013; Asemi
2014b; Hernandez 2014; Viana 2014; Jamilian 2015; Ma 2015;
Markovic 2016; NICE 2015).
Physical activity
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It is unusual for GDM treatment recommendation to advise any
physical activity modification alone. Some trials have evaluated
the effects of physical exercise for women with GDM or type
2 diabetes. Physical exercises are usually recommended as low-
impact activities, such as walking, swimming, stationary cycling
or special exercise classes for pregnant women (Davenport 2008;
Mottola 2008; de Barros 2010; Manders 2010; Barakat 2012;
Stafne 2012; ACOG 2015; Garrison 2015; Padayachee 2015).
Combined dietary modification and exercise
While often the initial treatment recommendation for women
diagnosedwithGDMis dietmodification, it is common in clinical
practice to combine diet with exercise advice during pregnancy
(ACOG 2013; NZ Ministry of Health 2014; Garrison 2015;
NICE 2015). This is often referred to as dietary and lifestyle advice
(Artal 2007), or lifestyle modification programmes where women
participate in a comprehensive program on nutrition, exercise,
and appropriate weight gain in pregnancy (Harris 2005; Cheung
2009; Shirazian 2010).
Pharmacological hypoglycaemic agents
Oral hypoglycaemic agents
When glycaemic treatment targets are unable to be achieved, phar-
macological hypoglycaemic agents may be considered. While tra-
ditionally this hasmeant subcutaneous insulin for the womanwith
GDM, there has been an increase in the use of oral pharmacologi-
cal hypoglycaemic agents as an alternative (Tieu 2010; Ogunyemi
2011). Oral agents have lower costs, are easier to administer, and
have greater acceptability for women with GDM (Ryu 2014). The
most commonly used oral agents are sulphonylureas, which in-
clude acetohexamide, chlorpropamide, tolazamide, tolbutamide
(first generation, usually not used to treat women with GDM)
and glyburide (glibenclamide), glipizide and glimepiride (second
generation) (Holt 2013; Kalra 2015); and biguanide (metformin)
(Cheung 2009; Simmons 2015).Other oral hypoglycaemic agents
used less frequently include alpha-glucosidase inhibitors (acar-
bose and miglitol) (Kalra 2015); thiazolidinediones (pioglitazone
and rosiglitazone) and meglitinides (repaglinide and nateglinide)
(Kavitha 2013).
Trials have compared different oral pharmacological hypogly-
caemic agents with each other, with placebo, or with subcutaneous
insulin and/or physical exercise and different diets (Langer 2000;
Bertini 2005; Moretti 2008; Cheung 2009; Balsells 2015; Carroll
2015; Casey 2015).
Despite the widespread use of oral pharmacological hypogly-
caemic agents, these are not licensed for use during pregnancy in
many countries (including theUSA, UK, Australia, NewZealand)
(Berggren 2013). This is due to the concern that they can cross
the placenta, in particular the first-generation oral hypoglycaemic
agents. At this stage, randomised controlled trials (RCTs) con-
ducted with glyburide (second-generation sulphonylureas) and
biguanide (metformin) have not demonstrated short-term harm
to the mother or her growing baby (Langer 2000; Bertini 2005;
Blumer 2013; Kelley 2015), but the information on long-term
safety of these drugs remains limited.
Insulin
Women with GDM, who have difficulty controlling their glucose
concentrations with lifestyle changes, such as diet and exercise,
with or without the addition of an oral pharmacological agent,
require insulin (Mpondo 2015). Human insulin does not cross the
placenta in clinically significant amounts and therefore is consid-
ered safe for the fetus when administered subcutaneously in preg-
nancy (Menon 1990; ADA 2015; Garrison 2015; Kelley 2015).
Subcutanous exogenous insulin is designed to mimic the phys-
iological secretion of endogenous insulin (Magon 2014; Home
2015). Some studieswith insulin analogues indicate these can cross
the placenta when an antigen-antibody complex is formed with
immunoglobulins, which can carry the insulin analogues though
the placenta (Jovanovic 2007; Durnwald 2013; Lv 2015). There
is a need for large RCTs to establish the safe use in pregnancy of
long-acting insulin analogues (glargine and detemir), as the effect
of the transplacental insulin bound immunoglobulin A (IgA) is
unclear (Balsells 1997; Negrato 2012; Durnwald 2013). While
fetal macrosomia has been identified in some observational and
RCTs of long-acting insulin analogues, other concerns, includ-
ing fetal death, have been raised (Gamson 2004; Negrato 2012;
Coiner 2014).
There are several methods of administering insulin analogues.His-
torically and currently, insulin analogues have been administered
subcutaneously as a basal-bolus regimen (given before each meal)
as this provides the most effective glycaemic control (Nachum
1999; Cheung 2009). These daily multiple subcutaneous injec-
tions may include rapid- (lispro, aspart, glulisine), intermediate-
(neutral protamine hagedorn (NPH)) and long-acting (glargine
and detemir) insulin analogues (Singh 2007;Horvath 2010). Fast-
acting and intermediate-acting insulin analogues are currently the
preferred choice of treatment for women with GDMbecause there
are limited data available for long-acting insulin in pregnancy
(Jovanovic 2007; Durnwald 2013).
An alternative insulin administration method is via a continu-
ous subcutaneous insulin infusion pump (CSII). Modern pumps
are small and lightweight, battery operated, and hold enough in-
sulin for several days. This means frequent daily injections are
not required. CSII pumps aim to maintain the basal rate of in-
sulin, reducing the risk of maternal hypoglycaemia, and decreas-
ing the risk of fasting hyperglycaemia. CSII pumps are not as-
sociated with worse maternal and perinatal outcomes (Simmons
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2001; Secher 2010; Bernasko 2012; Kesavadev 2016).Women us-
ing CSII pumps during pregnancy for GDM and type 2 diabetes
treatment preferred the flexible lifestyle with comparable health-
care costs (Gabbe 2000; Gonalez 2002; Wollitzer 2010).
Oral and nasal insulin are other alternatives to subcutaneous in-
sulin and are currently under development because of their con-
venience, quick liver absorption and potentially avoiding adverse
effects of weight gain and hypoglycaemia (Woodley 1994; Wang
1996; Carino 1999; Arbit 2004; Iyer 2010; Heinemann 2011;
Fonte 2013). Although some pharmaceutical companies have
stopped developing inhaled (nasal) insulin, some trials are still
ongoing (Hompesh 2009; Rosenstock 2009; Hollander 2010). It
must be noted that research trials for oral and nasal insulin do not
include women with GDM at this stage but are being considered
for future research.
Other interventions
Other interventions reported in the literature for preventingGDM
or treating women with GDM include dietary supplements and
nutraceuticals. The term nutraceutical was created in 1989 by Dr
StephenDeFelice, chairpersonof the Foundation for Innovation in
Medicine, who combined the terms nutrition and pharmaceutical.
Nutraceuticals are marketed as nutritional supplements and sold
with the intent to treat or prevent disease (Brower 1999; Gupta
2010; Lakshmana Prabu 2012). They are not governmentally reg-
ulated or licensed (Zeisel 1999; Rajasekaran 2008). Currently over
470 nutraceutical products are available with reported health ben-
efits (Brower 1999; Eskin 2005; Gupta 2010). While RCTs in-
volving nutraceuticals are scant in the literature for the treatment
or prevention of GDM, there is some evidence frommainly obser-
vational studies. Dietary fibre frompsyllium has been used for glu-
cose control and reducing lipid levels in hyperlipidaemia (Hamid
2000; Baljith 2007; Rajasekaran 2008; Babio 2010). Omega-3
fatty acids have been suggested to reduce glucose tolerance for
humans predisposed to diabetes because insulin is required for
synthesis of the long chain n-3 fatty acids (Sirtori 2002). The
omega-3 fatty acid docosahexaenoic acid (DHA) involved with
regulating insulin resistance has been recommended for women
with GDM (Coleman 2001; Sirtori 2002; Thomas 2006; Gupta
2010). Magnesium has been shown to improve insulin sensitiv-
ity in non-diabetic participants (Guerrero-Romer 2004; Mooren
2011;Wang 2013), as has chromiumpicolinate (Broadhurst 2006;
Martin 2006; Paivaa 2015), calcium and vitamin D (Dror 2011;
Burris 2012; Poel 2012; Asemi 2014a; Burris 2014). Cinnamon
and extracts of bitter melonmay have some effect as co-treatments
in the prevention of diabetes (Rajasekaran 2008; Hui 2009).
Nutraceuticals should not be confused with dietary supplements,
which are products intended to supplement the diet that contain
one or more ingredients such as vitamins, mineral, a herb, an
amino acid or a concentrate, metabolite, constituent, extract or
combinations of these (Rajasekaran 2008).
Myo-inositol, an isomer of inositol, is a dietary supplement of nat-
urally occurring sugar commonly found in cereals, corn, legumes,
and meat. Small, low quality RCTs have shown a potential bene-
ficial effect on improving insulin sensitivity and suggest that myo-
inositol may be useful for women in preventing GDM, but not for
treatment of GDM (Facchinetti 2013; Malvasi 2014; Crawford
2015; D’Anna 2015).
How the intervention might work
Treatment for women with GDM aims to normalise maternal
fasting and postprandial glucose concentrations and modify fe-
tal physiological responses to maternal hyperglycaemia, thereby
reducing maternal and associated fetal and neonatal short-term
morbidity. Two large randomised trials (Crowther 2005; Landon
2009), demonstrated reductions in birthweight and large-for-ges-
tational-age infants in women with GDMwho received treatment
compared with women with GDM who were not treated. Any
intervention that helps to normalise maternal glucose concentra-
tions may therefore be a useful treatment for women with GDM.
Human insulin stimulates glucose and amino acid uptake from
the blood to various tissues and stimulation of anabolic processes
for glycogen, protein, and lipid synthesis. Glucagon has opposing
effects, causing release of glucose from glycogen, release of fatty
acids from stored triglycerides, and stimulation of gluconeogene-
sis. Metabolic homeostasis is maintained by the balance between
insulin and glucagon (Wahlqvist 1978; Bantle 1983).
Different types of diet
One of the aims of dietary advice for women with GDM is to
prevent maternal hyperglycaemia. Different types of diets recom-
mended for treatment include low- or moderate-GI diets, high
fibre or high fibre-enriched diets, energy restricted diets, low car-
bohydrate diet or high complex carbohydrate diet and/or lowmo-
nounsaturated fat diets.
Carbohydrates absorbed following digestion are converted into
glucose (Wahlqvist 1978; Bantle 1983). Current recommenda-
tions for women with GDM are for carbohydrate-controlled and
low-GI diets, evenly distributed throughout the day, when remain-
ing within the recommended glucose treatment targets (Clapp
2002; Dornhorst 2002; Ludwig 2002). Glycaemic index quan-
titatively defines the effect of carbohydrate-based foods on glu-
cose concentrations (Foster-Powell 2002). Consumption of car-
bohydrates triggers the release of insulin and inhibits secretion of
glucagon. Glucagon stimulates gluconeogenesis and release of the
newly formed glucose from the liver into the blood. These actions
produce a rapid return to fasting blood glucose levels and storage
of glucose as glycogen or lipid (Kershaw 2006; Duncan 2007).
Likewise, a protein-rich meal leads to the release of insulin and
glucagon. This rise of insulin associated with the protein meal
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stimulates uptake of the glucose formed in the liver by muscle and
fat tissue (Nuttall 1984; van Loon 2000).
Other types of diets such as fat (polyunsaturated fatty acids may be
protective against impaired glucose tolerance, and saturated fatty
acids can increase glucose and insulin concentrations) and soluble
fibre (which may lower blood cholesterol by binding to bile acids)
are also thought to influence blood glucose concentrations (Zhang
2006; Babio 2010; Kim 2010).
Physical activity
Physical activity results in shifting fuel usage by the working mus-
cle from primarily non-esterified fatty acids (NEFAs) to a blend of
NEFAs, glucose, and muscle glycogen and improves insulin sen-
sitivity in skeletal muscle and glucose control (Sigal 2004; Asano
2014). Glucose enters skeletal muscle cells via facilitated diffu-
sion through a glucose transporter (GLUT4) and peripheral clear-
ance of glucose in skeletal muscle depending on the blood flow
to muscle through glycolysis and glycogenesis (Sakamoto 2002;
Rose 2005; Richter 2013). Translocation of the GLUT4 trans-
porter is induced by insulin and insulin-independent mechanisms
(Richter 2001; Sigal 2004; Richter 2013). The improvements in
insulin sensitivity after regular and sustained exercise, which im-
proves blood supply to active skeletal muscle, include a decrease
of insulin secretion and an increase of glucagon (Coderre 1995;
Wojtaszewski 2002; Sigal 2004; Clapp 2006).
Oral hypoglycaemic agents
Second-generation sulphonylureas such as glyburide (gliben-
clamide), glipizide, and glimepiride (Holt 2013; Kalra 2015) work
by lowering glucose concentration through stimulating the release
of insulin by binding to specific receptors in pancreatic β cell
plasma membrane (Simonson 1984; Groop 1987; Groop 1991).
First-generation sulphonylureas have been identified in the litera-
ture as crossing the placenta, being secreted in breastmilk, andhave
been associated with prolonged neonatal hypoglycaemia (Kemball
1970; Christesen 1998). Second-generation sulphonylureas are re-
ported in the literature as less likely to cross the placenta (Elliott
1991; Langer 2000; Kraemer 2006; Cheung 2009; Schwarz 2013;
Kalra 2015).
Biguanide (metformin) increases insulin sensitivity through the
rate of hepatic glucose production, hepatic glycogenolysis, and by
increasing insulin-stimulated uptake of glucose in skeletal muscles
(Sirtori 1994; Langer 2007; Cheung 2009; Kavitha 2013; Kalra
2015; Simmons 2015). This process reduces insulin resistance.
Biguanide does not stimulate the fetal pancreatic β cells to pro-
duce insulin, and hence, is not associated with neonatal hyperin-
sulinaemia (Sirtori 1994; Ho 2007; Kavitha 2013).
Alpha-glucosidase inhibitors (acarbose and miglitol) reduce post-
prandial hyperglycaemia by slowing the absorption of carbohy-
drates in the intestines (Lebovitz 1997; Ho 2007; Kalra 2015).
The effects of alpha-glucosidase inhibitors have not been stud-
ied well in pregnancy. Animal studies suggest that alpha-glucosi-
dase inhibitors are not teratogenic (Young 2009; Holt 2013; Kalra
2015; Simmons 2015).
Thiazolidenediones (pioglitazone and rosiglitazone, Kavitha
2013), activate the peroxisome proliferator-activated receptor (a
group of nuclear receptor proteins) reducing insulin resistance
(Young 2009). The pharmacodynamics of these drugs are similar
to glyburide (a second-generation sulphonylurea). Thiazolidene-
diones are bound to plasma proteins (99.8%) and are metabolised
in the liver (Stumvoll 2003; Langer 2007). While it appears that
thiazolidinediones are not teratogenic, a high risk of placental
transfer and an association with fetal death and growth restriction
have been reported (Chan 2005; Holt 2013).
Meglitinides (repaglinide and nateglinide) act similarly to sulpho-
nylurea but use different receptors by stimulating the pancreas to
release insulin in response to a meal (Kavitha 2013). Meglitinides
block ATP-dependent potassium channels in functioning pancre-
atic β cells leading to the opening of calcium channels resulting in
an influx of calcium. Increased intracellular calcium initiates and
enhances insulin secretion (Rendell 2004; Kavitha 2013). Megli-
tinides agents have only been studied in non-pregnant participants
with type 2 diabetes, and show some improvements with postpran-
dial glycaemic results and HbA1c (Goldberg 1998; Rosenstock
2004). At this stage, meglitinides can not be recommended for use
in pregnancy (Kavitha 2013).
Insulin
Human insulin is a pancreatic hormone (secreted by the β cells of
the pancreatic islets of Langerhans) that regulates the movement
of glucose from blood into cells. Insulin lowers glucose concentra-
tion by stimulating peripheral glucose uptake and by inhibiting
glucose production and release by the liver. Insulin inhibits lipoly-
sis, proteolysis and gluconeogenesis and increases protein synthesis
and conversion of excess glucose into fat (Kersten 2001; Wilcox
2005; Proud 2006). Treatment with exogenous subcutaneous in-
sulin for women with GDM aims to achieve as close as possible
physiological profile by mimicking the pancreatic basal insulin re-
lease. However, this is based on average plasma insulin profiles and
it is difficult to factor in the individual variability of absorption,
dietary intake and exercise (Hartman 2008; Grunberger 2013;
Pagliuca 2014). Insulin treatment for women with GDM can in-
clude short- or rapid- (lispro, aspart, glulisine) and intermediate-
and long acting- (neutral protamine hagedorn (NPH), glargine,
detemir) insulin analogues (Singh 2007; Horvath 2010; Pollex
2011; Ansar 2013; Magon 2014), given usually by daily multiple
or single subcutaneous injections guided by recommended gly-
caemic targets. Table 1 identifies how the different subcutaneous
insulin analogues act to achieve amore physiological profile. Please
note that some studies results cited in Table 1 are for pregnant
women who had either type 1 or type 2 diabetes only.More studies
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are needed that include women with GDM.
Other interventions
Supplemental nutraceuticals are believed to support the chem-
ical food elements (nutrients) needed for the human body’s
metabolism and prescribed when there is a diagnosis of a nutri-
ent depletion or required for strengthening the metabolism or
prevention of disease (Lakshmana Prabu 2012). Currently there
are over 470 nutraceuticals available including supplements for
GDM (Eskin 2005; Gupta 2010). The mechanism of action for
nutraceuticals and other dietary supplements are often not clear
and further high-quality research is needed.
Myo-inositol is required for cell membrane formation and works
on the insulin receptors of each cell so insulin can bind effectively
thus reducing insulin resistance (Croze 2013). It is involved with
mediating the pathway of intracellular insulin signals increasing
cellular effectiveness of insulinwithin the cell (Larner 2010). Small
randomised trials of low-quality conducted in Italy have shown
some effect in preventing GDM (D’Anna 2013; Facchinetti 2013;
Malvasi 2014; D’Anna 2015). Further high-quality research is
needed to establish if myo-inositol improves health outcomes for
mothers and their babies.
Why it is important to do this overview
There are several Cochrane systematic reviews about treatments
for women with GDM. These include different types of diet, ex-
ercise, subcutaneous insulin, oral hypoglycaemic agents and other
oral supplements as well as management recommendations such
as induction of labour, caesarean section, antenatal breast milk ex-
pression, and blood glucose monitoring. This makes it difficult for
clinicians, consumers, and guideline developers to easily access the
available information. A Cochrane overview of systematic reviews
would provide summary evidence of the effect on relevant health
outcomes of different treatments for women with GDM as a one-
stop resource for health professionals, consumers and guideline
developers aiding the simplifying of clinical treatment decision-
making, and assisting with the process of guideline development.
O B J E C T I V E S
To provide a comprehensive synthesis of evidence from Cochrane
systematic reviews of the benefits and harms associated with in-
terventions for treating GDM on women and their babies.
M E T H O D S
The methodology for data collection and analysis is based on
Chapter 22 (Overviews of reviews) of the Cochrane Handbook
of Systematic Reviews of Interventions (Becker 2011). Only pub-
lished Cochrane systematic reviews of randomised controlled tri-
als (RCTs) focusing on treatments for women with gestational di-
abetes mellitus (GDM) were considered in this overview noting
their publication and search dates. We did not attempt to update
individual Cochrane systematic reviews that were due for update
(two years since publication).
We contacted Cochrane Pregnancy and Childbirth to identify any
relevant new reviews and review updates that were being under-
taken and/or near completion for inclusion of the most up-date
versions of reviews. Cochrane protocols and title registrations for
interventions for womenwithGDMwere found through the same
process to identify future inclusions and were classified as ongoing
Cochrane systematic reviews (Appendix 1). These reviews will be
considered for inclusion in the update of this overview. Similarly,
reviews with pre-specified overview outcomes, but with no out-
come data (either no studies found or women with GDM did not
feature in the included trial/s), were classified as reviews await-
ing classification (Appendix 2) and will be added to this overview
when future updates of the reviews include relevant data.
Criteria for considering reviews for inclusion
Participants
The participants in the Cochrane systematic reviews were women
diagnosed with GDM receiving any form of treatment for GDM
(as identified by the review). Women with type 1 and type 2 dia-
betes were excluded.
Interventions
We considered all treatments for women with GDM including:
• Any dietary modifications (including low-moderate
glycaemic index (GI) diet, high to moderate GI diet, energy-
restricted diet, no energy restricted diet, Dietary Approaches to
Stop Hypertension (DASH) diet, low carbohydrate diet, high
carbohydrate diet, high unsaturated fat diet, low unsaturated fat
diet, low GI diet, high fibre moderate GI diet, soy protein-
enriched diet, high fibre diet, ethnic-specific diet).
• Any physical exercise (including brisk walking, resistance
exercises, circuit workouts, elastic band exercises, any form of
bicycling, low-intensity aerobic exercises, home-based exercises,
mindfulness, yoga).
• Pharmacological treatments (oral hypoglycaemic agents
including metformin, glibenclamide, acarbose, tolbutamide,
chlorpropamide or combination of these therapies or
subcutaneous insulin).
• Nutraceuticals or other dietary supplements (including
myo-inositol).
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• Other interventions as identified by included reviews
(including glycaemic treatment targets for GDM, management
of labour and birth for women with GDM, lifestyle
interventions).
Further descriptions of possible interventions are presented in
Description of the interventions.
Outcomes
GDM is a complex condition with potential for short- and long-
term adverse health outcomes and associated costs for the mother
and her baby/child/adult. We therefore selected GRADE out-
comes for the mother; the neonate/child/adult and health service.
Maternal
1. Hypertensive disorders of pregnancy (including pre-
eclampsia, pregnancy-induced hypertension, eclampsia).
2. Caesarean section.
3. Development of type 2 diabetes.
4. Perineal trauma.
5. Return to pre-pregnancy weight.
6. Postnatal depression.
7. Induction of labour.
Child (as neonate, child, adult)
1. Large-for-gestational age.
2. Perinatal mortality.
3. Death or serious morbidity composite.
4. Neonatal hypoglycaemia.
5. Adiposity.
6. Diabetes (type1, type 2).
7. Neurosensory disability.
Health service
1. Number of antenatal visits or admissions.
2. Length of postnatal stay (mother).
3. Length of postnatal stay (baby) (including neonatal
intensive care unit or special care baby unit).
4. Costs associated with the treatment.
Cochrane systematic reviews that had pre-specified some or all
the overview outcomes, but had no reported data or no included
trials, were categorised as reviews awaiting further classification
(Appendix 2) and will be reconsidered in future updates of this
overview review.
Search methods for identification of reviews
We searched the Cochrane Database of Systematic Reviews on 5
January 2018 using the term ’gestational diabetes’ in title, abstract,
keywords. We also contacted Cochrane Pregnancy and Childbirth
to identify any relevant planned or ongoing reviews. We did not
apply any language or date restrictions (see Figure 1). Reviews of
pregnant women with pre-existing diabetes were excluded.
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Figure 1. Search flow diagram
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Data collection and analysis
Cochrane systematic reviews published addressing any treatments
for women diagnosed with GDMwere selected. Reviews and stud-
ies including treatment for pregnant women with known type I
and type 2 diabetes were excluded. The methodology for data col-
lection was based on Chapter 22 of the of the Cochrane Handbook
of Sytematic Reviews of Interventions (Becker 2011). Where appro-
priate, the overview was prepared using Review Manager software
(Review Manager 2014).
Selection of reviews
Two overview authors independently assessed all potential
Cochrane systematic reviews for inclusion identified through the
search. We resolved disagreements through discussion. Overview
authors who were authors of potentially relevant reviews for in-
clusion were not involved in the assessment of those reviews for
the overview.
Data extraction and management
Two overview review authors, not involved in the included
Cochrane systematic reviews, independently extracted data using
a pre-defined data extraction form. We resolved any discrepancies
through discussion. Where any information from the reviews was
unclear or missing, we contacted the review authors.
Information from included reviewswas extracted on the following.
• Population demographics: we summarised participants’
characteristics with inclusion and exclusion criteria as reported in
the included reviews (Table 2).
• Review characteristics: we reported the number of included
trials and trial countries; design and publication years; the
number of participants (women, babies, and children) in each
review; the date of search conducted for each review; up-to-date
status (< two years from publication was considered up-to-date);
described the interventions and comparisons (Table 2); included
all pre-specified outcomes relevant to the overview (Table 3).
• Statistical summaries: we reported statistical summaries by
outcomes.
Assessment of methodological quality of included
reviews
Quality of included trials within reviews
We did not re-assess the quality of the trials in terms of risk of bias
within the included Cochrane systematic reviews according to the
review authors’ assessments. However, we did re-assess risk of bias
for trials where relevant outcomes had not been assessed using the
GRADE approach. These trials were assessed using the Cochrane
risk of bias tool and these assessments contributed to ascertain the
study’s quality according to GRADE criteria. We also noted and
reported the publication and search date for each included review
(Table 2).
Quality of evidence in the included reviews
Two overview authors who were not authors of the included
Cochrane systematic reviews independently extracted outcomes
that had been assessed using the GRADE approach in the re-
views. Where the relevant outcomes had not been assessed using
the GRADE approach, these were assessed independently by two
overview authors using GRADE (Balshem 2011; GRADEpro).
Where the overview authors disagreed with GRADE judgements
in the original review, we altered judgements and indicated where
this was applied (see Table 4).
GRADE assessment
GRADEpro uses five criteria: study limitations (risk of bias), con-
sistency of effect, imprecision, indirectness and publication bias
to assess the quality of the body of evidence for pre-specified
outcomes, as described in Chapter 5 of the GRADE Handbook.
GRADE rates evidence quality as:
• high (further research is very unlikely to change confidence
in the estimate of effect);
• moderate (further research is likely to have an important
impact on confidence in the estimate of effects and may change
the estimate);
• low (further research is very likely to have an important
impact on confidence in the estimate of effect and is likely to
change the estimate); or
• very low (any estimate of effect is very uncertain).
Where possible, we reported the quality of evidence as assessed
by the Cochrane Review authors. Where these assessments were
not available in the reviews, two overview authors (RM, JB) made
judgements independently.
Two overview authors (RM, JB) generated ’Summary of findings’
tables using GRADE for Cochrane systematic reviews included in
the overview that did not produce ’Summary of findings’ tables
using GRADE. This was applied for Han 2012.
Overall quality of the included reviews
We used two different quality measurement assessment tools to
assess the overall quality of the included reviews: ’Assessment of
Multiple Systematic Reviews’ (AMSTAR) (Shea 2007; Shea 2009)
and ’Risk of Bias in Systematic Reviews’ (ROBIS) (Whiting 2016).
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AMSTAR assessment
Two overview authors who were not involved with the included
Cochrane systematic reviews independently assessed the quality
of the reviews using AMSTAR. We resolved differences through
discussion. The AMSTAR instrument measures 11 components
to assess the methodological quality of a systematic review (Shea
2007; Shea 2009). Each AMSTAR domain is rated as:
• ’yes’ (Y) (clearly done);
• ’no’ (N) (clearly not done);
• ’cannot answer’ (CA); or
• ’not applicable’ (NA).
High-quality reviews score eight or more ’yes’ answers, moderate-
quality reviews score between four and seven, and low-quality
systematic reviews score three or fewer ‘yes’ answers.
AMSTAR score (of 11 criteria) Rating
8 to 11 High quality
4 to 7 Moderate quality
3 or fewer Low quality
The included Cochrane systematic reviews were assessed using the
following AMSTAR questions.
1. Was an apriori design provided?
2. Was there duplicate study selection and data extraction?
3. Was a comprehensive literature search performed?
4. Was the status of publication (i.e. grey literature) used as
an inclusion criterion?
5. Was a list of studies (included and excluded) provided?
6. Were the characteristics of the included studies provided?
7. Was the scientific quality of the included studies assessed
and documented?
8. Was the scientific quality of the included studies used
appropriately in formulating conclusions?
9. Were the methods used to combine the findings of studies
appropriate?
10. Was the likelihood of publication bias assessed?
11. Was the conflict of interest included?
A score out of 11 is given regardless of any ’cannot answer’ or ’not
applicable’ responses (https://amstar.ca/contact us.php).
ROBIS assessment
Two overview authors who were not involved with the included
Cochrane systematic reviews independently assessed the quality of
the reviews using ROBIS (Whiting 2016).We resolved differences
through discussion.
ROBIS considers risk of bias across four key domains. Each do-
main elicits information about possible limitations of the included
Cochrane systematic review through a series of questions. Domain
1 - three have five questions each and Domain 4 has six ques-
tions. Questions are answered with yes, no, or unclear. The risk
of bias for each domain is then judged and summarised as low,
high or unclear concerns. Once all four domains are assessed, an
overall judgement of risk of bias is made (low, high or unclear risk)
(Whiting 2016). The included Cochrane systematic reviews were
assessed using the following ROBIS domains.
Domain 1: study eligibility criteria.
Domain 2: identification and selection of studies.
Domain 3: data collection and study appraisal.
Domain 4: synthesis and findings.
Data synthesis
The characteristics of the included Cochrane systematic reviews
are described in Table 2. We did not examine indirect compar-
isons nor conduct network meta-analyses. We summarised the re-
sults of the included Cochrane systematic reviews by categorising
findings in the following framework organised by overview review
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outcomes.
• Effective interventions: indicating that the review found
moderate- to high-quality evidence of effectiveness for an
intervention.
• Promising interventions (more evidence needed): indicating
that the review found moderate-quality evidence of effectiveness
for an intervention, but more evidence is needed.
• Ineffective or possibly harmful interventions: indicating
that the review found moderate- to high-quality evidence of lack
of effectiveness for an intervention.
• Probably ineffective or harmful interventions (more
evidence needed): indicating that the review found moderate-
quality evidence suggesting lack of effectiveness for an
intervention, but more evidence is needed.
• No conclusions possible due to lack of evidence: indicating
that the review found low- or very low-quality evidence, or
insufficient evidence to comment on the effectiveness of an
intervention.
This approach to summarising the evidence was based on the pub-
lication of Effective Care in Pregnancy andChildbirth (Vol. 2:Ma-
terials and methods used in synthesizing evidence to evaluate the
effects of care during pregnancy and childbirth) (Chalmers 1989)
and a Cochrane overview of pain management in labour, which
categorised interventions as “what works”, “what may work”, and
“insufficient evidence to make a judgement“ (Jones 2012).
R E S U L T S
Our search of the Cochrane Database of Systematic Reviews on 5
January 2018 identified 52 reviews and published protocols from
9706 records, and four records from the Cochrane Pregnancy and
Childbirth group’s title registrations list, to provide a total of 56
records (Figure 1). Following screening of title and review abstracts
for eligibility we excluded 29 titles, protocols and reviews as inel-
igible.
We excluded nine publications that were full-text reviews, proto-
cols or registered titles (Figure 1). Further details are provided in
the description of excluded reviews section following.
Two additional registered titles (Wang 2013; Okesene-Gafa 2016)
and two protocols (Gill 2014; Rao 2017), which indicated treat-
ment for women with GDM and had some or all of the pre-spec-
ified primary and secondary outcomes of this overview, were clas-
sified as ongoing reviews (Appendix 1). When published, these
reviews will be considered for inclusion in future updates of this
overview.
A further four Cochrane systematic reviews were classified as re-
views awaiting further classification (Appendix 2). These reviews
include some or all of the pre-specified GRADE outcomes of this
overview, but either had no studies that met the inclusion crite-
ria, or no outcome data reported for women with GDM (Jefferys
2013; East 2014; Culliney 2016; Farrar 2016). These reviews will
be re-assessed for future updates of this overview (Figure 1).
We included 14 Cochrane systematic reviews in this overview. Of
these, 10 provided relevant outcome data reporting based on 128
RCTs (17,984 women; 16,305 babies, and 1441 children) (Han
2012; Brown 2016a; Martis 2016a; Raman 2017; Brown 2017a;
Brown 2017b; Brown 2017c; Brown 2017d; Han 2017; Biesty
2018; Figure 1; Table 2). RCTs reported in multiple reviews were
counted as one trial (Brown 2017b and Brown 2017c; Brown
2017b andHan 2017).However, when the same trial was reported
in multiple reviews, but with participant numbers from different
treatment arms (subsets), they were then counted as one trial each
(Han 2017 and Brown 2017c; Han 2012 and Han 2017; Brown
2017b and Brown 2017c).
Description of included reviews
Population
All 10 reviews that provided relevant data for this overview in-
cluded randomised trials that recruited women with GDM (Table
2).
Settings
The trials of the included reviews were conducted in a wide range
of countries including some low- and middle-income countries
(Table 2).
Interventions and comparisons
The 10 Cochrane systematic reviews that provided relevant data
for this overview included a total of 27 comparisons (Table 2).
• One review focused on any dietary modifications for
women with GDM:
◦ Different types of dietary advice for women with
gestational diabetes mellitus (Han 2017).
• One review focused on any exercise for women with GDM:
◦ Exercise for pregnant women with gestational diabetes for
improving maternal and fetal outcomes (Brown 2017c).
• One review focused oral pharmacological interventions for
treatment for women with GDM:
◦ Oral anti-diabetic pharmacological therapies for the
treatment of women with gestational diabetes (Brown 2017a).
• One review assessed nutraceuticals or other dietary
supplements for treatment for women with GDM:
◦ Dietary supplementation with myo-inositol in women
during pregnancy for treating gestational diabetes (Brown 2016a).
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• Three reviews assessed other management strategies for
women with GDM:
◦ Planned birth at or near term for improving health
outcomes for pregnant women with gestational diabetes and their
infants (Biesty 2018).
◦ Different intensities of glycaemic control for women with
gestational diabetes mellitus (Martis 2016a).
◦ Different methods and settings for glucose monitoring for
gestational diabetes during pregnancy (Raman 2017).
• One review assessed interventions for women with
hyperglycaemia not meeting gestational diabetes and type 2
diagnostic criteria:
◦ Interventions for pregnant women with hyperglycaemia
not meeting gestational diabetes and type 2 diagnostic criteria (Han
2012). The overview review authors agreed to include Han 2012
in this overview, as different countries have different diagnostic
levels for confirming that a pregnant woman has GDM. It is
highly likely that women with hyperglycaemia identified in one
country as not meeting the gestational diagnostic threshold for
GDM would be diagnosed as having GDM in another country.
• One review assessed lifestyle interventions for women with
GDM:
◦ Lifestyle interventions for the treatment of women with
gestational diabetes mellitus (Brown 2017b). Lifestyle
interventions include at least two or more interventions such as
dietary advice, self-monitoring blood glucose monitoring,
education via group sessions or individual, mindfulness eating,
yoga, relaxation, breathing, fetal growth monitoring, and other
antenatal tests. See characteristics of included reviews for further
intervention details (Table 2).
• One review assessed insulin treatment for women with
GDM:
◦ Insulin for the treatment of women with gestational
diabetes mellitus (Brown 2017d).
In total there were 128 RCTs in the 10 included Cochrane sys-
tematic reviews that provided relevant data which involved a total
of 17,984 women; 16,305 babies; and 1441 children (Table 2).
The 10 reviews included from one (Martis 2016a; Biesty 2018)
to 53 RCTs (Brown 2017d); 159 (Brown 2016a) to 7381 Brown
2017d women; 159 (Brown 2016a) to 6435 babies (Brown
2017d); and 674 (Brown 2017d) to 767 children (Brown 2017b).
Nine (90%) of the included reviews had conducted searches in the
last two years and were considered up-to-date (January 2016 to
August 2017) (Biesty 2018; Brown 2017a; Brown 2017b; Brown
2017c; Brown 2017d; Han 2017; Martis 2016a; Raman 2017).
One review listed the last search date as 30 September 2011 (Han
2012; Table 2).
Table 2 describes participant inclusion and exclusion criteria, in-
terventions, and comparisons for each review.
Outcomes reported
We listed the pre-specified overview outcomes and indicated if the
included reviews assessed these outcomes (Table 3).
Description of excluded reviews
We excluded nine publications that were full-text reviews, pro-
tocols or registered titles (Pelaez-Crisologo 2009; Martis 2016a;
Walkinshaw 1996;Walkinshaw 2006; Alwan 2009;Ceysens 2006;
De-Regil 2016; McCauley 2015; Rumbold 2015) (Figure 1).
These included a protocol that was withdrawn (Pelaez-Crisologo
2009), and subsequently published as a review (Raman 2017) and
included in the overview; the protocol for this overview (Martis
2016a); and two reviews that were withdrawn because they were
out of date (Walkinshaw 1996; Walkinshaw 2006). Walkinshaw
1996 was superseded by Alwan 2009, which has now been su-
perseded and split into three new reviews (Brown 2017a; Brown
2017b; Brown 2017d), which were included in this overview. A
superseded review (Ceysens 2006), which has been revised and
published (Brown 2017c), was included in this overview. Three
reviews presented no results for women with GDM treated who
were with vitamins and othermicronutrients (vitamin DDe-Regil
2016; vitamin A McCauley 2015; vitamin C Rumbold 2015;
Table 5).
Methodological quality of included reviews
Cochrane risk of bias assessments from included
reviews
Seven reviews in this overview stated that the overall judgement
for risk of bias of trials included in the reviews was unclear due to
lack of reporting of methodological details (Brown 2016a; Martis
2016a; Raman 2017; Brown 2017a; Brown 2017b; Brown 2017c;
Brown 2017d). One review reported an overall low risk (Biesty
2018) for most domains; one review reported an overall moderate-
to-high risk of bias for most included trials (Han 2012); and one
review reported an overall unclear to moderate risk of bias (Han
2017). Specific details of the assessment of risk of bias reported in
the included reviews is summarised in Table 6.
GRADE assessment
The quality of the evidence reported from studies in the 10 in-
cluded reviews that provided data for the overview as assessed by
the Cochrane Review authors using the GRADE method varied
widely, from very low- to high-quality. Most studies were assessed
as providing low- to very low-quality evidence (Table 7; Table 8;
Table 9).
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AMSTAR assessment
All 10 included reviews that provided data for the overview were
assessed at high methodological quality, and scored from 9 to 11
points using the AMSTAR tool (Han 2012; Brown 2016a; Martis
2016a; Han 2017; Raman 2017; Brown 2017a; Brown 2017b;
Brown 2017c; Brown 2017d; Biesty 2018; Table 10).
AMSTAR assessments of the 10 included reviews that provided
data for this overview were as follows:
1. All 10 reviews provided a priori design.
2. All 10 reviews reported duplicate study selection and data
extraction.
3. All 10 reviews performed a comprehensive literature search.
4. All 10 reviews included searches of grey literature.
5. All 10 reviews provided a list of included and excluded
studies.
6. All 10 reviews described the characteristics of the included
studies.
7. All 10 reviews assessed and documented the scientific
quality of the included studies.
8. All 10 reviews assessed the scientific quality of the included
studies appropriately in formulating conclusion.
9. Eight reviews combined the findings of studies using
appropriate methods. This was not applicable for two review
because both included only one RCT.
10. Six reviews assessed the likelihood of publication bias. Four
reviews did not mention that publication bias could not be
assessed because there were fewer than 10 included studies but
included test values or funnel plots.
11. Nine reviews clearly reported conflicts of interest.
ROBIS assessment
Overall, the ROBIS assessment for the 10 included reviews that
provided data was judged as low risk of bias (Han 2012; Brown
2016a; Martis 2016a; Han 2017; Raman 2017; Brown 2017a;
Brown 2017b; Brown 2017c; Brown 2017d; Biesty 2018; Table
11).
The assessment for each of the 10 included reviews of the four
domains of the ROBIS tool are as follows.
Domain 1: all reviews were considered of low concern for specifi-
cation of study eligibility criteria.
Domain 2: all reviews were considered of low concern regarding
methods used to identify and/or select studies.
Domain 3: all reviews were considered of low concern regarding
methods used to collect data and appraise studies.
Domain 4: all reviews were considered of low concern regarding
synthesis and findings.
Effect of interventions
We summarised the results of the included reviews by categorising
their findings using the following framework.
• Effective interventions: indicating that the review found
moderate to high-quality evidence of effectiveness for an
intervention.
• Promising interventions (more evidence needed): indicating
that the review found moderate-quality evidence of effectiveness
for an intervention, but more evidence is needed.
• Ineffective or possibly harmful interventions: indicating
that the review found moderate to high-quality evidence of lack
of effectiveness for an intervention.
• Probably ineffective or harmful interventions (more
evidence needed): indicating that the review found moderate-
quality evidence suggesting lack of effectiveness for an
intervention, but more evidence is needed.
• No conclusions possible due to lack of evidence: indicating
that the review found low- or very low-quality evidence, or
insufficient evidence to comment on the effectiveness of an
intervention, more evidence needed.
Further details are provided in Characteristics of included reviews
(Table 2); and pre-specified GRADE outcomes in Summary of
findings” tables for maternal (Table 7), child (as neonate, child,
adult) (Table 8) and health service (Table 9). An assessment sum-
mary of interventions for all overview review GRADE outcomes
is presented in Table 4.
Maternal
1.0 Hypertensive disorders of pregnancy (including pre-
eclampsia, pregnancy-induced hypertension, eclampsia as
defined in reviews)
Hypertensive disorders of pregnancy were reported at the end
of pregnancy in seven reviews using various outcomes (any hy-
pertensive disorder of pregnancy, pregnancy-induced hyperten-
sion, severe pregnancy-induced hypertension or pre-eclampsia,
pre-eclampsia, eclampsia) (Han 2012; Han 2017; Raman 2017;
Brown 2017a; Brown 2017b; Brown 2017c; Brown 2017d; Table
7). Evidence ranged from moderate- to very low-quality.
1.1 Any hypertensive disorders of pregnancy (not defined)
1.1.1 Glibenclamide versus placebo: RR 1.24, 95% CI 0.81
to 1.90; one trial, 375 women; very low-quality evidence (Brown
2017a).
1.1.2 Metformin versus glibenclamide: RR 0.70, 95% CI 0.38
to 1.30; three trials, 508 women;moderate-quality evidence (Brown
2017a).
1.1.3 Insulin versus oral therapy: RR 1.89, 95% CI 1.14 to
3.12; four trials, 1214 women; moderate-quality evidence (Brown
2017d).
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1.2 Pregnancy-induced hypertension
1.2.1 Glibenclamide versus placebo: RR 1.24, 95% CI 0.71 to
2.19; one trial, 375 women; low-quality evidence. Pregnancy-in-
duced hypertension was defined as persistent systolic blood pres-
sure≥ 140mmHgor diastolic bloodpressure≥ 90mmHg (Brown
2017a).
1.2.2 Metformin versus glibenclamide: RR 0.71, 95 % CI 0.37
to 1.37; two trials, 359 women; moderate-quality evidence. Preg-
nancy-induced hypertension was not defined (Brown 2017a).
1.2.3 Low- versus high-carbohydrate diet: RR 0.40, 95 % CI
0.13 to 1.22; one trial, 150 women; very low-quality evidence.
Pregnancy-induced hypertension was not defined (Han 2017).
1.2.4 High- versus low-unsaturated fat diet with matching
calories:RR0.54, 95%CI 0.06 to 5.26; one trial, 27 women; very
low-quality evidence. Pregnancy-induced hypertension was not de-
fined (Han 2017).
1.2.5 Ethnic specific diet versus standard healthy diet:RR0.33,
95 % CI 0.02 to 7.32; one trial, 20 women; very low-quality ev-
idence. Pregnancy-induced hypertension was not defined (Han
2017).
1.2.6 Insulin regimen A versus B: twice daily versus four times
daily RR 1.11, 95% CI 0.51 to 2.42; one trial, 274 women; low-
quality evidence. Pregnancy-induced hypertension was not defined
(Brown 2017d).
1.3 Pregnancy-induced hypertension or pre-eclampsia
combined
1.3.1 Glibenclamide versus placebo: RR 1.23, 95% CI 0.59
to 2.56; one trial, 375 women; low-quality evidence. Severe preg-
nancy-induced hypertension or pre-eclampsia was defined as pro-
teinuria ≥ 2 g in 24 hours, or ≥ 2+ on dipstick, blood pressure ≥
160 mmHg or diastolic pressure ≥ 110 mmHg, serum creatinine
> 1.0mg/dL, platelets < 100,000 mm³, aspartate aminotransferase
> 90 units/L, or symptoms such as persistent headache, scotomata
or epigastric pain (Brown 2017a).
1.3.2 Low-moderate versus moderate-high GI diet: RR 1.02,
95% CI 0.07 to 15.86; one trial, 95 women; very low-quality
evidence. Severe hypertension or pre-eclampsia was not defined
(Han 2017).
1.3.3 Telemedicine versus standard care for glucose monitor-
ing: RR 1.49, 95% CI 0.69 to 3.20; four trials, 275 women;
very low-quality evidence. Pregnancy-induced hypertension or pre-
eclampsia was not defined (Raman 2017).
1.4 Pre-eclampsia (not defined)
1.4.1 Metformin versus glibenclamide: RR 0.66, 95 % CI 0.11
to 3.82; one trial, 149 women; very low-quality evidence (Brown
2017a).
1.4.2 Energy- versus no energy-restricted diet: RR 1.00, 95%
CI 0.51 to 1.97; one trial, 117 women; low-quality evidence (Han
2017).
1.4.3 Dietary Approaches to Stop Hypertension (DASH) diet
versus control diet with matching macronutrient contents: RR
1.00, 95% CI 0.31 to 3.26; three trials, 136 women; moderate-
quality evidence (Han 2017).
1.4.4 High- versus low-unsaturated fat diet with matching
calories:RR not estimable as there were no events in either group;
one trial, 27 women;low-quality evidence (Han 2017).
1.4.5 Soy- versus no soy-protein diet: RR 2.00, 95 %CI 0.19 to
21.03; one trial, 68 women; very low-quality evidence (Han 2017).
1.4.6 Lifestyle intervention versus usual care or diet alone: RR
0.70, 95% CI 0.40 to 1.22; four trials, 2796 women; low-quality
evidence (Brown 2017b).
1.4.7 Exercise versus control: RR 0.31, 95% CI 0.01 to 7.09;
two trials, 48 women; low-quality evidence (Brown 2017c).
1.4.8 Intensive management versus routine care:RR 2.74, 95%
CI 0.26 to 29.07; one trial, 83 women; low-quality evidence (Han
2012).
1.4.9 Self- versus periodic-glucose monitoring: RR 0.18, 95%
CI 0.01 to 3.49; one trial, 59 women; very low-quality evidence
(Raman 2017).
1.4.10 Post- versus pre-prandial glucose monitoring: RR 1.00,
95% CI 0.15 to 6.68; one trial, 66 women; very low-quality evi-
dence (Raman 2017).
1.4.11 Insulin versus oral therapy: RR 1.14, 95% CI 0.86 to
1.52; 10 trials, 2060 women; moderate-quality evidence (Brown
2017d).
1.4.12 Insulin type A versus B: there were no events of pre-
eclampsia reported from one trial comparing human insulin with
insulin aspart in 320 women; Iow-quality evidence (Brown 2017d).
1.5 Eclampsia (not defined)
1.5.1 Low-moderate versus moderate-high GI diet: RR 0.34,
95% CI 0.01 to 8.14; one trial, 83 women; very low-quality evi-
dence (Han 2017).
2.0 Caesarean section
Casearean section was reported as an outcome in nine reviews
(Biesty 2018; Brown 2017a; Brown 2017b; Brown 2017c;Brown
2017d Han 2012; Han 2017; Martis 2016a; Raman 2017). See
Table 7. The quality of the evidence ranged frommoderate- to very
low-quality.
2.1 Induction of labour versus expectant management: RR
1.06, 95% CI 0.64 to 1.77; one trial, 425 women; very low-quality
evidence (Biesty 2018).
2.2 Glibenclamide versus placebo: RR 1.03, 95% CI 0.79 to
1.34; one trial, 375 women; very low-quality evidence (Brown
2017a).
2.3 Metformin versus glibenclamide: average RR 1.20, 95% CI
0.83 to 1.72; four trials, 554 women; low-quality evidence (Brown
2017a).
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2.4 Glibenclamide versus acarbose: RR 0.95, 95% CI 0.53 to
1.70; one trial, 43 women; low-quality evidence (Brown 2017a).
2.5 Low-moderate versusmoderate-highGI diet:RR0.66, 95%
CI 0.29 to 1.47; one trial, 63 women;very low-quality evidence
(Han 2017).
2.6 Energy- versus no energy-restricted diet: RR 1.12, 95% CI
0.80 to 1.56; two trials, 420 women; low-quality evidence (Han
2017).
2.7 DASH diet versus control diet with matching macronu-
trient contents: RR 0.53, 95% CI 0.37 to 0.76; two trials, 86
women; low-quality evidence (Han 2017).
2.8 Low- versus high-carbohydrate diet: RR 1.29, 95% CI 0.84
to 1.99; two trials, 179 women; low-quality evidence (Han 2017).
2.9 High- versus low-unsaturated fat diet with matching calo-
ries: RR 1.08, 95% CI 0.07 to 15.50; one trial, 27 women; very
low-quality evidence (Han 2017).
2.10 LowGI diet versus high fibre moderate-GI diet: RR 1.91,
95% CI 0.91 to 4.03; one trial, 92 women; very low-quality evi-
dence (Han 2017).
2.11 Diet + diet-related behavioural advice versus diet only:
RR 0.78, 95% CI 0.38 to 1.62; one trial, 99 women;very low-
quality evidence (Han 2017).
2.12 Soy- versus no soy-protein diet: RR 1.00, 95% CI 0.57 to
1.77; one trial 68 women;very low-quality evidence (Han 2017).
2.13 Ethnic-specific diet versus standard healthy diet:RR 1.20,
95% CI 0.54 to 2.67; one trial, 20 women; very low-quality evi-
dence (Han 2017).
2.14 Lifestyle intervention versus usual care or diet alone: RR
0.90, 95% CI 0.78 to 1.05; 10 trials, 3545 women; low-quality
evidence (Brown 2017b).
2.15 Exercise versus control:RR 0.86, 95% CI 0.63 to 1.16; five
trials, 316 women; moderate-quality evidence (Brown 2017c).
2.16 Intensive management versus routine care: RR 0.93, 95%
CI 0.68 to 1.27; three trials, 509 women; very low-quality evidence
(Han 2012).
2.17 Strict versus less strict glycaemic control: RR 1.35, 95%
CI 0.83 to 2.18; one trial, 171 women; very low-quality evidence
(Martis 2016a).
2.18 Telemedicine versus standard care for glucose monitor-
ing: average RR1.05, 95%CI 0.72 to 1.53; five trials, 478women;
very low-quality evidence (Raman 2017).
2.19 Self- versus periodic-glucosemonitoring: average RR1.18,
95% CI 0.61 to 2.27; two trials, 400 women; low-quality evidence
(Raman 2017).
2.20 Continuous- versus self-monitoring: RR 0.91, 95% CI
0.68 to 1.20; two trials, 179 women; very low-quality evidence
(Raman 2017).
2.21 Post- versus pre-prandial glucose monitoring: RR 0.62,
95% CI 0.29 to 1.29; one trial, 66 women; very low-quality evi-
dence (Raman 2017).
2.22 Insulin versus oral therapy:RR 1.03, 95%CI 0.93 to 1.14;
17 trials, 1988 women; moderate-quality evidence (Brown 2017d).
2.23 Insulin type A versus B: RR 1.00, 95% CI 0.91 to 1.09;
three trials, 410women;moderate-quality evidence (Brown 2017d).
2.24 Insulin versus diet: RR 0.85, 95% CI 0.50 to 1.42; two
trials, 133 women; very low-quality evidence (Brown 2017d).
2.25 Insulin versus exercise: RR 1.50, 95% CI 0.29 to 7.87; one
trial, 34 women; very low-quality evidence (Brown 2017d).
2.26 Insulin regimen A versus B: twice daily versus four times
daily RR 0.99, 95% CI 0.68 to 1.44; one trial, 274 women; very
low-quality evidence (Brown 2017d) or three times versus six times
daily RR 1.06, 95% CI 0.17 to 6.72; one trial, 37 women; very
low-quality evidence (Brown 2017d).
3.0 Development of type 2 diabetes
Development of type 2 diabetes was reported as an outcome in
three reviews (Brown 2017b; Brown 2017d; Han 2017; Table 7).
Time points for type 2 diabetes testing ranged from one to two
weeks postpartum (Han 2017) up to 13 months postpartum (Han
2017). The Brown 2017b review did not define the test or the
time point. The quality of the evidence ranged from moderate- to
very low-quality. There was no clear evidence of a difference for the
risk of development of type 2 diabetes for any of the comparisons
reporting this outcome.
3.1 Oral Glucose Tolerance Test (OGTT) for diagnosis of
type 2 diabetes
3.1.1 High- versus low-unsaturated fat diet with matching
calories: at one to two weeks postpartum RR 2.00, 95% CI 0.45
to 8.94; one trial, 24 women; very low-quality evidence or at four
to 13 months postpartum RR 1.00, 95% CI 0.10 to 9.61; one
trial, six women; very low-quality evidence (Han 2017).
3.1.2 Low-GI diet versus high fibre moderate-GI diet: at three
months postpartum RR 0.76, 95% CI 0.11 to 5.01; one trial, 58
women; very low-quality evidence (Han 2017).
3.1.3 Lifestyle intervention versus usual care or diet alone: RR
0.98, 95% CI 0.54 to 1.76; two trials, 486 women; low-quality
evidence (Brown 2017b). Test and time frame not defined in the
review.
3.1.4 Insulin versus oral therapy: RR 1.39, 95% CI 0.80 to
2.44; two trials, 754 women; moderate-quality evidence. One trial
reported data at the six to eight weeks postpartum OGTT and the
second trial reported data at one year postpartum (Brown 2017d).
3.1.5 Insulin versus diet: up to 15 years follow-up RR 0.98, 95%
CI 0.79 to 1.21; two trials, 653 women; very low-quality (Brown
2017d).
4.0 Perineal trauma/tearing
Perineal trauma/tearing was reported as an outcome by four re-
views (Biesty 2018; Brown 2017a; Brown 2017b; Raman 2017;
Table 7). The quality of the evidence ranged frommoderate- to very
low-quality. There was no clear evidence of a difference for the risk
18Treatments for women with gestational diabetes mellitus: an overview of Cochrane systematic reviews (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
of perineal trauma/tearing for any of the comparisons reporting
this outcome.
4.1 Induction of labour versus expectant management: RR
1.02, 95% CI 0.73 to 1.43; one trial, 373 women; low-quality
evidence (Biesty 2018).
4.2 Glibenclamide versus placebo: RR 0.98, 95% CI 0.06 to
15.62; one trial, 375 women; very low-quality evidence (Brown
2017a).
4.3 Metformin versus glibenclamide: RR 1.67, 95% CI 0.22 to
12.52; two trials, 308women; low-quality evidence (Brown 2017a).
4.4 Lifestyle intervention versus usual care or diet alone: RR
1.04, 95% CI 0.93 to 1.18; one trial, 1000 women; moderate-
quality evidence (Brown 2017b).
4.5 Continuous- versus self-monitoring blood glucose: very
low-quality evidence from one trial reported that ”There were no
statistically significant differences between the two groups ... in
maternal lacerations“. No data were available for meta-analysis”
(Raman 2017).
4.6 Post- versus pre-prandial glucose monitoring: RR 0.38,
95% CI 0.11 to 1.29; one trial, 66 women; very low-quality evi-
dence (Raman 2017).
5.0 Postnatal weight retention or return to pre-pregnancy
weight
Postnatal weight retention or return to pre-pregnancy weight was
reported as an outcome by four reviews (Brown 2017b; Brown
2017c; Brown 2017d; Han 2017; Table 7). The timing of the
measurement of the outcome varied among reviews and was re-
ported at six to eight weeks, three months, seven months, and 12
months. One review did not report the timing. Evidence ranged
from high- to very low-quality.
5.1 Lifestyle intervention versus usual care or diet alone: RR
1.20, 95% CI 0.67 to 2.17; one trial, 189 women; low-quality
evidence (Brown 2017b). Return to pre-pregnancy weight was de-
fined as the ability to meet postpartum weight goals at six weeks
postpartum.
5.2 Lifestyle intervention versus usual care or diet alone: there
was no clear difference for women who had GDM between the
lifestyle intervention and usual care or diet alone group (RR 1.59,
95% CI 0.99 to 2.57; one trial, 159 women; very low-quality
evidence) (Brown 2017b). Return to pre-pregnancy weight was
defined as the ability to meet postpartum weight goals at seven
months postpartum.
5.3 Lifestyle intervention versus usual care or diet alone: RR
1.75, 95% CI 1.05 to 2.90; one trial, 156 women; low-quality evi-
dence (Brown2017b). Return topre-pregnancyweightwas defined
as the ability to meet postpartum weight goals at seven months
postpartum.
5.4 Low GI diet versus high-fibre moderate GI diet: RR 1.15,
95% CI 0.43 to 3.07; one trial, 55 women; very low-quality evi-
dence (Han 2017). Return to pre-pregnancy weight was defined as
returned to within 1 kg of pre-pregnancy weight at three months
postpartum.
5.5 Exercise versus control: MD 0.11 kg/m², 95% CI -1.04
to 1.26; three trials, 254 women; high-quality evidence (Brown
2017c). The timing for follow-up of the outcome of return to pre-
pregnancy body mass index (BMI) was not defined.
5.6 Insulin versus oral therapy: postnatal weight at six to eight
weeks postpartum MD -1.60 kg, 95% CI -6.34 to 3.14; 1 trial,
167 women; low-quality evidence; or one year postpartum MD -
3.70 kg, 95% CI -8.50 to 1.10; one trial, 176 women; low-quality
evidence (Brown 2017d).
6.0 Postnatal depression
Postnatal depression was reported as an outcome by one review
(Brown 2017b). See Table 7. The quality of the evidence was low-
quality.
6.1 Lifestyle intervention versus usual care or diet alone: RR
0.49, 95% CI 0.31 to 0.78; one trial, 573 women; low-quality
evidence (Brown 2017b). Postnatal depression was defined as Ed-
inburgh Postnatal Depression Score > 12.
7.0. Induction of labour
Induction of labour was reported as an outcome by seven reviews
(Brown 2017a; Han 2017; Brown 2017b; Brown 2017c; Brown
2017d; Han 2012; Raman 2017; Table 7). The quality of the
evidence ranged from high- to very low-quality.
7.1 Glibenclamide versus placebo: RR 1.18, 95% CI 0.79 to
1.76; one trial, 375 women; very low-quality evidence (Brown
2017a).
7.2 Metformin versus glibenclamide: RR 0.81, 95% CI 0.61 to
1.07; one trial, 159 women; low-quality evidence (Brown 2017a).
7.3 Low-moderate versusmoderate-highGI diet:RR0.88, 95%
CI 0.33 to 2.34; one trial, 63 women; low-quality evidence (Han
2017).
7.4 Energy-restricted diet versus no energy-restricted diet: RR
1.02, 95% CI 0.68 to 1.53; one trial, 114 women; low-quality
evidence (Han 2017).
7.5 Lifestyle intervention versus usual care or diet alone: av-
erage RR 1.20, 95% CI 0.99 to 1.46; four trials, 2699 women;
moderate-quality evidence (Brown 2017b).
7.6 Exercise versus control: RR 1.38, 95% CI 0.71 to 2.68; one
trial, 40 women; very low-quality evidence (Brown 2017c).
7.7 Intensive management versus routine care: RR 17.69, 95%
CI 1.03 to 304.09; one trial, 83 women; very low-quality evidence
(Han 2012). There were six events of induction of labour for
women with GDM in the intensive management group but no
events in the control group.
7.8 Telemedicine versus standard care for glucose monitoring:
RR 1.06, 95% CI 0.63 to 1.77; one trial, 47 women; very low-
quality evidence (Raman 2017).
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7.9 Insulin versus oral therapy: average RR 1.30, 95% CI 0.96
to 1.75; 3 RCTs, 348 women; moderate-quality evidence (Brown
2017d).
Neonatal
8.0 Large-for-gestational age (defined as > 90th percentile in
all included reviews)
Large-for-gestational age was reported as an outcome by eight
reviews (Biesty 2018; Brown 2016a; Brown 2017a; Brown 2017b;
Brown 2017d; Han 2012; Han 2017; Raman 2017; Table 8). The
quality of the evidence ranged frommoderate- to very low-quality.
8.1 Induction of labour versus expectant management: RR
0.53, 95% CI 0.28 to 1.02; one trial, 425 babies; low-quality evi-
dence (Biesty 2018).
8.2 Glibenclamide versus placebo: RR 0.89, 95% CI 0.51
to 1.58; one trial, 375 babies; very low-quality evidence (Brown
2017a).
8.3 Metformin versus glibenclamide: RR 0.67, 95% CI 0.24 to
1.83; two trials, 246 babies; low-quality evidence (Brown 2017a).
8.4 Glibenclamide versus acarbose: RR 2.38, 95% CI 0.54
to 10.46; one trial, 43 babies; very low-quality evidence (Brown
2017a).
8.5Myo-inositol versus placebo:RR0.36, 95%CI 0.02 to 8.58;
one trial, 73 babies; very low-quality evidence (Brown 2016a).
8.6 Low-moderate versusmoderate-highGI diet:RR0.71, 95%
CI 0.22 to 2.34; two trials, 89 babies; low-quality evidence (Han
2017).
8.7 Energy- versus no energy-restricted diet: RR 1.17, 95%
CI 0.65 to 2.12; one trial, 123 babies; low-quality evidence (Han
2017).
8.8 Low- versus high-carbohydrate diet: RR 0.51, 95% CI 0.13
to 1.95; one trial, 149babies; very low-quality evidence (Han 2017).
8.9 High- versus low-unsaturated fat diet with matching calo-
ries: RR 0.54, 95% CI 0.21 to 1.37; one trial, 27 babies; very low-
quality evidence (Han 2017).
8.10 Low-GI diet versus high-fibre moderate-GI diet: RR 2.87,
95% CI 0.61 to 13.50; one trial, 92 babies; very low-quality evi-
dence (Han 2017).
8.11 Diet + diet-related behavioural advice versus diet only:
RR 0.73, 95% CI 0.25 to 2.14; one trial, 99 babies; very low-
quality evidence (Han 2017).
8.12 Ethnic-specific diet versus standard healthy diet:RR 0.14,
95%CI 0.01 to 2.45; one trial, 20 babies; very low-quality evidence
(Han 2017).
8.13 Lifestyle intervention versus usual care or diet alone: RR
0.60, 95%CI 0.50 to 0.71; six trials, 2994 babies;moderate-quality
evidence (Brown 2017b).
8.14 Intensive management versus routine care: RR 0.37, 95%
CI 0.20 to 0.66; three trials, 438 babies; low-quality evidence (Han
2012).
8.15 Telemedicine versus standard care for glucose monitor-
ing: RR 1.41, 95% CI 0.76 to 2.64; three trials, 228 babies; very
low-quality evidence (Raman 2017).
8.16 Self- versus periodic-glucose monitoring: RR 0.82, 95%
CI 0.50 to 1.37; two trials, 400 babies; low-quality evidence
(Raman 2017).
8.17 Post- versus pre-prandial glucose monitoring: RR 0.29,
95%CI 0.11 to 0.78; one trial, 66 babies; very low-quality evidence
(Raman 2017).
8.18 Continuous- versus self-monitoring blood glucose: RR
0.67, 95% CI 0.43 to 1.05; one trial, 106 babies; very low-quality
evidence (Raman 2017).
8.19 Insulin versus oral therapy: average RR 1.01, 95% CI 0.76
to 1.35; 13 trials, 2352 babies; moderate-quality evidence (Brown
2017d).
8.20 Insulin type A versus B: RR 1.21, 95% CI 0.58 to 2.55;
three trials, 411 babies; low-quality evidence (Brown 2017d).
8.21 Insulin versus diet: RR 0.85, 95% CI 0.41 to 1.78; one
trial, 202 babies; very low-quality evidence (Brown 2017d).
8.22 Insulin regimen A versus B: twice daily versus four times
daily RR 1.16, 95% CI 0.79 to 1.69; one trial, 274 babies; very
low-quality evidence (Brown 2017d) or three times versus six times
daily RR 0.35, 95% CI 0.04 to 3.08; one trial, 37 babies; very low-
quality evidence (Brown 2017d).
9.0 Perinatal (fetal and neonatal death) and later infant
mortality
Perinatal (fetal and neonatal death) and later infant mortality was
reported by seven reviews (Biesty 2018; Brown 2017a; Brown
2017b; Brown 2017c; Brown 2017d; Han 2017; Raman 2017;
Table 8). All seven reviews reported perinatal mortality. None re-
ported on later infantmortality. The quality of the evidence ranged
from moderate- to very low-quality. There was no clear evidence
of a difference for the risk of perinatal mortality for any of the
comparisons reporting this outcome.
9.1 Induction of labour versus expectant management: RR not
estimable - no events of perinatal mortality recorded for babies
born to mothers in either group; one trial, 425 babies; very low-
quality evidence (Biesty 2018).
9.2 Metformin versus glibenclamide: average RR 0.92, 95% CI
0.06 to 14.55; two trials, 359 babies; very low-quality evidence
(Brown 2017a). There were no deaths in each group in one trial
and one death in each group for the second trial.
9.3 Glibenclamide versus acarbose:RRnot estimable - no events
of perinatal mortality recorded for babies born to mothers in ei-
ther group; one trial, 43 babies; very low-quality evidence (Brown
2017a).
9.4 Energy- versus no energy restricted diet: RR not estimable -
no events of perinatal mortality; two trials, 423 babies; low-quality
evidence) (Han 2017).
9.5 Low- versus high-carbohydrate diet: RR 3.00, 95% CI 0.12
20Treatments for women with gestational diabetes mellitus: an overview of Cochrane systematic reviews (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
to 72.49; one trial, 150 babies; very low-quality evidence (Han
2017). There was one event in the control group.
9.6 Lifestyle intervention versus usual care or diet alone: RR
0.09, 95% CI 0.01 to 1.70; two trials, 1988 babies; low-quality
evidence (Brown 2017b). One trial had no events and one trial had
five events in the control group.
9.7 Exercise versus control: RR not estimable - no events of
perinatal mortality; one trial, 19 babies; very low-quality evidence
(Brown 2017c).
9.8 Telemedicine versus standard care for glucose monitoring:
RR not estimable - no events of perinatal mortality; two trials, 131
babies; very low-quality evidence (Raman 2017).
9.9 Self- versus periodic-glucose monitoring: RR 1.54, 95%
CI 0.21 to 11.24; two trials, 400 babies; very low-quality evidence
(Raman 2017).
9.10 Continuous- versus self-monitoring blood glucose: RR
not estimable - no events of perinatal mortality; two trials, 179
babies; very low-quality evidence (Raman 2017).
9.11 Insulin versus oral therapy:RR 0.85, 95%CI 0.29 to 2.49;
10 trials, 1463 babies; low-quality evidence (Brown 2017d),
9.12 Insulin versus diet: RR 0.74, 95% CI 0.41 to 1.33; four
trials, 1137 babies; moderate-quality evidence (Brown 2017d),
9.13 Insulin regimen A versus B: RR 3.04, 95% CI 0.13 to
74.07; one trial, 274 babies; very low-quality evidence; twice daily
versus four times daily (Brown 2017d).
10.0 Death or serious morbidity composite (as defined in
reviews, e.g. perinatal or infant death, shoulder dystocia,
bone fracture or nerve palsy)
Death or serious morbidity composite (as defined in reviews, e.g.
perinatal or infant death, shoulder dystocia, bone fracture or nerve
palsy) was reported as an outcome in five reviews (Brown 2017a;
Han 2017; Brown 2017b; Brown 2017c; Brown 2017d; Table
8). The components of the composite differed among trials. The
quality of the evidence ranged from moderate- to very low-quality.
10.1 Metformin versus glibenclamide: RR 0.54, 95% CI 0.31
to 0.94; one trial, 159 babies; low-quality evidence (Brown 2017a).
The morbidity composite included hypoglycaemia, hyperbiliru-
binaemia, macrosomia, respiratory illness, birth injury, stillbirth
or neonatal death.
10.2 Ethnic specific diet versus standard healthy diet: RR not
estimable - no events in either group; one trial, 20 babies; very low-
quality evidence (Han 2017). The morbidity composite included
hypoglycaemia, neonatal asphyxia, respiratory distress syndrome,
hyperbilirubinaemia, and hypocalcaemia.
10.3 Lifestyle intervention versus usual care or diet alone: av-
erage RR 0.57, 95% CI 0.21 to 1.55; two trials, 1930 babies; very
low-quality evidence (Brown 2017b). The death or serious mor-
bidity composite included death, shoulder dystocia, bone fracture,
and nerve palsy in one trial, and in the other trial included still-
birth, neonatal death, hypoglycaemia, hyperbilirubinaemia, ele-
vated cord-blood C-peptide, and birth trauma. The review au-
thors decided to include both trials in the meta-analysis because
the direction of the treatment effect is the same for both trials.
10.4 Exercise versus control: RR 0.56, 95% CI 0.12 to 2.61;
two trials, 169 babies; moderate-quality evidence (Brown 2017c).
10.5 Telemedicine versus standard care for glucose monitor-
ing: RR 1.06, 95% CI 0.68 to 1.66; one trial, 57 infants; very low-
quality evidence (Raman 2017).
10.6 Insulin versus oral therapy:RR 1.03, 95%CI 0.84 to 1.26;
two trials, 760 babies; moderate-quality evidence (Brown 2017d).
10.7 Insulin regimen A versus B:RR 1.69, 95%CI 1.08 to 2.64;
one trial 274 babies; very low-quality evidence Twice daily versus
four times daily (Brown 2017d).
11.0 Neonatal hypoglycaemia (as defined in the reviews)
Neonatal hypoglycaemia was reported as an outcome by eight re-
views (Biesty 2018; Brown 2016a; Brown 2017a; Brown 2017b;
Brown 2017c; Brown 2017d; Han 2017; Raman 2017; Table 8).
The quality of the evidence ranged from moderate- to very low-
quality. Six reviews provided no definition for neonatal hypogly-
caemia for specific comparisons, and five reviews provided defini-
tions for specific comparisons, although these definitions varied.
11.1 Neonatal hypoglycaemia (not defined in the reviews)
11.1.1 Induction of labour versus expectant management: RR
0.74, 95% CI 0.26 to 2.09; one trial, 425 babies; very low-quality
evidence (Biesty 2018).
11.1.2 Glibenclamide versus placebo: RR 1.97, 95% CI 0.36
to 10.62; one trial, 375 babies; very low-quality evidence (Brown
2017a).
11.1.3 Myo-inositol versus placebo: RR 0.05, 95% CI 0.00 to
0.85; one trial, 73 babies; low-quality evidence (Brown 2016a).
11.1.4 Energy- versus no energy-restricted diet: RR 1.06, 95%
CI 0.48 to 2.32; two trials, 408 babies; very low-quality evidence
(Han 2017).
11.1.5 Low- versus high-carbohydrate diet: RR 0.91, 95% CI
0.39 to 2.12; one trial, 149 babies; very low-quality evidence (Han
2017).
11.1.6 Ethnic specific diet versus standard healthy diet:RR not
estimable, no events in either group; one trial, 20 babies; very low-
quality evidence) (Han 2017).
11.1.7 Lifestyle intervention versus usual care or diet alone:
average RR 0.99, 95% CI 0.65 to 1.52; six trials, 3000 babies;
moderate-quality evidence (Brown 2017b).
11.1.8 Exercise versus control: RR 2.00, 95% CI 0.20 to 20.04;
one trial, 34 babies; low-quality evidence (Brown 2017c).
11.1.9 Self- versus periodic-glucose monitoring:RR 0.64, 95%
CI 0.39 to 1.06; two trials, 391 babies; low-quality evidence
(Raman 2017).
11.1.10 Insulin versus diet: average RR 0.88, 95% CI 0.34 to
2.24; 3 trials, 176 babies; very low-quality evidence (Brown 2017d).
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11.2 Neonatal hypoglycaemia (defined)
11.2.1 Metformin versus glibenclamide: RR 0.86, 95% CI
0.42 to 1.77; four trials, 554 babies; low-quality evidence (Brown
2017a). Hypoglycaemia defined as blood glucose level (BGL) <
2.2 mmol/L; < 40 mg/dL.
11.2.2 Glibenclamide versus acarbose: RR 6.33, 95% CI 0.87
to 46.32; one trial, 43 babies; very low-quality evidence (Brown
2017a). Hypoglycaemia defined as BGL < 2.2 mmol/L; < 40 mg/
dL.
11.2.3 Soy- versus no soy-protein diet:RR3.00, 95%CI 0.33 to
27.42; one trial, 68 babies; very low-quality evidence (Han 2017).
Hypoglycaemia defined as BGL < 1.7 mmol/L (< 30.6 mg/dL).
11.2.4 Intensive management versus routine care: RR 0.39,
95% CI 0.06 to 2.54; two trials, 426 babies; very low-quality evi-
dence (Han 2012). Hypoglycaemia defined in one trial as BGL <
1.7 mmol/L in two consecutive measurements and as BGL < 1.94
mmol/L in the other trial.
11.2.5 Telemedicine versus standard care for glucose monitor-
ing: RR 1.14, 95% CI 0.48 to 2.72; three trials, 198 babies; very
low-quality evidence (Raman 2017). Hypoglycaemia was defined
in one trial as BGL < 2.6 mmol/L,
11.2.6 Continuous- versus self-monitoring blood glucose: RR
0.79, 95% CI 0.35 to 1.78; two trials, 178 babies; very low-quality
evidence (Raman 2017). Hypoglycaemia was defined in one trial
as BGL ≤ 45 mg/dL (2.5 mmol/L).
11.2.7 Post- versus pre-prandial glucose monitoring: RR 0.14,
95% CI 0.02 to 1.10; one trial, 66 babies; very low-quality evi-
dence (Raman 2017). Hypoglycaemia was defined as≤ 30 mg/dL
requiring glucagon or dextrose infusion for treatment during the
first four days after birth.
11.2.8 Insulin versus oral therapy: average RR 1.14, 95% CI
0.85 to 1.52; 24 trials, 3892 babies; low-quality evidence (Brown
2017d). The definitions of neonatal hypoglycaemia varied among
the trials reporting a definition.
11.2.9 Insulin type A versus B: human insulin versus another
insulin preparation RR 2.28, 95% CI 0.06 to 82.02; three trials,
165 babies; very low-quality evidence (Brown 2017d).
11.2.10 Insulin versus diet:RR 0.88, 95%CI 0.34 to 2.24; three
trials, 176 babies; very low-quality evidence (Brown 2017d).
11.2.11 Insulin versus exercise: RR 0.50, 95% CI 0.05 to 5.01;
one trial, 34 babies; very low-quality evidence (Brown 2017d).
11.2.12 Insulin regimen A versus B: twice daily versus four times
daily RR 8.12, 95% CI 1.03 to 64.03; one trial, 274 babies; very
low-quality evidence (Brown 2017d).
12.0 Adiposity (including skinfold thickness measurements
(mm), fat mass)
Neonatal adiposity was reported as an outcome by two reviews
(Brown 2017b; Brown 2017d). No other measures of adiposity
were reported. See Table 8. The quality of the evidence was low-
to very quality.
12.1 Neonate
12.1.1 Lifestyle intervention versus usual care or diet alone: the
evidence suggested a reduction for whole-body neonatal fat mass
(estimated from skinfold thickness) for babies born to mothers
with GDM in the lifestyle intervention group compared to the
usual care or diet alone group (MD -37.30 g, 95% CI -63.97 g
to -10.63 g; one trial, 958 babies; low-quality evidence) (Brown
2017b).
12.1.2 Insulin versus oral therapy: skinfold sum (MD -0.80
mm, 95% CI -2.33 to 0.73; one trial, 82 infants; very low-qual-
ity evidence) or percentage fat mass (MD -1.60%, 95% CI -3.77
to 0.57; one trial, 82 infants; very low-quality evidence) (Brown
2017d).
12.2 Child
Childhood adiposity was reported as an outcome by two reviews
(Brown 2017b; Brown 2017d). See Table 8. The quality of the
evidence ranged from moderate- to very low-quality.
12.2.1 Lifestyle intervention versus usual care or diet alone:
RR 0.91 kg/m², 95% CI 0.75 to 1.11; three trials, 767 children;
moderate-quality evidence (Brown 2017b). Childhood adiposity
was measured as BMI > 85th percentile at four to five years follow-
up in one trial, seven to 11 years follow-up in the second included
trial, and five to 10 years follow-up in the third trial.
12.2.2 Lifestyle intervention versus usual care or diet alone:
MD 0.08 points, 95% CI -0.28 to 0.44; one trial, 199 children;
very low-quality evidence (Brown 2017b). Adiposity was measured
as BMI z score at four to five years follow-up.
12.2.3 Insulin versus oral anti-diabetic pharmacological ther-
apies:MD 0.50%, 95% CI -0.49 to 1.49; one trial, 318 children;
low-quality evidence (Brown 2017d). Adiposity was measured as
total fat mass (%) up to two-years of age.
12.3 Child as an adult
None of the included reviews reported any data for the child as
an adult for the outcome of adiposity (including BMI, skinfold
thickness, fat mass),
13.0 Diabetes (type 2) child as later infant/childhood
None of the included reviews reported any data for the child as
later infant/childhood for the development of diabetes.
14.0 Neurosensory disability in later childhood (as defined in
reviews)
One of the included reviews reported data for neurosensory dis-
ability in later childhood at 18 months follow-up (Brown 2017d).
The evidence was low quality.
14.1 Insulin versus oral therapy: any mild developmental delay
RR 1.07, 95% CI 0.33 to 3.44; one trial, 93 children; hearing
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impairment RR 0.31, 95%CI 0.01 to 7.49; one trial, 93 children;
or visual impairment RR 0.31, 95% CI 0.03 to 2.90; one trial, 93
children; all low-quality evidence (Brown 2017d).
Health service use
15.0 Number of antenatal visits or admissions
The number of antenatal visits or admissions was reported as an
outcomeby three reviews (Brown 2017b;Han2017;Raman 2017;
Table 9). The quality of the evidence ranged from moderate- to
very low-quality.
15.1 Soy protein-enriched diet versus no soy-protein diet: RR
0.75, 95% CI 0.18 to 3.10; one trial, 68 women; very low-quality
evidence (Han 2017). The number of antenatal visits or admissions
was defined as maternal hospitalisation.
15.2 Lifestyle intervention versus usual care or diet alone: RR
1.06, 95% CI 0.87 to 1.29; one trial, 1000 women; moderate-
quality evidence (Han 2017). The number of antenatal visits or
admissions was not defined.
15.3 Telemedicine versus standard care for glucose monitor-
ing:MD -0.36 visits, 95% CI -0.92 to 0.20; one trial, 97 women;
very low-quality of evidence (Raman 2017). The number of ante-
natal visits or admissions was defined as being a visit to hospital
or a health professional.
15.4 Self-monitoring versus periodic glucosemonitoring:MD
0.20 visits, 95% CI -1.09 to 1.49; one trial, 58 women; very low-
quality evidence (Raman 2017). The number of antenatal visits or
admissions was defined as visits with the diabetes team.
15.5 Insulin versus oral therapy: MD 1.00 visits, 95% CI -
0.08 to 2.08; one trial, 404 women; low-quality evidence (Brown
2017d). The number of antenatal visits or admissions was defined
as clinic visits.
16.0 Length of postnatal stay (mother)
None of the included reviews reportedmaternal length of postnatal
stay as an outcome.
17.0 Length of postnatal stay (baby) including neonatal
intensive care unit (NICU) or special care baby unit (SCBU)
Length of infants’ postnatal stay was reported as an outcome by
three reviews (Brown 2017d; Han 2017; Raman 2017; Table 9).
The quality of the evidence was very low-quality.
17.1 Diet + diet-related behavioural advice versus diet only:
RR 1.33, 95% CI 0.73 to 2.44; one trial, 99 babies; very low-
quality evidence) (Han 2017). The length of postnatal stay was
defined as more than four days.
17.2 Telemedicine versus standard care for glucose monitor-
ing: evidence from one included trial found no clear differences
in length of postnatal stay for the baby but data could not be in-
cluded in a meta-analysis (Raman 2017).
17.3 Continuous glucose monitoring versus self-monitoring
bloodglucose:MD-0.83days, 95%CI -2.35 to 0.69; one trial, 18
babies; very low-quality evidence (Raman 2017). The data referred
to stay in NICU.
17.4 Insulin versus oral anti-diabetic pharmacological thera-
pies: MD -0.20 days, 95% CI -1.79 to 1.39; three trials, 401 in-
fants; very low-quality evidence (Brown 2017d). The data referred
to stay in NICU.
18.0 Costs associated with the treatment
Costs associated with the treatment was reported as an outcome by
three reviews (Brown 2017b; Brown 2017d; Raman 2017). The
evidence was very low-quality.
18.1 Lifestyle intervention versus usual care or diet alone:
moderate-quality evidence showed costs (in AUD) were higher for
women with mild GDM and a singleton pregnancy in the lifestyle
intervention group compared to the usual care or diet alone group,
which was mainly due to increased surveillance and increased con-
tact with health professionals (one trial, 1000 women) (Brown
2017b). The data were reported as direct costs per 100 women,
but were not in a suitable format for inclusion in a meta-analysis
and are summarised in Table 12.
18.2 Telemedicine versus standard care for glucose monitor-
ing: very low-quality evidence from one included trial reported
that the intervention “...was less expensive for the health system
in terms of use of health professionals time” but no details were
provided (Raman 2017).
18.3 Self-monitoring versus periodic monitoring: very low-
quality evidence from a single trial reported that the direct costs,
including glucometer rental, equipment purchase, and reagent
strips, was less expensive for periodic glucose monitoring. Data
were not suitable for meta-analysis (Raman 2017).
18.4 Insulin versus oral anti-diabetic pharmacological thera-
pies: very low-quality evidence from one trial suggested that the
monthly costs of insulin were higher than for glibenclamide. Evi-
dence from one trial suggested that the costs of insulins (excluding
syringes) was higher than for metformin or for combined met-
formin and insulin. The data were not suitable for meta-analysis
(Brown 2017d).
D I S C U S S I O N
Summary of main results
This overview included 14 Cochrane Reviews, 10 of which re-
ported relevant data on27 comparative treatments forwomenwith
gestational diabetes mellitus (GDM) and borderline GDM. These
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10 Cochrane systematic reviews included 128 randomised con-
trolled trials (RCTs) involving 17,984 women, 16,305 babies, and
1441 children. RCTs reported in multiple reviews were counted
as one trial (Brown 2017b and Brown 2017c; Brown 2017b and
Han 2017).However, when the same trial was reported inmultiple
reviews, but with participant numbers from different treatment
arms (subsets), they were then counted as one trial each (Han 2017
and Brown 2017c; Han 2012 and Han 2017; Brown 2017b and
Brown 2017c).
Data were available from the included reviews for 16 of 18 pre-
specified overview outcomes. A summary of the main results ac-
cording to these overview review outcomes, following the frame-
work and its categories as outlined in the Data synthesis section,
are presented in Table 4.
We collated the interventions for treatment of womenwith GDM,
and for the GRADE health outcomes of this overview, according
to whether they had been found to be effective, promising, inef-
fective, probably ineffective, or no conclusion was made about ef-
fectiveness for health outcomes identified as important for women
and their babies:
• Effective interventions: indicating that the review found
moderate- to high-quality evidence of effectiveness for an
intervention.
• Promising interventions (more evidence needed): indicating
that the review found moderate-quality evidence of effectiveness
for an intervention, but more evidence is needed.
• Ineffective or possibly harmful interventions: indicating
that the review found moderate- to high-quality evidence of lack
of effectiveness for an intervention.
• Probably ineffective or harmful interventions (more
evidence needed): indicating that the review found moderate-
quality evidence suggesting lack of effectiveness for an
intervention, but more evidence is needed.
• No conclusions possible due to lack of evidence: indicating
that the review found low- or very low-quality evidence, or
insufficient evidence to comment on the effectiveness of an
intervention, more evidence needed.
The overall evidence of various interventions for the treatment of
women with GDM and their effects on the health of the woman
and her baby are limited by quantity and quality. Lifestyle inter-
ventions in comparison to usual care were found to be probably
’effective’ in reducing large-for-gestational age. There were no in-
terventions that could be classified as ’promising interventions’.
’Ineffective or harmful’ interventions included: lifestyle interven-
tions versus usual care which probably increase the risk of induc-
tion of labour (IOL); exercise versus control for return to pre-
pregnancy weight; and insulin versus oral therapy which proba-
bly increase the risk of IOL. ’Probably ineffective’ interventions
included insulin versus oral therapy, which probably increases the
risk of the hypertensive disorders of pregnancy. The evidence was
inconclusive for all other interventions. Some interventions are
multi-component and it was not possible to determine which spe-
cific components were most promising. Long-term health out-
comes for women and their infants and costs are not well reported.
Most of the dietary treatments assessed were from interventions
reported as single studies that had relatively small numbers of par-
ticipants, and only a few trials compared the same or similar di-
etary interventions.
This overview summarises the evidence fromCochrane systematic
reviews of RCTs for treatments for women with GDM on relevant
health outcomes and may be used by clinicians, clinical guideline
developers, consumers, and policymakers to aid decision making
to guide clinical practice, health services and future primary re-
search. For further information we suggest referring to the indi-
vidual Cochrane systematic reviews for details for the context and
components of the interventions.
For the mother
1.0 Hypertensive disorders of pregnancy (including
pre-eclampsia, pregnancy-induced hypertension,
eclampsia)
Summary for the risk of any hypertensive disorders of pregnancy (not defined) in women with GDM
Probably ineffective or harmful interventions
• Moderate-quality evidence suggested that insulin possibly increased the risk of hypertensive disorders of pregnancy (not
defined) compared with oral therapy.
No conclusions possible: low- to very low-quality evidence, or insufficient evidence to comment on the effectiveness, more
evidence needed
• Moderate-quality evidence showed no clear difference for metformin versus glibenclamide.
• Very low-quality evidence showed no clear difference for glibenclamide versus placebo
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Summary for the risk of pregnancy-induced hypertension in women with GDM
No conclusions possible: low- to very low-quality evidence, or insufficient evidence to comment on the effectiveness, more
evidence needed
• Moderate-quality evidence showed no clear difference for metformin versus glibenclamide.
• Low-quality evidence showed no clear difference for glibenclamide versus placebo or insulin regimen A versus B.
• Very low-quality evidence showed no clear difference for low- versus high-carbohydrate diet; high- versus low-unsaturated fat
diet with matching calories; and ethnic specific diet versus standard healthy diet
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Summary for the risk of pregnancy-induced hypertension or pre-eclampsia (combined) in women with GDM
No conclusions possible: low- to very low-quality evidence, or insufficient evidence to comment on the effectiveness, more
evidence needed
• Low-quality evidence showed no clear difference for glibenclamide versus placebo.
• Very low-quality evidence showed no clear difference for low-moderate versus moderate-high GI diet or telemedicine versus
standard care for glucose monitoring
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Summary for the risk of pre-eclampsia (not defined) in women with GDM
Probably ineffective or harmful interventions (more evidence needed): indicating that the review found moderate-quality
evidence suggesting lack of effectiveness for an intervention, more evidence needed
• Moderate-quality evidence showed no clear difference for the DASH diet versus control diet with matching macronutrient
contents or insulin versus oral therapy.
No conclusions possible: low- to very low-quality evidence, or insufficient evidence to comment on the effectiveness, more
evidence needed
• Low-quality evidence showed no clear difference for energy- versus no energy-restricted diet; high- versus low-unsaturated fat
diet with matching calories; lifestyle intervention versus usual care or diet alone; exercise versus control; intensive management
versus routine care or insulin type A versus B.
• Very low-quality evidence showed no clear difference for metformin versus glibenclamide; soy- versus no soy-protein diet or
managed by self- versus periodic-glucose monitoring or post- versus pre-prandial glucose monitoring
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Summary for the risk of eclampsia (not defined) for women with GDM
No conclusions possible: low- to very low-quality evidence, or insufficient evidence to comment on the effectiveness, more
evidence needed
• Very low-quality evidence showed no clear difference for low-moderate versus moderate-high GI diet
2.0 Caesarean section
Summary for the risk of caesarean section for women with GDM
No conclusions possible: low- to very low-quality evidence, or insufficient evidence to comment on the effectiveness, more
evidence needed
• Moderate-quality evidence showed no clear difference for insulin versus oral therapy or insulin type A versus B. Moderate-
quality evidence showed no clear difference (the direction of the effect suggested benefit) for exercise versus control.
• Low-quality evidence suggested a possible reduction for the risk of birth by caesarean section for the DASH diet compared to
the control diet with matching macronutrient contents group.
• Low-quality evidence showed no clear difference for metformin versus glibenclamide; glibenclamide versus acarbose; energy-
versus no energy-restricted diet; low- versus high-carbohydrate diet and lifestyle intervention versus usual care or diet alone.
• Very low-quality evidence showed no clear difference for induction of labour versus expectant management; glibenclamide
versus placebo; low-moderate versus moderate-high GI diet; low-GI diet versus high-fibre moderate-GI diet; diet + diet-related
behavioural advice versus diet only; soy- versus no soy-protein diet; high- versus low-unsaturated fat diet with matching calories;
ethnic specific diet versus standard healthy diet; intensive management versus routine care; strict versus less strict glycaemic control;
telemedicine versus standard care for glucose monitoring; self- versus periodic-glucose monitoring; continuous- versus self-
monitoring; post- versus pre-prandial glucose monitoring; insulin versus diet; insulin versus exercise or insulin regimen A versus B
3.0 Development of type 2 diabetes
Summary for the risk of development of type 2 diabetes for women with GDM
No conclusions possible: low- to very low-quality evidence, or insufficient evidence to comment on the effectiveness, more
evidence needed
• Moderate-quality evidence showed no clear difference for insulin versus oral therapy (up to one year postpartum).
• Low-quality evidence showed no clear difference for lifestyle intervention versus usual care or diet alone (diagnostic test or
timeframe not defined).
• Very low-quality evidence showed no clear difference for high- versus low-unsaturated fat diet with matching calories using the
Oral Glucose Tolerance Test (OGTT) for diagnosis of type 2 diabetes at one- to two-weeks postpartum or at four to 13 months
postpartum. There was no clear difference for the treatment with low-GI diet versus high fibre moderate-GI diet using the OGTT
at three months postpartum. There was no clear difference between insulin and diet up to 15 years follow-up
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4.0 Perineal trauma/tearing
Summary for the risk of perineal trauma for women with GDM
No conclusions possible: low- to very low-quality evidence, or insufficient evidence to comment on the effectiveness, more
evidence needed
• Moderate-quality evidence showed no clear difference for lifestyle intervention versus usual care or diet alone.
• Low-quality evidence showed no clear difference for induction of labour versus expectant management or metformin versus
glibenclamide.
• Very low-quality evidence showed no clear difference for glibenclamide versus placebo or continuous- versus self-monitoring
blood glucose
5.0 Postnatal weight retention or return to pre-
pregnancy weight
Summary for postnatal weight retention or return to pre-pregnancy weight for women with GDM
Ineffective or possibly harmful interventions: indicating that the review found moderate to high-quality evidence of lack of
effectiveness for an intervention
• Moderate-quality evidence showed no clear difference for return to pre-pregnancy BMI (at follow-up, timing not defined) for
women with GDM who were treated with exercise versus control.
No conclusions possible: low- to very low-quality evidence, or insufficient evidence to comment on the effectiveness, more
evidence needed
• Low-quality evidence suggested benefit by an increased number of women meeting postpartum weight goals, that is returning
to their pre-pregnancy weight at twelve months postpartum for women with GDM who were treated with lifestyle intervention
compared to usual care or diet alone.
• Low-quality evidence showed no clear difference for postnatal weight retention or return to pre-pregnancy weight at six weeks
postpartum for women with GDM who were treated with lifestyle intervention versus usual care or diet alone or insulin versus oral
therapy up to one-year follow-up.
• Very low-quality evidence showed no clear difference for postnatal weight retention or return to pre-pregnancy weight at three
months postpartum for women with GDM who were treated with low-GI diet versus high-fibre moderate-GI diet; or lifestyle
intervention versus usual care or diet alone at eight months postpartum
6.0 Postnatal depression
Summary for the risk of postnatal depression in women with GDM
No conclusions possible: low- to very low-quality evidence, or insufficient evidence to comment on the effectiveness, more
evidence needed
• Low-quality evidence suggested a decrease for the risk of developing postnatal depression when treated with lifestyle
intervention compared to usual care or diet alone
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7.0 Induction of labour
Summary for the risk of induction of labour for women with GDM
Ineffective or possibly harmful interventions: indicating that the review found moderate to high-quality evidence of lack of
effectiveness for an intervention
• Moderate-quality evidence showed no clear difference for lifestyle intervention versus usual care or diet alone. The direction of
the treatment effect suggests increased likelihood of IOL for women treated with lifestyle interventions. Insulin treatment may
possibly be associated with an increased risk of induction of labour compared with oral therapy but there is insufficient evidence.
No conclusions possible: low- to very low-quality evidence, or insufficient evidence to comment on the effectiveness, more
evidence needed
• Very low-quality evidence suggested an increased risk of induction in labour for intensive management compared to the routine
care.
• Low-quality evidence showed no clear difference for metformin versus glibenclamide; low-moderate versus moderate-high GI
diet or energy- versus no energy-restricted diet.
• Very low-quality evidence showed no clear difference for glibenclamide versus placebo, exercise versus control or telemedicine
versus standard care for glucose monitoring
8.0 Large-for-gestational age
Summary for risk of large-for-gestational age for infants born to mothers with GDM
Effective interventions: indicating that the review found moderate to high-quality evidence of effectiveness for an intervention
• Moderate-quality evidence suggested a benefit by a reduction in the risk of large-for-gestational age for babies born to mothers
who were treated with lifestyle intervention compared to the usual care or diet alone. The evidence was assessed as moderate due to
risk of bias concerns. However, it is still considered to be strong enough evidence to be considered under this category.
No conclusions possible: low to very low-quality evidence, or insufficient evidence to comment on the effectiveness, more
evidence needed
• Moderate-quality evidence found no clear difference for insulin or oral therapy.
• Low-quality evidence suggested a benefit by a reduction in the risk of large-for-gestational age for babies born to mothers who
were treated with intensive management compared to routine care.
• Low-quality evidence found no clear evidence of a difference for induction of labour compared to expectant management; or
with glibenclamide versus acarbose; low-moderate versus moderate-high GI diet; energy- versus no energy-restricted diet; insulin
type A versus B or management with self- versus periodic-glucose monitoring; intensive management versus routine care.
• Very low-quality evidence showed no clear difference for glibenclamide versus placebo; metformin versus glibenclamide; myo-
inositol versus placebo; low- versus high-carbohydrate diet; high- versus low-unsaturated fat diet with matching calories; low-GI
diet versus high-fibre moderate-GI diet; diet + diet-related behavioural advice versus diet only; or ethnic specific diet versus standard
healthy diet; insulin versus diet; insulin regimen A versus B or managed by telemedicine versus standard care for glucose monitoring.
• Very low-quality evidence showed a reduction in the risk of large-for-gestational age for babies born to mothers with GDM
managed by post- versus pre-prandial glucose monitoring
9.0 Perinatal (fetal and neonatal death) mortality
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Summary for the risk of perinatal (fetal and neonatal death) mortality for infants born to mothers with GDM
No conclusions possible: low- to very low-quality evidence, or insufficient evidence to comment on the effectiveness, more
evidence needed
• Moderate-quality evidence found no clear difference for insulin versus diet.
• Low-quality evidence showed no clear difference for energy- versus no energy-restricted diet; lifestyle intervention versus usual
care or diet alone or insulin versus oral anti-diabetic pharmacological therapies.
• Very low-quality evidence showed no clear difference for induction of labour versus expectant management; glibenclamide
versus acarbose; metformin versus glibenclamide; exercise versus control; low-diet versus high-carbohydrate diet; insulin regimen A
versus B or managed with telemedicine versus standard care; continuous- versus self-monitoring blood glucose or self- versus
periodic-glucose monitoring
10.0 Death or serious morbidity composite
Summary for the risk of death or serious morbidity composite for infants born to mothers with GDM
No conclusions possible: low- to very low-quality evidence, or insufficient evidence to comment on the effectiveness, more
evidence needed
• Moderate-quality evidence showed no clear difference for insulin versus oral anti-diabetic pharmacological therapies.
• Moderate-quality evidence showed no clear difference exercise versus control although the direction of the effect suggested
benefit favouring exercise.
• Low-quality evidence suggested a reduction in the risk of death or serious morbidity composite outcomes for babies born to
mothers with GDM who were treated with metformin compared to glibenclamide.
• Very low-quality evidence showed an increased risk of a death or serious morbidity composite for twice daily insulin regimen
versus four times daily insulin regimen.
• Very low-quality evidence showed no clear difference for ethnic specific diet versus standard healthy diet; lifestyle intervention
versus usual care or diet alone; or managed by telemedicine versus standard care for glucose monitoring
11.0 Neonatal hypoglycaemia
Summary for the risk of neonatal hypoglycaemia for infants born to mothers with GDM
No conclusions possible: low- to very low-quality evidence, or insufficient evidence to comment on the effectiveness, more
evidence needed
• Moderate-quality evidence showed no clear difference for the risk of neonatal hypoglycaemia (not defined) for babies born to
mothers with GDM who were treated with lifestyle intervention versus usual care or diet alone
• Low-quality evidence suggested a reduced risk of neonatal hypoglycaemia for babies born to mothers with GDM who were
treated with myo-inositol versus placebo (hypoglycaemia not defined).
• Low-quality evidence showed no clear difference for metformin versus glibenclamide; insulin versus oral hypoglycaemic
pharmacological therapies or managed with self- versus periodic-glucose monitoring (hypoglycaemia not defined).
• Very low-quality evidence showed no clear difference for glibenclamide versus acarbose (hypoglycaemia defined); exercise versus
32Treatments for women with gestational diabetes mellitus: an overview of Cochrane systematic reviews (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
control (hypoglycaemia not defined); soy- versus no soy-protein diet; intensive management versus routine care (hypoglycaemia
defined); induction of labour versus expectant management; glibenclamide versus placebo; energy- diet versus no energy-restricted
diet; low- versus high-carbohydrate diet; ethnic specific diet versus standard healthy diet (hypoglycaemia not defined); insulin type
A versus B; insulin versus diet; insulin versus exercise; insulin regimen A versus B; telemedicine versus standard care for glucose
monitoring or continuous- versus self-monitoring blood glucose (hypoglycaemia defined)
12.0 Adiposity (including skinfold thickness
measurements (mm), fat mass)
Summary for the risk of adiposity for the offspring born to mothers with GDM
For the neonate
No conclusions possible: low- to very low-quality evidence, or insufficient evidence to comment on the effectiveness, more
evidence needed
• Moderate-quality evidence found no clear difference in percentage fat mass for insulin versus oral therapy.
• Low-quality evidence suggested a benefit by a reduced whole-body neonatal fat mass for lifestyle intervention compared to
usual care or diet alone. As previous reported there was also a reduction for preterm birth, birthweight and macrosomia for these
babies in the treatment group.
• Very low-quality evidence found no clear difference for skinfold sum or percentage fat mass for insulin versus oral therapy.
For the child
No conclusions possible: low- to very low-quality evidence, or insufficient evidence to comment on the effectiveness, more
evidence needed
• Moderate-quality evidence showed no clear difference for childhood BMI for lifestyle intervention versus usual care or diet
alone at four to five years of age (one trial), seven to 11 years of age (one trial) or five to 10 years of age (one trial).
• Low-quality evidence showed no clear difference for childhood total fat mass (%) at two-year follow-up for insulin versus oral
therapy.
• Very low-quality evidence showed no clear difference in childhood BMI z score for lifestyle intervention versus usual care or
diet alone at four to five years of age
13.0 Diabetes (type 2) as a child/adult
No data were reported for this outcome in any of the included
reviews.
14.0 Neurosensory disability in later childhood
Summary for the risk of neurosensory disability in later childhood in children born to mothers with GDM
No conclusions possible: low- to very low-quality evidence, or insufficient evidence to comment on the effectiveness, more
evidence needed
• Low-quality evidence suggested no clear evidence of a difference for the risk of any mild developmental delay, hearing or visual
impairment in later childhood (18 months) for children born to mothers who had GDM treated with either insulin or oral anti-
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diabetic pharmacological therapies
15.0 Number of antenatal visits or admissions
Summary for the number of antenatal visits or admissions for women with GDM
No conclusions possible: low- to very low-quality evidence, or insufficient evidence to comment on the effectiveness, more
evidence needed
• Moderate-quality evidence showed no clear difference in the number of antenatal clinic visits for lifestyle interventions versus
usual care.
• Low-quality evidence showed no clear difference in the number of clinic visits for women treated with insulin versus oral anti-
diabetic pharmacological therapies.
• Very low-quality evidence showed no clear difference in number of antenatal visits or admissions for health service use for
women with GDM who were treated with soy protein-enriched diet versus no soy protein diet or managed by telemedicine versus
standard care for glucose monitoring or self- versus periodic-glucose monitoring
16.0 Length of postnatal stay (mother)
No data were reported for this outcome in any of the included
reviews.
17.0 Length of postnatal (baby) including neonatal
intensive care unit (NICU) or special care baby unit
(SCBU)
Summary for the for length of postnatal stay (baby) including NICU or SCBU
No conclusions possible: low- to very low-quality evidence, or insufficient evidence to comment on the effectiveness, more
evidence needed
• Very low-quality evidence showed no clear difference for length of postnatal stay for babies born to mothers with GDM who
were treated with diet + diet-related behavioural advice versus diet only; insulin versus oral anti-diabetic pharmacological therapies
or those managed by continuous- versus self-monitoring of blood glucose
18.0 Costs associated with the treatment
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Summary
No conclusions possible: low- to very low-quality evidence, or insufficient evidence to comment on the effectiveness, more
evidence needed
• Moderate-quality evidence suggested increased total costs per 100 women of approximately AUD 33,000 associated with the
treatment and of approximately AUD 6000 associated costs for the families of women with GDM who were treated with lifestyle
intervention compared to usual care or diet alone (Table 12). This was mainly due to increased surveillance and increased contact
with health professionals. The table was reprinted with permission from Brown 2017b. Although these data were assessed as being
’moderate-quality’, since it was based on narrative data, it could not be classified as ’promising’.
• Very low-quality evidence suggested decreased costs for telemedicine versus standard care and self-versus periodic-monitoring.
• Very low-quality evidence suggested increased costs for insulin versus oral antidiabetic pharmacological therapy
Overall completeness and applicability of
evidence
This overview review summarised published Cochrane systematic
reviews ofRCTsof different treatments forwomenwithGDMand
the effects on relevant health outcomes. Data were available from
the included reviews for 16 of 18 pre-specifiedGRADE outcomes.
None of the included reviews reported data for the infant as an
adult. The evidence in this overview review can be applied to
women with GDM in most countries as the trials of the included
reviews were conducted in a wide range of countries, although
there was a lack of trials from lower- or middle-income countries.
Evidence from published or planned Cochrane systematic reviews
is lacking on the use of micronutrients and phytochemicals such as
cinnamon, zinc, chromium, omega-3 fatty acids, and magnesium
to treat women with GDM. There are a large number of relevant
outcomes reported in the included reviews that we were unable to
address in this overview including short- and long-term maternal,
neonatal and child outcomes. We suggest that the reader refers to
the individual Cochrane Reviews for completeness.
Quality of the evidence
The included Cochrane systematic reviews were assessed with the
AMSTAR tool and found to be high quality overall (Table 10).
We used to ROBIS tool and assessed low overall risk of bias (Table
11).
Nine of the 10 included Cochrane systematic reviews that pro-
vided data for this overview used GRADE to assess for the qual-
ity of evidence for agreed GRADE pre-specified outcomes (Biesty
2018; Brown 2017a; Brown 2017b; Brown 2017c; Brown 2017d;
Brown 2016a; Han 2017; Martis 2016a; Raman 2017). We un-
dertook theGRADE assessments forHan 2012; these are included
in Table 7; Table 8; Table 9. All included reviews assessed the
risk of bias of the included randomised trials, following the cur-
rent guidance as outlined in the Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2011). The quality of included
randomised trials in these reviews were highly variable within and
among the included reviews from high risk of bias to low risk of
bias. Evidence was often downgraded for imprecision as evidence
was based on one trial with small numbers, with wide confidence
intervals and performance bias for not blinding participants and
personnel to the intervention. Also, for many of the interventions
being assessed, masking of participants and health professionals
to the interventions was not possible. Where the authors of this
overview disagreed with GRADE judgements in the original re-
view, we altered the judgements and indicated where this had been
done (Table 4).
Potential biases in the overview process
Wewere aware that there were risks of introducing bias at all stages
of the overview review process and took steps to minimise this.
All included Cochrane systematic reviews used a published proto-
col that aimed to minimise bias and we similarly developed and
published a Cochrane overview protocol (Martis 2016b). A min-
imum of two overview authors independently assessed Cochrane
systematic reviews for inclusion, carried out data extraction and
quality assessment, and assessed the quality of the evidence using
the ARMSTAR, ROBIS and GRADE approaches. One potential
source of bias relates to authors of this overview being authors of
some of the included reviews. As pre-specified in our protocol, data
extraction and quality assessment for these reviews was carried out
by two overview authors who were not the review authors. Where
the authors of this overview disagreed with GRADE judgements
in the original review, we altered the judgements, and indicated
where this had been done (Table 4).
We undertook a comprehensive search of the Cochrane Database
of Systematic Reviews without language or date restrictions, and
identified published reviews (Figure 1), as well as planned and on-
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going reviews (registered titles and protocols) (Appendix 1).While
the included reviews were judged to be of high quality and low
risk of bias, one included review was not considered to be up-to-
date (Han 2012). It is possible that additional trials assessing inter-
ventions for women with hyperglycaemia not meeting gestational
diabetes diagnostic criteria have been published, but are not yet
included in the relevant Cochrane systematic review. Han 2012
assessed interventions for women with hyperglycaemia not meet-
ing gestational diabetes and type 2 diagnostic criteria. We agreed
to include the review in this overview, as different countries have
different diagnostic levels for confirming that a pregnant woman
has GDM. It is highly possible that women with hyperglycaemia
identified in one country as not meeting the gestational diagnos-
tic threshold for GDM would be diagnosed as having GDM in
another country. This could be a potential bias for over reporting
results.
Furthermore, recent trials of treatments for women with GDM
may have been conducted, but not yet published. Once published,
the trials may be included in the relevant Cochrane systematic
reviews. Such new evidence will be considered for inclusion in an
update of this overview.
Agreements and disagreements with other
studies or reviews
We did not identify any other overview of Cochrane systematic
reviews, and as far as we are aware, we have included all relevant
Cochrane systematic reviews assessing treatments for women with
GDM.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There is insufficient high-quality evidence about the effects on
health outcomes of relevance for women with GDM and their
babies for many of the comparisons in this overview comparing
treatment interventions for women with GDM.
Lifestyle interventions that include advice on diet and physical
activity have become the mainstay of treatment, and are recom-
mended in many national clinical practice guidelines. Many of
the lifestyle and exercise interventions reported in the reviews are
multi-component, and identifying which of any of the individ-
ual components are effective or not effective is not possible with
the evidence currently available. Most dietary treatments assessed
in the included reviews are from interventions reported as single
studies, with small numbers of participants, and only a few trials
have compared the same or similar dietary interventions.
Lifestyle changes (including as aminimumhealthy eating, physical
activity, and self-monitoring of blood sugar levels) was the only in-
tervention that showed possible health improvements for women
and their babies. Lifestyle interventions may result in fewer babies
being large. Conversely, in terms of harms, lifestyle interventions
may also increase the number of inductions. Taking insulin was
also associated with an increase in hypertensive disorders, when
compared to oral therapy. There was very limited information on
long-term health and health services costs.
For further information we suggest referring to the individual
Cochrane systematic reviews for details on the context and com-
ponents of the interventions.
Implications for research
This overview review highlights that there is insufficient evidence
tomake conclusions on the effects for many treatments for women
with GDM on relevant health outcomes.
High-quality research is required to identify the most effective
components or combination of components in lifestyle interven-
tions.
Lifestyle includingdietary interventionsmay also be beneficial, but
any effect is currently difficult to identify because of the multiple
comparisons, often small sample sizes, and few trials.
Further research should be sufficiently powered to enable impor-
tant differences in relevant core clinical outcomes, identified in this
overview, for women with GDM and their infants to be detected.
Outcomes should include long-term outcomes and the costs for
treatments, family and service costs.
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Table 1. Type of subcutaneous insulin and action towards achieving a physiological profile
Type of Insulin Action
Short- and rapid-acting insulin
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Table 1. Type of subcutaneous insulin and action towards achieving a physiological profile (Continued)
Lispro Amino acid substitutions (inverting lysine at position 28 and proline at position 29 on
the β-chain of the insulin molecule), monomeric in tissues (Magon 2014; Home 2015).
Peak insulin action achieved within 1 hour after injection and duration of action 2 to 4
hours (Durnwald 2008). Antibody levels not increased over those seen with regular human
insulin. Does not seem to cross the placenta (Jovanovic 2007)
Aspart Amino acid substitutions (proline at position 28 on the β-chain of the insulin molecule
with negatively charged aspartic acid), monomeric in tissues (Magon 2014; Home 2015)
. Peak action 31-70 minutes for 2 to 4 hours and lowers postprandial glucose levels
significantly better than human insulin (Jovanovic 2007; Magon 2014). No evidence that
insulin aspart is teratogenic (Hod 2005)
Glulisine Amino acid substitutions and reformulation, rapidly monomeric in tissues (Home 2015).
Produces peak blood glucose level at 15-20 minutes and lowers postprandial glucose levels
significantly better than human insulin (Jovanovic 2007). Adverse effects on embryo-fetal
development were only seen at animal maternal toxic dose levels inducing hypoglycaemia.
No clinical data currently available for the use of Insulin glulisine in pregnancy (Magon
2014)
Intermediate- and long-acting insulin
Neutral Protamine Hagedorn (NPH) Protamine crystal suspension (Home 2015). NPH has an onset of action approximately
after 90 minutes and a duration of action up to 16 to 18 hours (Jovanovic 2007; Magon
2014). No randomised controlled trials currently to confirm safety during pregnancy but
several case reports and one case-control study indicate no fetal morbidity or macrosomia
(Magon 2014)
Detemir Slowly absorbed and binds to albumin through a fatty-acid chain attached to the lysine at
residue B29 resulting in reduction in its free level which slows distribution to peripheral
target tissues with a duration of action of up to 24 hours (Magon 2014). Significant
improvement in fasting plasma glucose with insulin detemir during pregnancy for T1DM
without an increased incidence of hypoglycaemia, including at night. No adverse maternal
or neonatal effects were identified (Mathiesen 2012; Callesen 2013; Hod 2014). Suffecool
2015 conducted a small study including 11 women with GDM and five women with type
2 diabetes receiving detemir assessing maternal and cord blood at birth. The results showed
that while maternal detemir levels were in the expected range for adults, the hormone was
undetectable in the cord blood, indicating that detemir does not cross the human placenta.
Larger studies and randomised controlled trials are needed to confirm
Glargine Slowly absorbed and replaces the human insulin amino acid asparagine at position A21 of
the A chain with glycine and two arginine molecules are added to one end (C-terminal) of
the B-chain with onset of action approximately after 90 minutes of injection and lasting
for about 24 hours (Price 2007; Ansar 2013). Studies in non-pregnant participants have
indicated that insulin glargine has a smooth peak-free profile of action, with a reduced
incidence of nocturnal hypoglycaemia and better glycaemic control (Graves 2006; Magon
2014;Woolderink 2005). Concerns regarding insulin glargine’s use in pregnancy are raised
from case-control, case reports and retrospective studies (including women with T1DM,
T2DM and some with GDM) that have shown six- to eight-fold increased affinity for
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Table 1. Type of subcutaneous insulin and action towards achieving a physiological profile (Continued)
insulin growth factor (IGF)-1 receptor compared with human insulin. However, results of
these studies found no association with increased fetal macrosomia or neonatal morbidity
with the use of glargine in pregnancy (Bolli 2000; Egerman2009; Lv 2015; Pöyhönen-Alho
2007). No randomised controlled trials currently to confirm safety during pregnancy
AbbreviationL GDM - gestational diabetes mellitus; T1DM - type 1 diabetes mellitus; T2DM - type 2 diabetes mellitus
Table 2. Characteristics of included reviews
Review ID Date of search and
date assessed as up
to date
No. included tri-
als (countries, de-
sign and publica-
tion years)
No. of participants
in included trials
Inclusion and ex-
clusion criteria for
types of partici-
pants
Interventions and
comparisons
Biesty 2018
Elective delivery
in diabetic pregnant
women
Search:
15 August 2017
Up-to-date: 15 Au-
gust 2017
Up-to-date
Trials: 1 RCT
Countries: Mul-
ticentre (Israel, Italy
and Slovenia)
Published:
2017: 1 RCT
425 women 425 ba-
bies no children
Women diagnosed
with gestational dia-
betes. Women with
pre-gestational dia-
betes were excluded
and trials where data
for women with
GDM and pre-ges-
tational data could
not be separated
Planned birth (in-
duction of labour or
caesarean section) at
or near term ges-
tation versus expec-
tant management
Brown 2017a
Oral anti-dia-
betic pharmacologi-
cal therapies for the
treatment of women
with gestational dia-
betes
Search:
16 May 2016
(databases);
14 May 2016 (clin-
ical trial registries)
Up-to-date: 14 May
2016
Up-to-date
Trials: 11 RCTs
Countries:
Brazil
(3 RCTs); India
(2 RCTs); Israel
(1 RCT);
UK
(1 RCT);
South Africa (1
RCT);
USA
(3 RCTs)
Published:
1971: 1 RCT
2005: 1 RCT
2006: 1 RCT
2010: 1 RCT
2012: 1 RCT
2014: 1 RCT
2015: 5 RCT
1487 women
1487 babies
no children
Women diagnosed
with GDM (diag-
nosis as defined by
the individual trial)
. Women with type
1 or type 2 diabetes
diagnosed prior to
pregnancy were ex-
cluded
Compar-
ing oral pharmaco-
logical anti-diabetic
agents used during
pregnancy (in-
cluding metformin,
glibenclamide, acar-
bose, tolbutamide,
chlorpropamide or
combination
of these therapies)
with either placebo
or no pharmaco-
logical treatment or
one agent versus an-
other agent or ver-
sus another inter-
vention but not in-
sulin
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Table 2. Characteristics of included reviews (Continued)
Brown 2017b
Lifestyle
interventions for the
treatment of women
with gestational dia-
betes
Search:
14 May 2016
Up-to-date: 14 May
2016
Up-to-date
Trials: 15 RCTs
Country:
Australia
(1 RCT);
Australia and UK
(1 RCT);
Canada
(1 RCT);
China
(2 RCTs);
Italy
(1 RCT);
Iran
(2 RCTs);
Thailand
(1 RCT);
UK
(1 RCT); United
Arab Emirates
(1 RCT); USA
(4 RCTs)
Published:
1989: 1 RCT
1997: 1 RCT
2000: 1 RCT
2003: 1 RCT
2004: 1 RCT
2005: 1 RCT
2008: 2 RCT
2009: 1 RCT
2011: 1 RCT
2014: 5 RCT
4501 women 3768
babies 767 children
Women diagnosed
with GDM (diag-
nosis as defined by
the individual trial).
Women
with known type 1
or type 2 diabetes
were excluded
Comparing lifestyle
interventions
(a combination of at
least two or more,
including standard
dietary advice, with
or without adjunc-
tive pharmacother-
apy (oral anti-dia-
betic pharmacologi-
cal therapies or in-
sulin)) verus stan-
dard care, expectant
management or an-
other lifestyle inter-
ventions or combi-
nationof lifestyle in-
terventions
Intensive inter-
vention were de-
fined in included
reviews as: standard
dietary advice,
glucose monitoring
five days a week,
HbA1c monthly,
serial ultrasound,
Doppler studies,
cardiotocography
(CTG monitoring)
compared with
usual care (dietary
advice, HbA1c
monthly); or indi-
vidualised-dietary
advice, advice on
self-monitoring of
blood glucose) com-
pared with usual
care; or structured
pharmaceutical
care, structured
education, self-
monitoring of
blood glucose com-
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Table 2. Characteristics of included reviews (Continued)
pared with usual
care (no additional
education or phar-
macist counselling)
; or individualised
advice on diet,
exercise and breast-
feeding compared
with usual care
(printed material
only in prenatal
and postnatal
period; or dietary
counselling, self-
glucose monitoring,
bi-weekly review,
monitoring of fetal
growth, amniotic
volume and cardiac
size compared with
usual care (no
dietary counselling)
; or diet and exercise
advice, self-moni-
toring of blood glu-
cose, insulin if re-
quired, fortnightly
specialist review)
versus usual care
(no details). Other
interventions used
were:Group session
on education and
diet followed by
specific dietary
advice compared
with group session
on education and
diet followed by
standard clinical
care and advice; or
diet alone compared
with diet plus
supervised exer-
cise; or relaxation
training (education,
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Table 2. Characteristics of included reviews (Continued)
breathing, muscle
relaxation, mental
imagery, and con-
tacted by telephone
by the researcher
three times per
week) compared
with usual care (no
details); or nutri-
tional counselling
and diet therapy ±
insulin plus self-
monitoring of
blood glucose com-
pared with usual
care ± insulin plus
self-monitoring of
blood glucose; or
intensive education
and spiritual inter-
vention compared
with standard edu-
cation; or face-to-
face education (risks
of GDM, training
on glycaemic con-
trol, exercise, diet,
medication and
follow-up) com-
pared with usual
care (no details); or
individualised and
group dietary and
physical activity
counselling, self-
monitoring blood
glucose compared
with usual care
(group education
on exercise and
physical activity, not
specifically taught
blood glucose
self-monitoring)
; or mindfulness
eating and yoga
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Table 2. Characteristics of included reviews (Continued)
compared with
standard diabetes
care (no details)
; or combined
behavioural and
exercise compared
with individualised-
dietary advice alone
Brown 2017c
Exercise for preg-
nant women with
gestational diabetes
for improving ma-
ternal and fetal out-
comes
Search:
27 August
2016 (and 18 Au-
gust 2016 for trial
registries)
Up-to-date:
18 August 2016
Up-to-date
Trials: 11 RCTs
Countries:
Australia (1RCT);
Brazil
(3 RCTs); Canada
(2 RCTs);
Italy
(1 RCT);
Thailand
(1 RCT);
USA
(3 RCTs)
Published:
1989: 1 RCT
1991: 1 RCT
1997: 1 RCT
2004: 1 RCT
2010: 1 RCT
2012: 1 RCT
2014: 4 RCT
2015: 1 RCT
638 women 638 ba-
bies
no children
Pregnant women di-
agnosed with GDM
(as defined by trial-
ists).
Women
with known pre-
gestational diabetes
(type 1 or type 2 dia-
betes) were excluded
Compar-
ing any type of ex-
ercise programme (±
standard care) at any
stage of pregnancy
versus standard care
or another interven-
tion
Exercises sum-
marised from re-
views included indi-
vidualised exercises
follow-up by kine-
siologist; timed ex-
ercises 2 to 4 times
weekly with or with-
out supervision and
telephone coun-
selling; brisk walk-
ing or resistance ex-
ercises: 30 minutes
circuit
workout with elas-
tic-band ex-
ercises; exercises in
lab conditions on
cycles; home-based
exercises; supervised
arm
ergometer training
plus diet; low-inten-
sity aerobic train-
ing in cycle-ergome-
ter and mindfulness
eating and yoga ex-
ercise
Brown 2017d
Insulin for the treat-
ment
of women with ges-
Search:
1 May 2017
Up-to-date
1 May 2017
Trials: 53 RCTs
Countries:
Australia
7381 women
6435 babies
674 children
Women diagnosed
with GDM (diag-
nosis as defined by
Insulin with met-
formin; insulin with
glibenclamide; in-
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Table 2. Characteristics of included reviews (Continued)
tational diabetes Up-to-date (1 RCT);
Australia and New
Zealand
(1 RCT);
Brazil
(3 RCTs);
Canada
(1 RCT);
Egypt
(3 RCTs);
Finland
(3 RCTs);
Ghana
(1 RCT);
India
(8 RCTs);
Iran
(5 RCTs);
Israel
(1 RCT);
Italy
(2 RCTs);
Malaysia
(1 RCT);
Pakistan
(3 RCTs);
Poland
(1 RCT);
South Africa (1
RCT);
Sweden
(1 RCT);
Turkey
(1 RCT);
Unkown
(1 RCT);
USA
(15 RCTs)
Published:
1971 1 RCT
1975 2 RCTs
1978 1 RCT
1985 1 RCT
1990 1 RCT
1993 1 RCT
1999 2 RCTs
2000 1 RCT
2002 2 RCTs
the individual trial)
. Women with type
1 or type 2 diabetes
diagnosed prior to
pregnancy were ex-
cluded
sulin with acarbose;
insulin with a com-
bina-
tion of metformin
and glibenclamide;
one preparation of
insulin with another
preparation of in-
sulin; insulin with
diet; insulinwith ex-
ercise; different reg-
imens of insulin
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Table 2. Characteristics of included reviews (Continued)
2003 2 RCT
2005 2 RCTs
2007 7 RCTs
2008 3 RCTs
2009 1 RCT
2010 1 RCT
2011 2 RCTs
2012 3 RCTs
2013 5 RCTs
2014 5 RCTs
2015 5 RCTs
2016 5 RCTs
Brown 2016a
Dietary supplemen-
tation with myo-in-
osi-
tol inwomenduring
pregnancy for treat-
ing gestational dia-
betes
Search:
14 May 2016
Up-to-date: 14 May
2016
Up-to-date
Trials: 2 RCTs
Countries:
Italy
(2 RCTs)
Published:
2011: 1 RCT
2013: 1 RCT
159 women 159 ba-
bies no children
Pregnant
women with a diag-
nosis of GDM (as
defined by trialists)
. Women with pre-
existing type 1 or
type 2 diabetes were
excluded
Comparing
any dose of myo-in-
ositol, alone or in a
combination prepa-
ration
for the treatment of
women with GDM
with women who
received no treat-
ment, placeboor an-
other intervention
The two included
trials assessed 4 g
myo-inositol + 400
µg folic acid orally
per day and exercise
and dietary advice
versus placebo 400
µg folic acid orally
per day and exercise
and dietary advice
Han 2017
Different types of
dietary advice for
women with gesta-
tional diabetes mel-
litus
Search:
8 March 2016
Up-to-date: 22
March 2016
Up-to-date
Trials: 19 RCTs
Countries: Australia
(3 RCTs),
Canada
(2 RCTs),
China
(2 RCTs), Denmark
(1 RCT),
Italy
(2 RCTs); Iran
(4 RCTs); Mexico
(1 RCT); Poland
(1 RCT); Spain
(1 RCT); USA
1398 women 1398
babies no children
Women with GDM
regardless of ges-
tation, age, parity
or plurality. Exclu-
sion criteria not de-
scribed
Comparing any
dietary advice
with each other;
comparing two
or more forms
of the same type
of dietary advice
with each other
and/or different
intensities of dietary
interventions with
each other. These
trials include: low-
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Table 2. Characteristics of included reviews (Continued)
(2 RCTs)
Published:
1990: 1 RCT
1995: 1 RCT
1997: 1 RCT
2000: 1 RCT
2001: 1 RCT
2007: 1 RCT
2009: 1 RCT
2010: 1 RCT
2011: 2 RCT
2012: 1 RCT
2013: 3 RCT
2014: 2 RCT
2015: 3 RCT
moderate GI diet
versus moderate-
high GI diet, en-
ergy-restricted diet
versus no energy-re-
stricted diet, DASH
(DietaryApproaches
to
StopHypertension)
diet versus control
diet with matching
macronutrient
contents, low-
carbohydrate diet
versus high-car-
bohydrate diet,
high unsaturated
fat diet versus low
unsaturated diet
with
match-
ing calories, low-GI
diet versus high-fi-
bre moderate-
GI diet, diet recom-
mendation anddiet-
related behavioural
advice ver-
sus diet recommen-
dation, soy protein-
enriched diet ver-
sus no soy protein
diet, high-fibre ver-
sus stan-
dard-fibre diet, eth-
nic-specific diet ver-
sus standard healthy
diet
Han 2012
Interven-
tions for pregnant
women with hyper-
glycaemia not meet-
ing gestational dia-
betes and type 2 dia-
betes diagnostic cri-
teria
Search:
30 September 2011
Up-to-date: 21
November 2011
Not up-to-date
Trials: 4 RCTs
Countries:
Canada
(1 RCT); Italy
(1 RCT);
USA
(2 RCTs)
Published:
1989: 1 RCT
1999: 1 RCT
543 women 543 ba-
bies no children
Pregnant
women with hyper-
glycaemia, regard-
less of gestation, age,
parity or plurality,
who do not meet
the diagnostic crite-
ria for GDM based
on OGTT results
defined by trialists.
Comparing
any form of man-
agement for women
with pregnancy hy-
per-
glycaemia not meet-
ing GDM criteria
with standard ante-
natal care, included
any type of dietary
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2005: 1 RCT
2011: 1 RCT
Women with pre-
ex-
isting diabetes mel-
litus and previously
treated GDM were
not eligible
advice (standard or
individualised), ex-
ercise and lifestyle
advice (standard or
individualised) and
drug treatment in-
cluding insulin and
oral drugs with one
type of interven-
tion compared with
standard antenatal
care
Martis 2016a
Different intensities
of glycaemic con-
trol for women with
gestational diabetes
mellitus
Search:
31 January 2016
Up-to-date: 31 Jan-
uary 2016
Up-to-date
Trials: 1 RCT
Country: Canada
Published:
1998: 1 RCT
180 women 180 ba-
bies no children
All pregnantwomen
diagnosed
with GDM (screen-
ing and subsequent
diagnosis and diag-
nos-
tic criteria as identi-
fied in the individ-
ual trials). Women
with known pre-ex-
isting type 1 or type
2 diabetes are ex-
cluded
Comparing
any glycaemic treat-
ment targets used to
guide treatment for
women with GDM
with another gly-
caemic target
Strict intensity of
glycaemic control is
defined in this one
trial as: pre-pran-
dial 5.0mmol/L (90
mg/dL) and at one-
hour postprandial:
6.7 mmol/L (120
mg/dL). Less strict
glycaemic control is
defined as: pre-
prandial 5.8 mmol/
L (104 mg/dL) and
at one-hour post-
prandial 7.8 mmol/
L (140 mg/dL)
Raman 2017
Different methods
and settings for glu-
cose monitoring for
gestational diabetes
during pregnancy
Search:
30 September 2017
Up-to-date: Octo-
ber 2017
Up-to-date
Trials: 11 RCTs
Countries:
Canada
(1 RCT); China
(1 RCT); Finland
(1 RCT); Ireland
(1 RCT); Italy
(1 RCT); Spain
(1 RCT);
USA
(5 RCTs)
Published:
1272 women Women diagnosed
with GDM during
their current preg-
nancy, as defined by
individual trialists.
Women of any age,
gestation and par-
ity were included.
Women with pre-
existing type 1 or
type 2 diabetes were
excluded
Comparing differ-
ent methods (in-
cluding timing and
frequency) or set-
tings, or both, for
blood glucose mon-
itoring
Com-
pared telemedicine
versus standard care;
self monitoring ver-
sus periodic glucose
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1995: 1 RCT
1997: 1 RCT
2002: 1 RCT
2003: 1 RCT
2007 2 RCT
2009: 1 RCT
2010: 1 RCT
2012: 1 RCT
2015: 1 RCT
2016: 1 RCT
monitoring; contin-
uous glucose mon-
itoring system ver-
sus self-monitoring;
modem verus tele-
phone transmission;
postprandial versus
pre-prandial glucose
monitoring
Abbreviations: GDM - gestational diabetes mellitus; RCT - randomised controlled trial; OGTT oral glucose tolerance test; GI gas-
trointestinal; HbA1c Haemoglobin A1c
Table 3. Pre-specified overview outcomes in included reviews
Included
review
Biesty
2018
Brown
2017a
Brown
2017b
Brown
2017c
Brown
2017d
Brown
2016a
Han
2017
Han
2012
Martis
2016a
Raman
2017
Maternal
Hyper-
tensive
disorders
of preg-
nancy
(in-
cluding
preeclamp-
sia, preg-
nancy-
induced
hyper-
tension,
eclampsia
as de-
fined in
reviews)
X
√ √ √ √ √ √ √
sec-
ondary
outcome
and pre-
eclampsia
only
in this re-
view
√ √
Mode of
birth
(cae-
sarean
section)
√ √
called
’cae-
sarean
section’ in
the
review
√ √ √ √
called
’cae-
sarean
section’ in
the
review
√ √
includes
also nor-
mal vagi-
nal birth
and oper-
ative vagi-
nal birth
√
sec-
ondary
outcome
called
’cae-
sarean
section’ in
√
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Table 3. Pre-specified overview outcomes in included reviews (Continued)
the
review
Develop-
ment of
type 2 di-
abetes
X
√ √ √ √ √ √
X
√ √
Induc-
tion of
labour
X
√ √ √ √ √ √ √ √ √
Perineal
trauma/
tearing
√
(called
’in-
tact per-
ineum)’
in review
√ √ √ √ √ √ √ √ √
Post-
natal de-
pression
√ √ √ √ √ √ √
X
√ √
Postnatal
weight re-
tention or
return to
pre-preg-
nancy
weight
X
√ √ √ √ √ √ √ √ √
Develop-
ment of
type 2 di-
abetes
X
√
X
√ √
X
√ √
X
√
Neonatal/child/adult
Perinatal
(fetal and
neona-
tal death)
and later
infant
mortality
√ √ √ √
does not
include
later in-
fant mor-
tality
√ √
called
’perinatal
mortal-
ity (still-
birth and
neona-
tal mor-
tality)’
in review;
does not
√
does not
include
later in-
fant mor-
tality
√
does not
include
later in-
fant mor-
tality
√
later in-
fant mor-
tality not
stated
√
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Table 3. Pre-specified overview outcomes in included reviews (Continued)
include
later in-
fant mor-
tality
Large-
for-gesta-
tional age
(as
defined in
reviews)
√ √ √ √ √ √ √ √ √ √
Death
or serious
morbid-
ity com-
posite (as
defined in
reviews,
e.g. peri-
natal
or infant
death,
shoul-
der dysto-
cia, bone
fracture
or nerve
palsy)
X
√ √ √ √ √ √
X
√ √
Neu-
rosensory
disabil-
ity in later
child-
hood (as
defined in
reviews)
x
√ √ √ √ √
called
’neu-
rosensory
disability’
in this re-
view
√
X
√ √
Adiposity
neonate
(in-
cluding
skinfold
thickness
measure-
ments
(mm),
fat mass);
X
√ √ √ √ √ √ √
three sep-
arate out-
comes:
BMI, fat
mass/fat-
free mass,
skinfold
thickness
√ √
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Table 3. Pre-specified overview outcomes in included reviews (Continued)
Adiposity
child (in-
cluding
BMI,
skinfold
thickness,
fat mass);
Adiposity
- adult
(includ-
ing BMI,
skinfold
thickness,
fat mass)
measure-
ments
Neona-
tal hypo-
glycaemia
(as
defined in
the
reviews)
√ √ √ √ √ √ √ √ √ √
Diabetes
(type
2) child,
adult
X
√ √ √ √ √ √ √ √ √
Health service use
Number
of antena-
tal visits
or admis-
sions
X
√ √ √ √ √ √ √
visits
only, not
admis-
sions
√ √
Length of
stay
in neona-
tal inten-
sive
care unit
or special
care baby
unit
X
√ √ √
called
’duration’
√
X X X X
√
Length of
postnatal
stay (ma-
ternal)
X
√ √ √
called
’duration
of ma-
√ √ √ √ √ √
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Table 3. Pre-specified overview outcomes in included reviews (Continued)
ternal and
neonatal
hospital
stay(ante-
natal,
neona-
tal, post-
natal)’
Length of
post-
natal stay
(baby)
√ √ √ √
called
’duration
of ma-
ternal and
neonatal
hospital
stay(ante-
natal,
neona-
tal, post-
natal)’
√ √ √ √ √ √
Costs as-
soci-
ated with
the treat-
ment
X
√
called
’costs as-
soci-
ated with
the inter-
vention’
√ √
called
’costs as-
soci-
ated with
the inter-
vention’
√
called
’costs as-
soci-
ated with
the inter-
vention’
√ √ √
only
’costs
for blood
glucose
monitor-
ing dur-
ing preg-
nancy’
√ √
√
= pre-specified overview review outcome included in the Cochrane systematic review
X = pre-specified overview review outcome NOT included in the Cochrane systematic review
Table 4. Summary of main results table
Overview
Review
Outcomes
High-quality evidence Moderate-quality evidence Low-quality evidence
or
very low-quality evidence
Primary
outcomes
- maternal
Benefit Harm No clear
difference
Benefit Harm No clear
difference
Benefit Harm No clear
difference
1.0
Hyperten-
Insulin ver-
sus oral
Met-
formin ver-
Gliben-
clamide
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Table 4. Summary of main results table (Continued)
sive disor-
ders of
pregnancy
(including
pre-
eclamp-
sia, preg-
nancy-in-
duced hy-
perten-
sion,
eclampsia
1.1
Any hyper-
tensive dis-
orders of
preg-
nancy, not
defined
therapy
(Brown
2017d)
sus gliben-
clamide
(Brown
2017a)
ver-
sus placebo
(Brown
2017a)
Very low
1.2 Preg-
nancy-in-
duced hy-
pertension
Met-
formin ver-
sus gliben-
clamide
(Brown
2017a)
Gliben-
clamide
ver-
sus placebo
(Brown
2017a)
Low
Low- versus
high-
carbohy-
drate diet (
Han 2017)
Very low*
High- ver-
sus low-un-
saturated
fat diet
with
match-
ing calories
(Han
2017)
Very low*
Ethnic
specific diet
versus stan-
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Table 4. Summary of main results table (Continued)
dard
healthy diet
(Han
2017) Very
low*
Insulin reg-
imen A ver-
sus
B (Brown
2017d)*
Low
1.3 Preg-
nancy-in-
duced hy-
perten-
sion or pre-
eclampsia
combined
Gliben-
clamide
ver-
sus placebo
(Brown
2017a)
Low
Low-mod-
erate versus
moder-
ate-high GI
diet
(Han
2017) Very
low
Telemedicine
versus
standard
care for
glucose
monitoring
(Raman
2017) Very
low
1.4 Pre-
eclampsia
DASH
1 diet ver-
sus control
diet with
matching
macronu-
trient con-
tents
Met-
formin ver-
sus gliben-
clamide
(Brown
2017a)
Very low
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(Han
2017)*
Insulin ver-
sus oral
therapy
(Brown
2017d)
En-
ergy- versus
no energy-
restricted
diet (Han
2017)
Low
High- ver-
sus low-un-
saturated
fat diet
with
matching
calories (
Han 2017)
Low*
Soy protein
versus
no soy pro-
tein diet
(Han
2017) Very
low*
Lifestyle in-
tervention
versus usual
care or diet
alone
(Brown
2017b)
Low
Exercise
versus con-
trol
(Brown
2017c)
Low
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Intensive
manage-
ment
versus rou-
tine care (
Han 2012)
Low*
Insulin
type A ver-
sus
B (Brown
2017d)
Low*
Self- versus
periodic-
glucose
monitor-
ing (Raman
2017) Very
low
Post- versus
pre-pran-
dial glucose
monitor-
ing (Raman
2017) Very
low
1.5
Eclampsia
Low-mod-
erate versus
moder-
ate-high GI
diet (Han
2017) Very
low
2.0 Cae-
sarean sec-
tion
Exercise
versus con-
trol
(Brown
2017c)
Insulin ver-
sus oral
therapy
(Brown
2017d)
In-
duction of
labour ver-
sus expec-
tant man-
agement
(Biesty
2018) Very
low
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Insulin
type A ver-
sus
B (Brown
2017d)*
Gliben-
clamide
ver-
sus placebo
(Brown
2017a)
Very low
Met-
formin ver-
sus gliben-
clamide
(Brown
2017a)
Low
Gliben-
clamide
versus acar-
bose
(Brown
2017a)
Low
Low-mod-
erate versus
moder-
ate-high GI
diet (Han
2017) Very
low
En-
ergy- versus
no energy-
restricted
diet (Han
2017) Low
DASH
1 diet ver-
sus control
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diet with
matching
macronu-
trient con-
tents (Han
2017)
Low*
Low- versus
high-
carbohy-
drate diet (
Han 2017)
Low*
High- ver-
sus low-un-
saturated
fat diet
with
match-
ing calories
(Han
2017) Very
low*
Low-
GI diet ver-
sus high-fi-
bre moder-
ate-GI diet
(Han
2017) Very
low*
Diet + diet-
related be-
havioural
advice ver-
sus diet
only (Han
2017) Very
low*
Soy- versus
no soy-pro-
tein diet
(Han
2017) Very
low*
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Ethnic
specific diet
versus stan-
dard
healthy diet
(Han
2017) Very
low*
Lifestyle in-
tervention
versus usual
care or diet
alone
(Brown
2017b)
Low
Intensive
manage-
ment ver-
sus routine
care (Han
2012)
Very low*
Strict
2 versus less
strict
glycaemic
con-
trol (Martis
2016a)
Very low
Insulin reg-
imen A ver-
sus
B (Brown
2017d)
Very low*
Insulin
versus exer-
cise (Brown
2017d)
Very low*
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Insulin ver-
sus diet (
Brown
2017d)
Very low*
Post- versus
pre-pran-
dial glucose
monitor-
ing (Raman
2017) Very
low*
Self- versus
pe-
riodic- glu-
cose moni-
tor-
ing (Raman
2017) Low
Telemedicine
versus stan-
dard care
glucose
monitoring
(Raman
2017) Very
low
Continu-
ous- versus
self-
monitor-
ing (Raman
2017) Very
low
3.0 Devel-
opment of
type 2 dia-
betes
3.
1.1OGTT
3 Test)
for diagno-
sis of type
High- ver-
sus low-un-
saturated
fat diet
with
match-
ing calories
(Han
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2 diabetes
at one to
two weeks
post-
partum or
at four to
13 months
postpar-
tum
2017) Very
low*
3.1.
2 OGTT3
for diagno-
sis of type 2
diabetes at
three
months
postpar-
tum
Low-
GI diet ver-
sus high fi-
bre moder-
ate-GI diet
(Han
2017)
Very low*
3.1.
3 Diagnos-
tic test and
time frame
not
defined
Lifestyle in-
tervention
versus usual
care or diet
alone
(Brown
2017b)
Low3.
1.4OGTT
3 test 6-8
weeks
postpar-
tum
Insulin ver-
sus oral
ther-
apy (Brown
2017d)
3.1.5 Up
to 15 years
follow-up.
Diagnos-
tic test not
defined
Insulin ver-
sus diet (
Brown
2017d)
Very low*
4.
0 Perineal
trauma/
tearing
Lifestyle in-
terven-
tion versus
usual care/
diet alone (
Brown
2017b)
Induction
of labour
verus
expec-
tant man-
agement (
Biesty
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2018)
Low*
Met-
formin ver-
sus gliben-
clamide
(Brown
2017a)
Low
Gliben-
clamide
ver-
sus placebo
(Brown
2017a)
Very low
Continu-
ous- versus
self- moni-
tor-
ing (Raman
2017) Very
low*
Post- versus
pre-pran-
dial glucose
monitor-
ing (Raman
2017) Very
low*
5.0 Post-
natal
weight re-
tention or
return to
pre-
pregnancy
weight
Exercise
versus con-
trol
(Brown
2017c) (at
follow-up,
timing not
defined)
Lifestyle in-
tervention
versus usual
care or diet
alone
(Brown
2017b)
(at
12 months
post par-
tum) Low
Lifestyle in-
tervention
versus usual
care or diet
alone
(Brown
2017b)
(at 6 weeks
post par-
tum) Low
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Low-
GI diet ver-
sus high-fi-
bre moder-
ate-GI diet
(Han
2017)
(at 3
months
post par-
tum) Very
low*
Lifestyle in-
tervention
versus usual
care or diet
alone
(Brown
2017b)
(at 7
months
post par-
tum) Very
low
Insulin ver-
sus oral
ther-
apy (Brown
2017d) (up
to 1-year
postpar-
tum) Low
6.
0 Postna-
tal depres-
sion
Lifestyle in-
tervention
versus usual
care or diet
alone
(Brown
2017b)
Low
7.0 In-
duction of
labour
Lifestyle in-
tervention
versus usual
care or diet
alone
Gliben-
clamide
ver-
sus placebo
(Brown
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(Brown
2017b)*
Insulin ver-
sus oral
ther-
apy (Brown
2017d)
2017a)
Very low
Met-
formin ver-
sus gliben-
clamide
(Brown
2017a)
Low
Low-mod-
erate versus
moder-
ate-high GI
diet
(Han
2017) Low
En-
ergy- versus
no energy-
restricted
diet (Han
2017)
Low
Exercise
versus con-
trol (Brown
2017c)
Very low$
Intensive
manage-
ment
versus rou-
tine care (
Han 2012)
* Very low
Telemedicine
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versus
standard
care for
glucose
monitoring
(Raman
2017) Very
low
8.0 Large-
for-gesta-
tional
age (LGA)
(defined
as > 90th
percentile
in all in-
cluded re-
views)
Lifestyle in-
tervention
versus usual
care or diet
alone
(Brown
2017b)
Insulin ver-
sus oral
ther-
apy (Brown
2017d)
Intensive
manage-
ment ver-
sus routine
care
(
Han 2012)
Low*
In-
duction of
labour ver-
sus expec-
tant man-
agement (
Biesty
2018)
Low
Gliben-
clamide
ver-
sus placebo
(Brown
2017a)
Very low
Met-
formin ver-
sus gliben-
clamide
Brown
2017a)
Low
Gliben-
clamide
versus acar-
bose
(Brown
2017a)
Very low$
Myo-inos-
itol versus
placebo4
(Brown
2016a)
Very low$
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Low-mod-
erate versus
moder-
ate-high GI
diet
(Han
2017)
Very low
En-
ergy- versus
no energy-
restricted
diet (Han
2017)
Low
Low- versus
high-car-
bohydrate
diet
(Han
2017) Very
low*
High- ver-
sus low-un-
saturated
fat diet
with
match-
ing calories
(Han
2017) Very
low
Low-
Gi diet ver-
sus high-fi-
bre moder-
ate-GI diet
(Han
2017)*
Very low
Diet + diet-
related be-
havioural
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advice ver-
sus diet
only (Han
2017) Very
low*
Ethnic
specific diet
versus stan-
dard
healthy diet
(Han
2017) Very
low*
Telemedicine
versus
standard
care for
glucose
monitoring
(Raman
2017) Very
low
Self- versus
periodic-
glucose
monitor-
ing (Raman
2017) Low
Continous-
versus self
monitoring
blood glu-
cose
(Raman
2017) Very
low
Post- versus
pre-pran-
dial glucose
monitor-
ing (Raman
2017) Very
low*
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Table 4. Summary of main results table (Continued)
Insulin
type A ver-
sus
B (Brown
2017d)
Low*
Insulin ver-
sus diet (
Brown
2017d)
Very low*
Insulin reg-
imen A ver-
sus
B (Brown
2017d)
Very low*
9.
0 Perina-
tal death
(fetal and
neona-
tal death)
only
Insulin ver-
sus diet (
Brown
2017d)*
In-
duction of
labour ver-
sus expec-
tant man-
agement
(Biesty
2018) Very
low
Met-
formin ver-
sus gliben-
clamide
(Brown
2017a)
Very low
Gliben-
clamide
versus acar-
bose
(Brown
2017a)
Very low$
En-
ergy- versus
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Table 4. Summary of main results table (Continued)
no energy-
restricted
diet
(Han
2017) Low
Low- versus
high-car-
bohydrate
diet
(Han
2017) Very
low*
Lifestyle in-
tervention
versus usual
care or diet
alone
(Brown
2017b)
Low
Exercise
versus con-
trol
(Brown
2017c)
Very low$
Telemedicine
versus
standard
care for
glucose
monitoring
(Raman
2017) Very
low
Self- versus
periodic-
glucose
monitor-
ing (Raman
2017) Very
low
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Table 4. Summary of main results table (Continued)
Continu-
ous- versus
self-
monitoring
blood glu-
cose
Raman
2017 Very
low
Insulin ver-
sus oral
ther-
apy (Brown
2017d)
Low
Insulin reg-
imen A ver-
sus
B (Brown
2017d)
Very low*
10.
0Death or
serious
morbidity
com-
posite (as
defined in
reviews, e.
g. perina-
tal or in-
fant
death,
shoul-
der dysto-
cia, bone
fracture or
nerve
palsy)
Exercise
versus con-
trol
(Brown
2017c)
Insulin ver-
sus oral
therapy
(Brown
2017d)
Met-
formin ver-
sus gliben-
clamide
(Brown
2017a)
Low
Insulin reg-
imen A ver-
sus
B (Brown
2017d)
Very low*
Ethnic
specific diet
versus stan-
dard
healthy diet
(Han
2017) Very
low*
Lifestyle in-
tervention
versus usual
care or diet
alone
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Table 4. Summary of main results table (Continued)
(Brown
2017b)
Very low
Telemedicine
versus
standard
care for
glucose
monitoring
(Raman
2017) Very
low
11.
0 Neona-
tal hypo-
glycaemia
11.
1 Neonatal
hypogly-
caemia not
defined
Lifestyle in-
tervention
versus usual
care or diet
alone
(Brown
2017b)
Myo-in-
ositol ver-
sus placebo
4 (Brown
2016a)
Low
In-
duction of
labour ver-
sus expec-
tant man-
agement (
Biesty
2018) Very
low*
Gliben-
clamide
versus
placebo
(Brown
2017a)
Very low
Energy re-
stricted diet
versus no
energy re-
stricted diet
(Han
2017) Very
low
Low-carbo-
hydrate
diet versus
high-
carbohy-
drate diet (
Han 2017)
Very low*
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Table 4. Summary of main results table (Continued)
Ethnic
specific diet
versus stan-
dard
healthy diet
(Han
2017) Very
low*
Exercise
versus con-
trol
(Brown
2017c)
Very low$
Self-
versus peri-
odic-glu-
cose moni-
tor-
ing (Raman
2017) Low
Insulin ver-
sus diet
(Brown
2017d)*
Very low
11.2.
Neonatal
hypogly-
caemia de-
fined
Met-
formin ver-
sus gliben-
clamide
(BGL < 2.
2 mmol/L;
< 40 mg/
dL) (Brown
2017a)
Low
Gliben-
clamide
versus acar-
bose
(BGL < 2.2
mmol/L; <
40 mg/dL)
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Table 4. Summary of main results table (Continued)
(Brown
2017a)
Very low$
Soy- versus
no soy-pro-
tein diet
(BGL < 1.
7 mmol/L
(< 30.6mg/
dL) (Han
2017) Very
low*
Intensive
manage-
ment
versus rou-
tine care ev-
idence
(BGL < 1.7
mmol/L in
two consec-
utive mea-
sure-
ments (one
trial) and as
BGL < 1.
94 mmol/L
(one trial))
(Han
2012) Very
low*
Telemedicine
versus
standard
care for
glucose
monitoring
(Raman
2017) Very
low
Defined as
<2.6
mmol/L in
one trial
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Table 4. Summary of main results table (Continued)
Continu-
ous- versus
self-
monitoring
blood glu-
cose
(Raman
2017) Very
low
Defined as
≤ 2.5
mmol/L in
one trial
Post- versus
pre-pran-
dial glucose
monitor-
ing (Raman
2017) Very
low*
Defined as
≤ 30 mg/
dL requir-
ing
glucagon or
dextrose in-
fusion
in first four
days after
birth
Insulin ver-
sus oral
ther-
apy (Brown
2017d)
Low
Defini-
tions varied
between
trials.
Insulin
type A ver-
sus
B (Brown
2017d)
Very low*
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Table 4. Summary of main results table (Continued)
Insulin ver-
sus diet (
Brown
2017d)
Very low*
Insulin
versus exer-
cise (Brown
2017d)
Very low*
Insulin reg-
imen A ver-
sus
B (Brown
2017d)
Very low*
12.0 Adi-
posity (in-
clud-
ing skin-
fold thick-
ness mea-
sure-
ments (fat
mass g)
12.1
Neonate
Lifestyle in-
tervention
versus usual
care or diet
alone
(Brown
2017b)
(whole-
body
neonatal fat
mass)
Low*
Insulin ver-
sus oral
therapy
(Brown
2017d)
(skinfold
sum) Very
low*
Insulin ver-
sus oral
ther-
apy (Brown
2017d) (%
fat mass)
Very low$
12.2
Childhood
Lifestyle in-
tervention
versus usual
care or diet
alone
(Child-
hood BMI
at 4 to 5
years of age
(one trial)
; 7 to 11
years of age
Insulin ver-
sus oral
ther-
apy (Brown
2017d) (%
fat mass)
Low
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(one trial; 5
to 10 years
of age (one
trial)
) (Brown
2017b)
Lifestyle in-
tervention
versus usual
care or diet
alone (at 4
to 5 years
of age) (
Brown
2017b)
(BMI z
score)
Very low
13.0 Dia-
betes type
2 child
as later in-
fant/
child-
hood/
adulthood
No data reported for this outcome in any of the included reviews
14.0 Neu-
rosensory
disabil-
ity in later
childhood
Insulin ver-
sus oral
therapy
(any
mild devel-
opmental
delay, hear-
ing and vi-
sual im-
pairment)
(Brown
2017d)
Low
15.
0 Number
of antena-
tal vis-
its or ad-
missions
Lifestyle in-
tervention
versus usual
care or diet
alone
Soy- versus
no soy-pro-
tein diet (
Han 2017)
Very low*
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Table 4. Summary of main results table (Continued)
(Brown
2017b)
Telemedicine
versus
standard
care for
glucose
monitoring
(Raman
2017) Very
low
Self- versus
periodic-
glucose
monitor-
ing (Raman
2017) Very
low
Insulin ver-
sus oral
ther-
apy (Brown
2017d)
Low*
16.0
Length of
post-
natal stay
(mother)
No data reported for this outcome in any of the included reviews
17.0
Length of
post-
natal stay
(baby) in-
cluding
NICU/
SCBU
Diet + diet-
related be-
havioural
advice ver-
sus diet
only (Han
2017) Very
low*
Continu-
ous- versus
self-
monitoring
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Table 4. Summary of main results table (Continued)
blood glu-
cose
(Raman
2017) Very
low*
Insulin ver-
sus oral
ther-
apy (Brown
2017d)
Very low*
18.0 Costs
associ-
ated with
the treat-
ment
Lifestyle in-
tervention
versus usual
care or diet
alone
(Brown
2017b)*
The cost
data are
based on
narrative
data
Telemedicine
versus
standard
care for
glucose
monitoring
(Raman
2017)
Very low*
Self- versus
periodic-
monitoring
Telemedicine
versus
standard
care for
glucose
monitoring
(Raman
2017) Very
low*
Insulin ver-
sus oral
ther-
apy (Brown
2017d)
Very low*
∗The GRADE judgement was made by two authors of this overview
$The GRADE judgment was amended from the original review by authors of this overview
1 DASH is an acronym for Dietary Approaches to Stop Hypertension
2Strict intensity of glycaemic control (stricter) defined in review as: pre-prandial 5.0 mmol/L (90 mg/dL) and one hour post-prandial
6.7 mmol/L (120 mg/dL) and less strict glycaemic control (liberal) defined in review as: pre-prandial 5.8 mmol/L (104 mg/dL) and
one hour post-prandial 7.8 mmol/L (140 mg/dL)
3OGTT is an acronym for Oral Glucose Tolerance Test
44 g myo-inositol + 400 µg folic acid orally per day and exercise and dietary advice versus placebo 400 µg folic acid orally per day and
exercise and dietary advice
NICU - neonatal intensive care unit
SCBU - special care baby unit
BMI - body mass index
LGA - large for gestational age
GI - gastrointestinal
BGL - blood glucose level
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Table 5. Characteristics of excluded reviews
Review ID and title Reason for exclusion
Alwan 2009
Treatments for gestational diabetes
Most pre-specified overview outcomes included but this review
was too large and has now been split into three reviews
Two reviews are currently published as ‘Oral anti-diabetic phar-
macological therapies for the treatment of women with
gestational diabetes’ Brown 2017a and ‘Lifestyle interventions
for the treatment of women with gestational diabetes’ (Brown
2017b) and are included reviews in this overview. The other one
is currently published as a protocol entitled ’Insulin for the treat-
ment of women with gestational diabetes’ New Reference (ongo-
ing Cochrane systematic reviews - protocol and title registrations
Appendix 1). The reviews and the protocol include all overview
pre-specified primary outcomes for maternal and neonatal out-
comes and all overview pre-specified secondary outcomes for ma-
ternal, maternal long-term, fetal/neonatal, later infant/childhood,
child as an adult and health services use
Ceysens 2006
Exercise for diabetic pregnant women
This review, which included some of the pre-specified overview
primary and secondary outcomes, was not up-to-date
and has now been superseded with a new title and is now pub-
lished as a review entitled ‘Exercise for pregnant women with
gestational diabetes for improving maternal and fetal outcomes’
(Brown 2017c) (Table 2 Characteristics of included reviews) and is
an included review in this overview for assessment
De-Regil 2016
Vitamin D supplementation for women during pregnancy
Some primary and secondary overview review pre-specified out-
comes included but not later infant/childhood, child as an adult
and health service use outcomes
Pregnant women with pre-existing conditions (i.e. gestational di-
abetes) were excluded
McCauley 2015
Vitamin A supplementation during pregnancy for maternal and
newborn outcomes
Some overview review pre-specified outcomes included. Neonatal
primary outcome: perinatal mortality; Maternal secondary out-
comes: postpartum infection andmaternalmortality. Fetal/neona-
tal secondary outcomes: stillbirth, preterm birth (< 37 weeks’
gestation) and birthweight. No maternal long-term, later infant/
childhood, child as an adult and health service use secondary out-
comes
No outcome data for women with GDM separated out for the
above outcomes
Rumbold 2015
Vitamin C supplementation in pregnancy
Some overview review pre-specified outcomes included. Mater-
nal primary outcome: hypertensive disorder of pregnancy and
caesarean. Neonatal primary outcome: death or serious morbid-
ity composite and neurosensory disability; maternal secondary
outcomes: postpartum haemorrhage, maternal mortality, and
women’s view of care. Fetal/neonatal secondary outcomes: still-
birth, neonatal death, gestational age at birth, preterm birth (< 37
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Table 5. Characteristics of excluded reviews (Continued)
weeks’ gestation), five-minute Apgar < 7, birthweight, respiratory
distress syndrome and neonatal jaundice. No later infant/child-
hood, child as an adult and health service use secondary outcomes.
Of the 29 studies included in this review five studies excluded
women with any diabetes in pregnancy
No outcome data for women with GDM separated out for the
above outcomes
Walkinshaw 1996
Dietary regulation for gestational diabetes
Pre-specified outcomes not available as this review has been with-
drawn and is now included in the review currently published as
’Different types of dietary advice for women with gestational di-
abetes mellitus’ (Han 2017), which is an included review in this
overview review
Walkinshaw 2006
Very tight versus tight control for diabetes in pregnancy
Pre-specified outcomes not available as this review has been with-
drawn because it is out-of-date. The review team were unable to
prepare the update and it is now included in the review currently
published as ‘different intensities of glycaemic control for women
with gestational mellitus’ (Martis 2016a)
Abbreviation: GDM - gestational diabetes mellitus
Table 6. Cochrane risk of bias assessments from included reviews
Review ID and title Summary of trial limitations (risk of
bias)
Overall risk of bias
Biesty 2018
Elective delivery in diabetic
pregnant women
Sequence generation: 1 RCT low risk
Allocation concealment: 1 RCT low risk
Blinding (participants and personnel): 1
RCT high risk
Blinding (outcome assessors):
1 RCT high risk
Incomplete outcomedata:1RCT low risk
Selective reporting: 1 RCT low risk
Other: 1 RCT low risk
”We assessed the overall risk of bas as be-
ing low for most domains, apart from per-
formance, detection and attrition bias (for
outcome perineum intact) which we as-
sessed as being high risk.“
Brown 2017a
Oral anti-diabetic pharmacological
therapies for the treatment of women with
gestational diabetes
Sequence generation: 5 RCTs low risk; 6
unclear risk
Allocation concealment: 6 RCTs low risk;
5 RCTs unclear risk
Blinding (participants and personnel): 2
RCTs low risk; 7 RCTs high risk; 2 RCTs
unclear risk
Blinding (outcome assessors): 2 RCTs
low risk; 9 RCTs unclear risk
Incomplete outcome data: 7 RCT low
risk; 2 RCTs high risk; 2 RCTs unclear risk
”The overall risk of bias was ’unclear’ due
to inadequate reporting of methodology.“
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Table 6. Cochrane risk of bias assessments from included reviews (Continued)
Selective reporting: 3 RCTs low risk; 8
RCTs high risk
Other: 3 RCTs low risk; 6 RCTs high risk;
2 RCTs unclear risk
Brown 2017b
Lifestyle interventions for the
treatment of women with
gestational diabetes
Sequence generation: 10 RCTs low risk; 5
RCTs unclear risk
Allocation concealment: 5 RCTs low risk;
10 RCTs unclear risk
Blinding (participants and personnel): 9
RCTs high risk;
4 RCTs low risk; 2 RCTs unclear risk
Blinding (outcome assessors): 6 RCTs
low risk; 9 RCTs unclear risk
Incomplete outcome data: 3 RCTs high
risk; 10 RCTs low risk; 2 RCTs unclear risk
Selective reporting: 11 RCTs high risk; 3
RCTs low risk; 1 RCT unclear risk
Other: 2 RCTs high risk; 13 RCTs low risk
“Overall the evidence was judged to be
of unclear risk of bias due to inadequate
reporting of allocation concealment and
blinding of outcome assessors and selective
outcome reporting. There is variation be-
tween the trials with regards to the content
of the lifestyle interventions. The evidence
is dominated by two large trials (Crowther
2005; Landon 2009) that included 1000
women and 958 women, respectively. Both
of these trials were judged to be at low risk
of bias.”
Brown 2017c
Exercise for pregnant women
with gestational diabetes for
improving maternal and fetal outcomes
Sequence generation: 4 RCTs low risk; 7
RCTs unclear risk
Allocation concealment: 3 RCTs low risk;
8 RCTs unclear risk
Blinding (participants and personnel): 3
RCTs high risk; 8 RCTs unclear risk
Blinding (outcome assessors):
2 RCTs low risk; 9 RCTs unclear risk
Incomplete outcome data: 2 RCTs high
risk; 3 RCTs low risk; 6 RCTs unclear risk
Selective reporting: 1 RCT low risk; 10
RCTs unclear risk
Other: 3 RCTs low risk; 8 RCTs unclear
risk
“We judged the overall risk of bias of the
included studies to be unclear due to lack
of methodological details.”
Brown 2017d
Insulin for the treatment of women with
gestational diabetes
Sequence generation: 23 RCTs low risk;
29 RCTs unclear risk; 1 RCT high risk
Allocation concealment: 19 RCTs low
risk; 33 RCTs unclear risk; 1 RCT high risk
Blinding (participants and personnel): 2
RCTs low risk; 11 RCTs unclear risk; 40
RCTs high risk
Blinding (outcome assessors):
5 RCTs low risk; 44 RCTs unclear risk; 4
RCTs high risk
Incomplete outcome data: 31 RCTs low
risk; 14 RCTs unclear risk; 8 RCTs high
risk
Selective reporting: 5 RCTs low risk; 14
“Overall, the risk of bias was unclear.”
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Table 6. Cochrane risk of bias assessments from included reviews (Continued)
RCTs unclear risk; 34 RCTs high risk
Other: 26 RCTs low risk; 7 RCTS unclear
risk; 20 RCTs high risk
Brown 2016a
Dietary supplementation with
myo-inositol in women during
pregnancy for treating
gestational diabetes
Sequence generation: 2 RCTs low risk
Allocation concealment: 1 RCT low risk;
1 RCT unclear risk
Blinding (participants and personnel): 1
RCT low risk; 1 RCT unclear risk
Blinding (outcome assessors):
2 RCTs unclear risk
Incomplete outcome data: 1 RCT low
risk; 1 RCT unclear risk
Selective reporting: 1 RCT high risk; 1
RCT unclear risk
Other: 2 RCTs low risk
“Overall, the risk of bias of the included
studies was judged to be unclear due to the
lack of key methodological information.”
Han 2017
Different types of dietary
advice for women with
gestational diabetes mellitus
Sequence generation: 11 RCTs low risk; 8
RCTs unclear risk
Allocation concealment: 4 RCTs low risk;
14 RCTs unclear risk; 1 RCT high risk
Blinding (participants and personnel): 4
RCTs low risk; 2 RCTs unclear risk; 13
RCTs high risk
Blinding (outcome assessors):
2 RCTs low risk, 16 RCTs unclear risk;
1 RCT high risk
Incomplete outcome data: 14 RCTs low
risk; 3 RCTs unclear risk; 2 RCTs high risk
Selective reporting: 16 RCTs unclear risk;
3 RCTs high risk
Other: 2 RCTs low risk
“In this update, we included 19 trials ran-
domising 1398 women with GDM, at an
overall unclear to moderate risk of bias.”
Han 2012
Interventions for pregnant
women with hyperglycaemia
not meeting gestational
diabetes and type 2 diabetes
diagnostic criteria
Sequence generation: 4 RCTs unclear risk
Allocation concealment: 1 RCT low risk;
3 RCTs unclear risk
Blinding (participants and personnel): 4
RCTs high risk
Blinding (outcome assessors):
4 RCTs unclear risk
Incomplete outcome data: 2 RCTs low
risk; 2 RCTs high risk
Selective reporting: 3 RCTs low risk; 1
RCT high risk
Other: 4 RCTs low risk
“Three included studies were at moderate
to high risk of bias and one study
was at low to moderate risk of bias.”
Martis 2016a
Different intensities of
glycaemic control for
women with gestational diabetes mellitus
Sequence generation: 1 RCT unclear risk
Allocation concealment: 1 RCT unclear
risk
Blinding (participants and personnel): 1
“The overall quality of the included trial
was judged to be unclear as conference ab-
stract only.”
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Table 6. Cochrane risk of bias assessments from included reviews (Continued)
RCT high risk
Blinding (outcome assessors):
1 RCT unclear risk
Incomplete outcome data: 1RCTunclear
risk
Selective reporting: 1 RCT high risk
Other: 1 RCT high risk
Raman 2017
Different methods and settings for glucose
monitoring for gestational diabetes during
pregnancy
Sequence generation: 3 RCTs low risk; 6
RCTs unclear risk; 2 RCTs high risk
Allocation concealment: 1 RCT low risk;
8 RCTs unclear risk; 1 RCT high risk
Blinding (participants and personnel):
11 RCTs high risk
Blinding (outcome assessors): 10 RCTs
unclear risk; 1 RCT high risk
Incomplete outcome data: 6 RCTs low
risk; 3 RCTs unclear risk; 2 RCTs high risk
Selective reporting: 9 RCTs unclear risk;
2 RCTs high risk
Other: 8 RCTs low risk; 3 RCTs unclear
risk
“Overall risk of bias is unclear.”
Table 7. GRADE Summary of findings table - Maternal
Interven-
tion and com-
parison
As-
sumed risk with
comparator
Correspond-
ing risk with in-
tervention*
Relative effect
(95% CI)
of
participants
(studies)
Quality of the
evidence
(GRADE)
Comments
from included
reviews in quo-
tation marks
Comments
without quota-
tionmarks from
overview review
authors
1.0 Hypertensive disorders of pregnancy (including pre-eclampsia, pregnancy-induced hypertension, eclampsia, as defined in
reviews)
Brown 2017a
Glibenclamide
versus placebo
Any hyperten-
sive disorders of
pregnancy, not
defined
167 per 1000 207 per 1000
(135 to 317)
RR 1.24
(0.81 to 1.90)
375
(1 RCT)
Very low “Ev-
idence is based
on one study and
93% were His-
panic women,
results may not
be generalisable
to other popu-
lations. There is
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Table 7. GRADE Summary of findings table - Maternal (Continued)
risk of bias, as
we did not find
a published pro-
tocol and there
were more out-
comes reported
in the published
paper than were
listed in the trial
registration doc-
ument.”
Brown 2017a
Metformin ver-
sus
glibenclamide
Any hyperten-
sive disorders of
pregnancy, not
defined
88 per 1000 62 per 1000
(33 to 114)
RR 0.70
(0.38 to 1.30)
508
(3 RCTs)
Moderate “All studies were
open label, some
risk of bias.”
Brown 2017d
Insulin versus
oral therapy
Any hyperten-
sive disorders of
pregnancy, not
defined
36 per 1000 69 per 1000
(42 to 114)
RR 1.89 (1.14 to
3.12)
1214
(4 RCTs)
Moderate Evidence down-
graded for study
limitations
Brown 2017a
Glibenclamide
versus placebo
Pregnancy-
induced hyper-
tension
102 per 1000 127 per 1000
(73 to 224)
RR 1.24 (0.71 to
2.19)
375
(1 RCT)
Low Evidence is based
on one study and
imprecision as
wide confidence
interval crossing
the line of no ef-
fect
Brown 2017a
Metformin ver-
sus
glibenclamide
Pregnancy-
induced hyper-
tension
108 per 1000 77 per 1000
(40 to 148)
RR 0.71 (0.37 to
1.37)
359
(2 RCT)
Moderate Risk of perfor-
mance bias
as study partic-
ipants and care
providers
were not blinded
in both trials and
additionally one
trial had report-
ing bias
for not reporting
pre-speci-
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Table 7. GRADE Summary of findings table - Maternal (Continued)
fied outcome for
macrosomia
Han 2017
Low-
versus high-car-
bohydrate diet
Pregnancy-
induced hyper-
tension
133 per 1000 53 per 1000
(17 to 163)
RR 0.40
(0.13 to 1.22)
150
(1 RCT)
Very low Evidence is based
on one study and
imprecision as
wide confidence
interval crossing
the line of no ef-
fect. Risk of per-
formance bias as
study
participants and
care providers
were not blinded
Han 2017
High- ver-
sus low-unsatu-
rated fat
diet with match-
ing calories
Pregnancy-
induced hyper-
tension
143 per 1000 77 per 1000
(9 to 751)
RR 0.54 (0.06 to
5.26)
27
(1 RCT)
Very low Evidence is based
on one study and
imprecision as
wide confidence
interval crossing
the line of no ef-
fect. Risk of per-
formance bias as
study
participants and
care providers
were not blinded
Han 2017
Ethnic specific
diet versus stan-
dard healthy diet
Pregnancy-
induced hyper-
tension
100 per 1000 33 per 1000
(2 to 732)
RR 0.33
(0.02 to 7.32)
20
(1 RCT)
Very low Evidence is based
on one study and
imprecision as
wide confidence
interval crossing
the line of no ef-
fect. Risk of per-
formance bias as
study
participants and
care providers
were not blinded
and reporting
bias as outcomes
were reported in
figures with
no variance mea-
sures and no ac-
cess to the study
protocol
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Table 7. GRADE Summary of findings table - Maternal (Continued)
Brown 2017d
Insulin regimen
A versus B
Pregnancy-
induced hyper-
tension
80 per 1000 88 per 1000
(41 to 193)
RR 1.11 (0.51 to
2.42)
274
(1 RCT)
Low Twice daily ver-
sus four times
daily.
Downgraded for
imprecision (sin-
gle study, low
event rates, wide
confidence inter-
vals)
Brown 2017a
Glibenclamide
versus placebo
Severe
hypertension or
pre-eclampsia
65 per 1000 79 per 1000
(38 to 165)
RR 1.23 (0.59 to
2.56)
375
(1 RCT)
Low Evidence is based
on one study and
imprecision as
wide confidence
interval crossing
the line of no ef-
fect
Han 2017
Low-moderate
versus moderate-
high GI diet
Severe
hypertension or
pre-eclampsia
21 per 1000 21 per 1000
(2 to 333)
RR 1.02 (0.07 to
15.86)
95
(1 RCT)
Very low “Ev-
idence is based
on one study in
China. Study re-
sults may not be
gener-
alisable to other
populations. Im-
precision as wide
confidence inter-
val crossing the
line of no effect
with few events
and small sample
size.”
Raman 2017
Telemedicine
versus standard
care for glucose
monitoring
Pregnancy-
induced hyper-
tension or pre-
eclampsia
58 per 1000 87 per 1000
(40 to 187)
RR 1.49 (0.69 to
3.20)
275
(4 RCTs)
Very low Downgraded for
study limitations
(poten-
tially or very se-
rious design lim-
itations) and im-
precision (wide
confidence inter-
vals, small sam-
ple size and few
events)
Brown 2017a
Metformin ver-
sus
41 per 1000 27 per 1000
(4 to 155)
RR 0.66
(0.11 to 3.82)
149
(1 RCT)
Very low Evidence is based
on one study and
imprecision as
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glibenclamide
Pre-eclampsia
wide confidence
interval crossing
the line of no ef-
fect. Study
participants and
care providers
were not blinded
Han 2017
Energy- ver-
sus no energy-re-
stricted diet
Pre-eclampsia
222 per 1000 222 per 1000
(113 to 437)
RR 1.00 (0.51 to
1.97)
117
(1 RCT)
Low “Evi-
dence is based on
one study. Im-
precision as wide
confidence inter-
val crossing the
line of no effect
and small sample
size.”
Han 2017
DASH1 diet ver-
sus control
diet with match-
ing macronutri-
ent contents
Pre-eclampsia
74 per 1000 74 per 1000
(0.31 to 240)
RR 1.00 (0.31 to
3.26)
136
(3 RCTs)
Moderate Imprecision as
wide confidence
interval crossing
the line of no ef-
fect
Han 2017
High- ver-
sus low-unsatu-
rated fat
diet with match-
ing calories
Pre-eclampsia
See comment see comment RR Not
estimable
27
(1 RCT)
Low Evidence is based
on one study.
Risk of perfor-
mance bias
as study partic-
ipants and care
providers were
not blinded. Fur-
ther risk of bias
as both groups of
participants
were unbalanced
for BMI at base-
line. There were
no events in both
groups
Han 2017
Soy- versus no
soy-protein diet
Pre-eclampsia
29 per 1000 59 per 1000
(6 to 619)
RR 2.00 (0.19 to
21.03)
68
(1 RCT)
Very low Evidence is based
on one study.
Impreci-
sion as wide con-
fidence interval
crossing the line
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of no effect. Risk
of performance
bias, as partici-
pants and per-
sonnel were not
blinded
Brown 2017b
Lifestyle
intervention ver-
sus usual care or
diet alone
Pre-eclampsia
129 per 1000 90 per 1000
(51 to 157)
RR 0.70 (0.40 to
1.22)
2796
(4 RCTs)
Low “Evidence of in-
consistency with
I² > 70% down-
graded two lev-
els.”
Brown 2017c
Exercise versus
control
Pre-eclampsia
43 per 1000 13 per 1000
(0 to 308)
RR 0.31 (0.01 to
7.09)
48
(2 RCTs)
Low “Wide con-
fidence intervals
crossing the line
of no effect and
low event rates
with a small sam-
ple size are sug-
gestive of impre-
cision and lack of
clarity for most
items related to
risk of bias.”
Han 2012
In-
tensive manage-
ment versus rou-
tine care
Pre-eclampsia
21 per 1000 57 per 1000
(5 to 619)
RR 2.74 (0.26 to
29.07)
83
(1 RCT)
Low Evi-
dence is based on
one small study
with few events
and serious de-
sign limitations
and imprecision
with wide con-
fidence intervals
crossing the line
of no effect
Raman 2017
Self- versus peri-
odic-glucose
monitoring
Pre-eclampsia
74 per 1000 13 per 1000
(139 to 519)
RR 0.18 (0.01 to
3.49)
was reported as
RR 0.17 in text
of review but in
forest plot it is
RR 0.18
58
(1 RCT)
Very low Evi-
dence is based on
one small study
and risk of per-
formance bias as
study partic-
ipants and care
providers were
not blinded. All
other risk of bias
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as-
sessments are un-
clear. Wide con-
fidence interval
crossing the line
of no effect
Raman 2017
Post- versus pre-
prandial glucose
monitoring
Pre-eclampsia
61 per 1000 61 per 1000
(9 to 405)
RR 1.00
(0.15 to 6.68)
66
(1 RCT)
Very low Evidence down-
graded for
study limitations
and imprecision
(wide confidence
intervals crossing
the line of no ef-
fect; single trial
and small sample
size)
Brown 2017d
Insulin versus
oral therapy
Pre-eclampsia
77 per 1000 88 per 1000
(66 to 117)
RR 1.14 (0.86 to
1.52)
2060
(10 RCTs)
Moderate Evidence down-
graded for study
limitations
Brown 2017d
Insulin type A
versus B
Pre-eclampsia
No events No events Not estimable 320
(1 RCT)
Low There
were no events of
pre-eclampsia re-
ported in either
group
Evidence was
downgraded for
study limitations
and imprecision
(single trial, no
events)
Han 2017
Low-moderate
versus moderate-
high GI diet
Eclampsia
24 per 1000 8 per 1000
(0 - 195)
RR 0.34 (0.01 to
8.14)
83
(1 RCT)
Very low “Ev-
idence is based
on one study in
China. Study re-
sults may not be
gener-
alisable to other
populations. Im-
precision as wide
confidence inter-
val crossing the
line of no effect
with few events
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and small sample
size.”
2.0 Caesarean section
Biesty 2018
Induction of
labour versus ex-
pectant manage-
ment
118 per 1000 126 per 1000
(76 to 210)
RR 1.06 (0.64 to
1.77)
425
(1 RCT)
Very low Evidence is based
on one
study with de-
sign limitations
and imprecision
with wide con-
fidence intervals
crossing the line
of no effect
Brown 2017a
Glibenclamide
versus placebo
360 per 1000 371 per 1000
(285 to 483)
RR 1.03 (0.79 to
1.34)
375
(1 RCT)
Very low “Ev-
idence is based
on one study and
93% were His-
panic women,
results may not
be generalisable
to other popu-
lations. There is
risk of bias, as
we did not find
a published pro-
tocol and there
were more out-
comes reported
in the published
paper than were
listed in the trial
registration doc-
ument.”
Brown 2017a
Metformin ver-
sus
glibenclamide
392 per 1000 470 per 1000
(325 to 674)
average RR 1.20
(0.83 to 1.72)
554
(4 RCTs)
Low “Three of
the four studies
were open label
and three of four
studies were un-
clear for blind-
ing of outcome
asses-
sors. Two stud-
ies reported ad-
ditional out-
comes that were
not pre-specified
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and heterogene-
ity was high.”
Brown 2017a
Glibenclamide
versus acarbose
526 per 1000 500 per 1000
(279 to 895)
RR 0.95 (0.53,
1.70)
43
(1 RCT)
Low “Ev-
idence is based
on one study.
Method of ran-
domisation was
unclear and the
study was open-
label.”
Han 2017
Low-moderate
versus moderate-
high GI diet
344 per 1000 277 per 1000
(100 to 506)
RR 0.66 (0.29 to
1.47)
63 (1 RCT) Very low “Evi-
dence is based on
one study with
unclear risk of se-
lection and de-
tection bias and
high risk of per-
for-
mance bias. Im-
precision as wide
confidence inter-
val crossing the
line of no effect
and small sample
size.”
Han 2017
Energy- ver-
sus no energy-re-
stricted diet
228 per 100 255 per 1000
(182 to 356)
RR 1.12 (0.80 to
1.56)
420
(2 RCTs)
Low “Design limita-
tions: two stud-
ies at unclear risk
of selection bias;
one study at high
risk of perfor-
mance bias
and unclear risk
of detection bias.
Imprecisionwith
wide confidence
intervals crossing
the line of no ef-
fect.”
Han 2017
DASH1 diet ver-
sus control
diet with match-
ing macronutri-
ent contents
837 per 1000 444 per 1000
(310 to 636)
RR 0.53 (0.37 to
0.76)
86
(2 RCTs)
Low Downgraded for
study limitations
(unclear risk of
bias for alloca-
tion
concealment and
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selective report-
ing in both trials
and additionally
in one trial risk
of bias for blind-
ing of partici-
pants, personnel
and outcome as-
sessors) and im-
precision (small
sample size)
Han 2017
Low-
versus high-car-
bohydrate diet
278 per 1000 358 per 1000
(233 to 553)
RR 1.29
(0.84 to 1.99)
179
(2 RCTs)
Low Risk of perfor-
mance bias
as study partic-
ipants and care
providers were
not blinded. Ad-
ditioan-
lly one study had
a high risk of bias
for selective re-
porting as lim-
ited data was re-
ported and no
access to study
protocol
Han 2017
High- ver-
sus low-unsatu-
rated fat
diet with match-
ing calories
71 per 1000 77 per 1000
(5 to 1000)
RR 1.08 (0.07 to
15.50)
27
(1 RCT)
Very low Evidence is based
on one study and
imprecision as
wide confidence
interval crossing
the line of no ef-
fect. Risk of per-
formance bias as
study partic-
ipants and care
providers were
not blinded. Fur-
ther risk of bias
as both groups of
participants were
unbalanced for
BMI at baseline
Han 2017
Low-GI diet ver-
sus high-fi-
bre moderate-GI
178 per 1000 340 per 1000
(162 to 716)
RR 1.91
(0.91 to 4.03
92
(1 RCT)
Very low Evidence is based
on one study and
imprecision as
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diet wide confidence
interval crossing
the line of no ef-
fect. Risk of de-
tection and attri-
tion bias as study
outcome as-
sessors were not
blinded and in-
complete data re-
ported. Baseline
for blood glucose
concentration
were unbalanced
between groups
Han 2017
Diet
+ diet-related be-
havioural advice
versus diet only
260 per 1000 203 per 1000
(99 to 421)
RR 0.78 (0.38 to
1.62)
99
(1 RCT)
Very low Evi-
dence is based on
one small study
and risk of per-
formance bias as
study
participants and
care providers
were not blinded
Han 2017
Soy- versus no
soy-protein diet
412 per 1000 412 per 1000
(235 to 729)
RR 1.00
(0.57 to 1.77)
68
(1 RCT)
Very low Evi-
dence is based on
one small study
and risk of per-
formance bias as
study
participants and
care providers
were not blinded
Han 2017
Ethnic specific
diet versus stan-
dard healthy diet
500 per 1000 600 per 1000
(270 to 1000)
RR 1.20 (0.54 to
2.67)
20
(1 RCT)
Very low Evidence is based
on one study and
imprecision as
wide confidence
interval crossing
the line of no ef-
fect. Risk of per-
formance bias as
study
participants and
care providers
were not blinded
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and reporting
bias as outcomes
were reported in
figures with
no variance mea-
sures and no ac-
cess to the study
protocol
Brown 2017b
Lifestyle
intervention ver-
sus usual care or
diet alone
380 per 1000 342 per 1000
(296 to 399)
RR 0.90 (0.78 to
1.05)
3545
(10 RCTs)
Low “Evidence of se-
lective reporting
inmore than half
of the trials re-
porting this out-
come and evi-
dence of incon-
sistency with I²
= > 50% but
< 70%. There
is some sugges-
tion of asymme-
try observed in
the funnel plot.”
Brown 2017c
Exercise versus
control
319 per 1000 274 per 1000 RR 0.86 (0.63 to
1.16)
316
(5 RCTs)
Moderate “Lack of clarity
for most items
related to risk of
bias.”
Han 2012
In-
tensive manage-
ment versus rou-
tine care
249 per 1000 232 per 1000
(169 to 316)
RR 0.93 (0.68 to
1.27)
509
(3 RCTs)
Very low Evidence based
on three RCTs
with serious/very
serious de-
sign limitations
and imprecision
with wide con-
fidence intervals
crossing the line
of no effect
Martis 2016a
Strict intensity2
of glycaemic
control ver-
sus less strict gly-
caemic control
244 per 1000 330 per 1000
(203 to 532)
RR 1.35
(0.83 to 2.18)
171
(1 RCT)
Very low “Evidence based
on one trial that
was only pub-
lished in con-
ference abstract
form
Lack of detail to
make a judge-
ment about ran-
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dom
sequence gener-
ation, allocation
concealment, at-
trition bias and
reporting bias.
Open label study
and no details re-
garding blinding
of outcome as-
sessors was re-
ported. Wide
confidence inter-
vals that cross the
line of no effect.
”
Raman 2017
Telemedicine
versus standard
care for glucose
monitoring
444 per 1000 467 per 1000
(320 to 680)
Average RR 1.05
(0.72 to 1.53)
478
(5 RCTs)
Very low Downgraded for
study limitations
(potentially or
very serious de-
sign limitations)
and imprecision
(wide confidence
intervals) and in-
consistency (I² =
62%)
Raman 2017
Self- versus peri-
odic-glucose
monitoring
228 per 1000 270 per 1000
(139 to 519)
RR 1.18 (0.61 to
2.27)
400
(2 RCTs)
Low Evidence down-
graded for study
limita-
tions and impre-
cision (wide con-
fidence intervals
crossing the line
of no effect)
Raman 2017
Contin-
uous- versus self-
monitoring
500 per 1000 455 per 1000
(340 to 600)
RR 0.91 (0.68 to
1.20)
179
(2 RCTs)
Very low Evidence down-
graded for
study limitations
and imprecision
(wide confidence
intervals crossing
the line of no
effect and small
sample sizes)
Raman 2017
Post-prandial
versus pre-pran-
394 per 1000 244 per 1000
(114 to 508)
RR 0.62 (0.29 to
1.29)
66
(1 RCT)
Very low Evidence down-
graded for
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dial monitoring study limitations
and imprecision
(wide confidence
intervals crossing
the line of no ef-
fect; single trial
and small sample
size)
Brown 2017d
Insulin versus
oral therapy
394 per 1000 405 per 1000
(366 to 449)
RR 1.03 (0.93 to
1.14)
1988
(17 RCTs)
Moderate Evidence down-
graded for study
limitations (lack
of blinding)
Brown 2017d
Insulin type A
versus B
763 per 1000 763 per 1000
(695 to 832)
RR 1.00; (0.91
to 1.09)
410
(3 RCTs)
Moderate Evidence down-
graded for study
limitations (in-
sufficient details)
Brown 2017d
Insulin versus
diet
328 per 1000 279 per 1000
(164 to 466)
RR 0.85 (0.50 to
1.42)
133
(2 RCTs)
Very low Evidence down-
graded for study
limitations (in-
ad-
equate randomi-
sation and al-
location conceal-
ment, insuffi-
cient details) and
imprecision (few
studies and small
sample size)
Brown 2017d
Insulin versus ex-
ercise
118 per 1000 176 per 1000
(34 to 926)
RR 1.50; (0.29
to 7.87)
34
(1 RCT)
Very low Evidence down-
graded for study
lim-
itations (insuffi-
cient details) and
imprecision (sin-
gle small study,
wide confidence
intervals)
Brown 2017d
Insulin regimen
A versus B
Twice daily ver-
sus four times
daily
Three times ver-
283 per 1000
105 per 1000
280 per 1000
(192 to 407)
112 per 1000
(18 to 707)
RR 0.99 (0.68 to
1.44)
RR 1.06 (0.17 to
6.72)
274
(1 RCT)
37
(1 RCT)
Very low Evidence down-
graded for study
lim-
itations (insuffi-
cient details) and
imprecision (sin-
gle small study,
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sus six times
daily
wide confidence
intervals)
3.0 Development of type 2 diabetes
Han 2017
High- ver-
sus low-unsatu-
rated fat
diet with match-
ing calories
OGTT3 for di-
agno-
sis of type 2 di-
abetes at one to
two weeks post-
partum
167 per 1000 333 per 1000
(75 to 1000)
RR 2.00
(0.45 to 8.94)
24
(1 RCT)
Very low Evidence is based
on one study and
imprecision as
wide confidence
interval crossing
the line of no ef-
fect. Risk of per-
formance bias as
study partic-
ipants and care
providers were
not blinded. Fur-
ther risk of bias
as both groups of
participants were
unbalanced for
BMI at baseline
Han 2017
Low-GI diet ver-
sus high fi-
bre moderate-GI
diet
OGTT3for di-
agnosis of
type 2 diabetes
at three months
postpartum
80 per 1000 61 per 1000
(9 to 401)
RR 0.76, (0.11
to 5.01)
58
(1 RCT)
Very low Imprecision - ev-
idence is based
on one study and
wide confidence
interval crossing
the line of no ef-
fect. Risk of de-
tection and attri-
tion bias as study
outcome as-
sessors were not
blinded and in-
complete data re-
ported. Baseline
for blood glucose
concentration
were unbalanced
between groups
Han 2017
High- ver-
sus low-unsatu-
rated fat
diet with match-
ing calories
OGTT3for di-
333 per 1000 333 per 1000
(33 to 1000)
RR 1.00
(0.10 to 9.61)
6
(1 RCT)
Very low Evidence is based
on one study and
imprecision as
wide confidence
interval crossing
the line of no ef-
fect. Risk of per-
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ag-
nosis of type 2
diabetes at four
to 13 months
postpartum
formance bias as
study partic-
ipants and care
providers were
not blinded. Fur-
ther risk of bias
as both groups of
participants were
unbalanced for
BMI at baseline
Brown 2017b
Lifestyle
intervention ver-
sus usual care or
diet alone
Test and time
frame not de-
fined
83 per 1000 81 per 1000
(45 to 146)
RR 0.98 (0.54 to
1.76)
486
(2 RCTs)
Low “Evidence of risk
of bias with one
of the two stud-
ies not blinding
participants/re-
searcher and ev-
idence of risk of
bias for attrition.
”
Brown 2017d
Insulin versus
oral therapy
Up to one-year
postpartum
52 per 1000 73 per 1000
(42 to 128)
RR 1.39 (0.80 to
2.44)
754
(2 RCTs)
Moderate Evidence down-
graded for study
lim-
itations (blind-
ing and insuffi-
cient details to
judge randomi-
sation and al-
location conceal-
ment)
Brown 2017d
Insulin versus
diet
Up to 15 years
postpartum
345 per 1000 338 per 1000
(272 to 417)
RR 0.98; (0.79
to 1.21)
653
(2 RCTs)
Very low Evidence down-
graded for study
limitations (in-
ad-
equate randomi-
sation and al-
location conceal-
ment, insuffi-
cient details) and
imprecision (few
studies and small
sample size)
4.0 Perineal trauma
Biesty 2018
Induction of
labour versus ex-
263 per 1000 268 per 1000
(192 to 376)
RR 1.02 (0.73 to
1.43)
373
(1 RCT)
Low Evidence was
downgraded for
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pectant manage-
ment
study limitations
and imprecision
(single study)
Outcome mea-
sured as ’intact
perineum’
Brown 2017a
Glibenclamide
versus placebo
5 per 1000 5 per 1000
(0 to 84)
RR 0.98
(0.06 to 15.62)
375
(1 RCT)
Very low “Ev-
idence is based
on one study and
93% were His-
panic women,
results may not
be generalisable
to other popula-
tions.
We did not find
a published pro-
tocol and there
were more out-
comes reported
in the published
paper than were
listed in the trial
registration doc-
ument”
“There are wide
confidence inter-
vals
crossing the line
of no effect and
low event rates
suggestive of im-
precision. Event
rates were low
1/189 for anti-
diabetic pharma-
cological therapy
and 1/186 in the
control
(placebo) group.
”
Brown 2017a
Metformin ver-
sus
glibenclamide
6 per 1000 11 per 1000
(1 to 81)
RR 1.67 (0.22 to
12.52)
308
(2 RCTs)
Low “All studies were
open label and
wide con-
fidence intervals
along with low
event rates sug-
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gest imprecision.
Low event rates
(2/154 for met-
formin and 1/
154 for gliben-
clamide.”
Brown 2017b
Lifestyle
intervention ver-
sus usual care or
diet alone
498 per 1000 518 per 1000
(463 to 588)
RR 1.04
(0.93 to 1.18)
1000
(1 RCT)
Moderate “Imprecision -
evidence is based
on a single trial.”
Raman 2017
Contin-
uous- versus self-
monitoring
See comment See comment - 73
(1 RCT)
Very low One
included trial re-
ported “There
were no statis-
tically significant
dif-
ferences between
the two groups..
. in maternal lac-
erations.”
Evidence down-
graded for study
limitations and
imprecision (sin-
gle trial, small
sample size)
Raman 2017
Post- versus pre-
prandial glucose
monitoring
242 per 1000 92 per 1000
(27 to 313)
RR 0.38 (0.11 to
1.29)
66
(1 RCT)
Very low Evidence down-
graded for study
lim-
itations (insuffi-
cient details and
lack of blinding)
imprecision (sin-
gle small study,
low event rates,
wide confidence
intervals)
5.0 Postnatal weight retention or return to pre-pregnancy weight
Brown 2017b
Lifestyle
intervention ver-
sus usual care or
diet alone
At six weeks
173 per 1000 208 per 1000
(116 to 376)
RR 1.20 (0.67 to
2.17)
189
(1 RCT)
Low Imprecision - ev-
idence based on
one
trial. Evidence of
risk of bias as
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postpartum participants and
researchers were
not blinded and
selective report-
ing. Wide con-
fidence interval
crossing the line
of no effect
Han 2017
Low-GI diet ver-
sus high fi-
bre moderate-GI
diet
At three months
postpartum
217 per 1000 250 per 1000
(93 to 667)
RR 1.15 (0.43 to
3.07)
555
(1 RCT)
Very low Imprecision - ev-
idence based on
one
trial. Evidence of
risk of bias as
participants and
researchers were
not blinded and
attrition bias for
incomplete data.
Wide confidence
interval crossing
the line of no ef-
fect
Brown 2017b
Lifestyle
intervention ver-
sus usual care or
diet alone
At seven
months
postpartum
239 per 1000 379 per 1000
(236 to 613)
RR 1.59 (0.99 to
2.57)
159
(1 RCT)
Very low Imprecision - ev-
idence based on
one trial. Evi-
dence of risk of
bias as partici-
pants
and researchers
were not blinded
and selective re-
porting evident.
Wide confidence
interval crossing
the line of no ef-
fect
Brown 2017b
Lifestyle
intervention ver-
sus usual care or
diet alone
At 12 months
postpartum
214 per 1000 375 per 1000
(225 to 621)
RR 1.75 (1.05 to
2.90)
156
(1 RCT)
Low “Impreci-
sion - evidence is
based on a single
trial. Evidence of
risk of bias as un-
clear allocation
concealment and
no blinding of
participants and
researchers.”
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Brown 2017c
Exercise versus
control
At follow-up
(timing not de-
fined)
The maternal
BMI (follow-up)
kg/m² was 0
MD 0.11 higher
(-1.04 lower to 1.
26 higher)
MD 0.11
(-1.04 to 1.26)
254
(3 RCTs)
High No evidence
of significant risk
of bias, inconsis-
tency or impreci-
sion
Brown 2017d
Insulin versus
oral therapy
Six
to eight weeks
postpartum
One year post-
partum
The
mean weight at 6
to 8 weeks post-
partum was 80.8
kg
The mean
weight
at one-year post-
partum was 81.8
kg
MD
1.60 kg lower (6.
34 kg lower to 3.
14 kg higher)
MD
3.70 kg lower (8.
50 kg lower to 1.
10 kg higher)
MD 1.60 kg (-6.
34 to 3.14)
MD -3.70 kg (-
8.50 to 1.10)
167
(1 RCT)
176
(1 RCT)
Low
Low
Evidence down-
graded for study
limitations (lack
of blinding; in-
suf-
ficient method-
ological de-
tails to judge ran-
domisation or al-
location conceal-
ment) and im-
precision (wide
confidence inter-
vals and a single
study)
6.0 Post-natal depression
Brown 2017b
Lifestyle
intervention ver-
sus usual care or
diet alone
169 per 1000 83 per 1000
(53 to 132)
RR 0.49
(0.31 to 0.78)
573
(1 RCT)
Low “Impre-
cision - evidence
is based on a sin-
gle trial and ev-
idence of risk of
attrition bias.”
7.0 Induction of labour
Brown 2017a
Glibenclamide
versus placebo
188 per 1000 222 per 1000
(149 to 331)
RR 1.18
(0.79 to 1.76)
375
(1 RCT)
Very low “Ev-
idence is based
on one study and
93% were His-
panic women,
results may not
be generalisable
to other popula-
tions.
We did not find
a published pro-
tocol and there
were more out-
comes reported
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in the published
paper than were
listed in the trial
registration doc-
ument.”
Brown 2017a
Metformin ver-
sus
glibenclamide
613 per 1000 496 per 1000
(374 to 655)
RR 0.81 (0.61 to
1.07)
159
(1 RCT)
Low “Ev-
idence is based
on one study.
Method of ran-
domisation was
unclear and the
study was open-
label”
Han 2017
Low-moderate
versus moderate-
high GI diet
219 per 1000 193 per 1000
(72 to 512)
RR 0.88 (0.33 to
2.34)
63
(1 RCT)
Low “One
small study at
unclear risk of se-
lection and de-
tection bias and
high risk of per-
formance bias.
Wide confidence
interval crossing
the line of no ef-
fect.”
Han 2017
Energy- ver-
sus no energy-re-
stricted diet
451 per 1000 460 per 1000
(307 to 690)
RR 1.02 (0.68 to
1.53)
114
(1 RCT)
Low “One
small study at
unclear risk of se-
lection and de-
tection bias and
wide confidence
interval crossing
the line of no ef-
fect.”
Brown 2017b
Lifestyle
intervention ver-
sus usual care or
diet alone
211 per 1000 252 per 1000
(220 to 285)
Average RR 1.20
(0.99 to 1.46)
2699
(4 RCTs)
Moderate Evidence of risk
of bias
Brown 2017c
Exercise versus
control
400 per 1000 552 per 1000
(284 to 1000)
RR 1.38 (0.71 to
2.68)
40
(1 RCT)
Very low “Imprecision
- low event rates
and small sam-
ple size. Lack of
clarity for most
items related to
risk of bias.”
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Table 7. GRADE Summary of findings table - Maternal (Continued)
Han 2012
In-
tensive manage-
ment versus rou-
tine care
0 per 1000 0 per 1000
(0 to 0)
RR 17.69 (1.03
to 304.09)
83
(1 RCT)
Very low Evi-
dence is based on
one small study
with few events
and serious de-
sign limitations
and imprecision
with wide con-
fidence intervals
crossing the line
of no effect
Raman 2017
Telemedicine
versus standard
care for glucose
monitoring
538 per 1000 571 per 1000
(339 to 953)
RR 1.06 (0.63 to
1.77)
47
(1 RCT)
Very low Downgraded for
study limitations
and impre-
cision (wide con-
fidence intervals,
small sample size
and low events)
Brown 2017d
Insulin versus
oral therapy
408 per 1000 535 per 1000
(424 to 669)
Average RR 1.30
(0.96 to 1.75)
348
(3 RCTs)
Moderate Evidence down-
graded for study
limitations (lack
of blinding)
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and
the relative effect of the intervention (and its 95% CI).
CI: confidence interval; RCT: randomised controlled trial; RR: risk ratio; OR: odds ratio
GRADE Working Group grades of evidence
High quality: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate quality:We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect,
but there is a possibility that it is substantially different
Low quality:Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the
effect
Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the
estimate of effect
1 DASH is an acronym for Dietary Approaches to Stop Hypertension
2Strict intensity of glycaemic control (stricter) defined in review as: pre-prandial 5.0 mmol/L (90 mg/dL) and one hour post-prandial
6.7 mmol/L (120 mg/dL) and less strict glycaemic control (liberal) defined in review as: pre-prandial 5.8 mmol/L (104 mg/dL) and
one hour post-prandial 7.8 mmol/L (140 mg/dL)
3OGTT is an acronym for Oral Glucose Tolerance Test
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Table 8. GRADE Summary of findings table - Child (as neonate, child, adult)
Interven-
tion and com-
parison and
outcome
As-
sumed risk with
comparator
Correspond-
ing risk with in-
tervention*
Relative effect
(95% CI)
of
participants
(studies)
Quality of the
evidence
(GRADE)
Comments
from included
reviews in quo-
tation marks
Comments
without quota-
tionmarks from
overview review
authors
8.0 Large-for-gestational age (LGA) (as defined in reviews)
Biesty 2018
Induction of
labour versus ex-
pectant manage-
ment
LGA defined as
> 90th
percentile
114 per 1000 60 per 1000
(32 to 116)
RR 0.53
(0.28 to 1.02)
425
(1 RCT)
Low Evidence is based
on one small
study with de-
sign limitations.
Wide confidence
intervals crossing
the line of no ef-
fect
Brown 2017a
Glibenclamide
versus placebo
LGA defined >
90th percentile
118 per 1000 105 per 1000
(60 to 187)
RR 0.89
(0.51 to 1.58)
375
(1 RCT)
Very low “Ev-
idence is based
on one study and
93% were His-
panic women,
results may not
be generalisable
to other popu-
lations. There is
risk of bias, as
we did not find
a published pro-
tocol and there
were more out-
comes reported
in the published
paper than were
listed in the trial
registration doc-
ument.”
Brown 2017a
Metformin ver-
sus
glibenclamide
LGA defined as
> 90th
percentile
193 per 1000 129 per 1000
(46 to 354)
RR 0.67
(0.24 to 1.83)
246
(2 RCTs)
Low “Allocation con-
cealment
was unclear in
one study and
one study was
open label. In-
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Table 8. GRADE Summary of findings table - Child (as neonate, child, adult) (Continued)
consistent as het-
erogeneity was I²
= 54%, which
could not be ex-
plained by the
diagnostic crite-
ria used.”
Brown 2017a
Glibenclamide
versus acarbose
LGA defined as
> 90th
percentile
105 per 1000 251 per 1000
(57 to 1000)
RR 2.38
(0.54 to 10.46)
43
(1 RCT)
Very low “Evidence
is based on one
small study with
wide confidence
intervals and evi-
dence of selective
reporting.”
Brown 2016a
Myo-inositol
versus placebo2
LGA defined as
> 90th centile
26 per 1000 9 per 1000
(1 to 226)
RR 0.36 (0.02 to
8.58)
73
(1 RCT)
Very low “Evidence
is based on one
small study with
low event rates
- 0/35 events in
myo-inosi-
tol group and 1/
38 events
in the placebo
group.”
Han 2017
Low-moderate
versus moderate-
high GI diet
LGA defined as
≥ 90th per-
centile for ges-
tational age
146 per 1000 104 per 1000
(32 to 342)
RR 0.71 (0.22 to
2.34)
89
(2 RCTs)
Low “One study at
unclear risk of se-
lection bias and
two studies at
risk of perfor-
mance bias
and unclear risk
of detection bias.
Wide confidence
intervals crossing
the line of no
effect and small
sample size.”
Han 2017
Energy- ver-
sus no energy-re-
stricted diet
LGA defined as
≥ 90th per-
centile for ges-
tational age
246 per 1000 288 per 1000
(160 to 522)
RR 1.17 (0.65 to
2.12)
123
(1 RCT)
Low “One study at
unclear risk of se-
lection and de-
tection bias and
wide confidence
interval crossing
the line of no
effect and small
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Table 8. GRADE Summary of findings table - Child (as neonate, child, adult) (Continued)
sample size.”
Han 2017
Low-
versus high-car-
bohydrate diet
LGA defined as
≥ 90th per-
centile for ges-
tational age
80 per 1000 41 per 1000
(10 to 156)
RR 0.51 (0.13 to
1.95)
149
(1 RCT)
Very low Imprecision - ev-
idence is based
on one study and
wide confidence
interval crossing
the line of no ef-
fect. Risk of per-
formance bias as
participants and
researchers were
not blinded
Han 2017
High- ver-
sus low-unsatu-
rated fat
diet with match-
ing calories
LGA defined as
≥ 90th per-
centile for ges-
tational age
571 per 1000 309 per 1000
(120 to 783)
RR 0.54 (0.21 to
1.37)
27
(1 RCT)
Very low Imprecision - ev-
idence is based
on one study and
wide confidence
interval crossing
the line of no ef-
fect. Risk of per-
formance bias as
participants and
researchers were
not blinded.
Base-
lines for BMI
were unbalanced
between groups
Han 2017
Low-Gi diet ver-
sus high-fi-
bre moderate-GI
diet
LGA defined as
≥ 90th per-
centile for ges-
tational age
44 per 1000 128 per 1000
(27 to 600)
RR 2.87 (0.61 to
13.50)
92
(1 RCT)
Very low Imprecision - ev-
idence
is based on one
study and wide
confidence inter-
val crossing the
line of no effect.
Risk of detection
bias as outcome
assessors were
not blinded. In-
complete data re-
ported (attrition
bias) and blood
glucose concen-
tration unbal-
anced at baseline
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Table 8. GRADE Summary of findings table - Child (as neonate, child, adult) (Continued)
Han 2017
Diet
+ diet-related be-
havioural advice
versus diet only
LGA defined as
≥ 90th per-
centile for ges-
tational age
140 per 1000 102 per 1000
(35 to 300)
RR 0.73 (0.25 to
2.14)
99
(1 RCT)
Very low Imprecision - ev-
idence is based
on one study and
wide confidence
interval crossing
the line of no ef-
fect. Risk of per-
formance bias as
participants and
personnel were
not blinded
Han 2017
Ethnic specific
diet versus stan-
dard healthy diet
LGA defined as
≥ 90th per-
centile for ges-
tational age
300 per 1000 42 per 1000
(3 to 735)
RR 0.14 (0.01 to
2.45)
20
(1 RCT)
Very low Imprecision - ev-
idence is based
on one study and
wide confidence
interval crossing
the line of no ef-
fect. Risk of per-
formance bias as
participants and
per-
sonnel were not
blinded and se-
lective reporting
(reporting bias).
Low event rates,
as there were no
events in the in-
tervention group
and three events
in the control
group
Brown 2017b
Lifestyle
intervention ver-
sus usual care or
diet alone
LGA not de-
fined
189 per 1000 113 per 1000
(95 to 134)
RR 0.60 (0.50 to
0.71)
2994
(6 RCTs)
Moderate “Several
included studies
had high risk of
bias for lack of
blinding, incom-
plete out-
come data and
selective report-
ing. Allocation
concealment was
in unclear in two
of the six studies.
”
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Table 8. GRADE Summary of findings table - Child (as neonate, child, adult) (Continued)
Han 2012
In-
tensive manage-
ment versus rou-
tine care
LGA defined as
≥ 90th per-
centile for ges-
tational age
171 per 1000 63 per 1000
(34 to 113)
RR 0.37 (0.20 to
0.66)
438
(3 RCTs)
Low Evidence based
on three stud-
ies with serious/
very serious de-
sign limitations
Raman 2017
Telemedicine
versus standard
care for glucose
monitoring
LGA not de-
fined
126 per 1000 178 per 1000
(96 to 333)
RR 1.41 (0.76 to
2.64)
228
(3 RCTs)
Very low Evidence down-
graded for
study limitations
and imprecision
(wide confidence
intervals crossing
the line of no ef-
fect; small sam-
ple size and few
events
Raman 2017
Self- versus peri-
odic-glucose
monitoring
LGA not de-
fined
142 per 1000 117 per 1000
(71 to 195)
RR 0.82 (0.50 to
1.37)
400
(2 RCTs)
Low Evidence down-
graded for study
limita-
tions and impre-
cision (wide con-
fidence intervals
crossing the line
of no effect)
Raman 2017
Continuous-
versus self-moni-
toring blood glu-
cose
LGA not de-
fined
527 per 1000 353 per 1000
(227 to 554)
RR 0.67 (0.43 to
1.05)
106
(1 RCT)
Very low Evidence down-
graded for
study limitations
and imprecision
(wide confidence
intervals crossing
the line of no
effect and small
sample size)
Raman 2017
Post- versus pre-
prandial glucose
monitoring
LGA not de-
fined
424 per 1000 123 per 1000
(47 to 331)
RR 0.29
(0.11 to 0.78)
66
(1 RCT)
Very low Evidence down-
graded for im-
precision (wide
confidence inter-
vals crossing the
line of no effect,
single trial, small
sample sizes) and
study limitations
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Table 8. GRADE Summary of findings table - Child (as neonate, child, adult) (Continued)
Brown 2017d
Insulin versus
oral therapy
Birthweight >
90th percentile
159 per 1000 161 per 1000
(121 to 215)
average RR 1.01
(0.76 to 1.35)
2352
(13 RCTs)
Moderate Evidence down-
graded for study
limitations (lack
of blinding)
Brown 2017d
Insulin type A
versus B
LGA not de-
fined
58 per 1000 70 per 1000
(34 to 148)
RR 1.21 (0.58 to
2.55)
411
(3 RCTs)
Low Evidence down-
graded for study
limitations (in-
sufficient details)
and imprecision
(wide confidence
intervals)
Brown 2017d
Insulin versus
diet
LGA not de-
fined
133 per 1000 113 per 1000
(55 to 237)
RR 0.85 (0.41 to
1.78)
202
(1 RCT)
Very low Evidence down-
graded for study
limitations (in-
sufficient details)
and imprecision
(single study, low
events, wide con-
fidence intervals)
Brown 2017d
Insulin regimen
A versus B
Twice daily ver-
sus four times
daily
Three times ver-
sus six times
daily
LGA not de-
fined
261 per 1000
158 per 1000
303 per 1000
(206 to 441)
55 per 1000
(6 to 486)
RR 1.16; (0.79
to 1.69)
RR 0.35; (0.04
to 3.08)
274
(1 RCT)
37
(1 RCT)
Very low Evidence down-
graded for study
lim-
itations (insuffi-
cient details) and
imprecision (sin-
gle small study,
wide confidence
intervals)
9.0 Perinatal mortality (fetal and neonatal death) and later infant mortality
Biesty 2018
Induction of
labour versus ex-
pectant manage-
ment
Perinatal death
See comment See comment RR not
estimable
425
(1 RCT)
Very low Evidence is based
on one
small study with
no events andde-
sign limitations
Brown 2017a
Metformin ver-
sus
glibenclamide
Perinatal death
6 per 1000 5 per 1000
(0 to 83)
Average RR 0.92
(0.06 to 14.55)
359
(2 RCTs)
Very low “Open
label studies with
no evidence of
blinding of par-
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Table 8. GRADE Summary of findings table - Child (as neonate, child, adult) (Continued)
ticipants or re-
searchers. Event
rates were very
low. One study
had no event of
perinatal death
in either themet-
formin nor the
glibenclamide
group. The sec-
ond study had
one death in each
group.”
Brown 2017a
Glibenclamide
versus acarbose
Perinatal death
0 per 1000 0 per 1000
(0 to 0)
RR not
estimable
43
(1 RCT)
Very low “Evidence based
on a single small
study with wide
confidence inter-
vals. No events
were reported in
either
group. There is
evidence of selec-
tive reporting.”
Han 2017
Energy-
versus no energy
restricted diet
Perinatal death
0 per 1000 0 per 1000
(0 to 0)
RR not
estimable
423
(2 RCTs)
Low “Two studies at
unclear risk of se-
lection bias. One
study at high risk
of performance
bias and unclear
risk of detection
bias. There were
no events in ei-
ther
group and rela-
tively small sam-
ple sizes.”
Han 2017
Low-
versus high-car-
bohydrate diet
Perinatal death
0 per 1000 0 per 1000
(0 to 0)
RR 3.00 (0.12 to
72.49)
150
(1 RCT)
Very low Evidence is based
on one study and
imprecision as
wide confidence
interval crossing
the line of no ef-
fect. Risk of per-
formance bias as
study partic-
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Table 8. GRADE Summary of findings table - Child (as neonate, child, adult) (Continued)
ipants and care
providers were
not blinded. Low
event rates (one
event in the con-
trol group)
Brown 2017b
Lifestyle
intervention ver-
sus usual care or
diet alone
Perinatal death
5 per 1000 0 per 1000
(0 to 9)
RR 0.09 (0.01 to
1.70)
1988
(2 RCTs)
Low “There is evi-
dence of impre-
cision with wide
confidence inter-
vals
and low events
rates (5 perinatal
deaths in
one trail’s control
group) and one
of the two tri-
als did not blind
participants/
researchers.”
Brown 2017c
Exercise versus
control
0 per 1000 0 per 1000
(0 to 0)
RR not
estimable
19
(1 RCT)
Very low Im-
precision - There
are no events in
either group and
the sample size is
only 19 infants
“There is a
lack of clarity for
most items asso-
ciated with risk
of bias.”
Raman 2017
Telemedicine
versus standard
care for glucose
monitoring
0 per 1000 0 per 1000
(0 to 0)
RR not
estimable
131
(2 RCTs)
Very low There were no
events reported
for this outcome.
Evidence down-
graded for study
limitations and
imprecision (no
events and small
sample sizes)
Raman 2017
Self- versus peri-
odic-glucose
monitoring
5 per 1000 8 per 1000
(1 to 57)
RR 1.54 (0.21 to
11.24)
400
(2 RCTs)
Very low Evidence down-
graded for study
limita-
tions and impre-
cision (wide con-
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Table 8. GRADE Summary of findings table - Child (as neonate, child, adult) (Continued)
fidence intervals
crossing the line
of no effect and
few events)
Raman 2017
Continuous-
versus self-moni-
toring blood glu-
cose
0 per 1000 0 per 1000
(0 to 0)
RR not
estimable
179
(2 RCTs)
Very low There were no
events of peri-
natal death re-
ported in the two
RCTs
Evidence
was downgraded
for study limita-
tions and impre-
cision (no events
and small sample
sizes)
Brown 2017d
Insulin versus
oral therapy
8 per 1000 7 per 1000
(2 to 20)
RR 0.85 (0.29 to
2.49)
1463
(10 RCTs)
Low Evidence down-
graded for study
limitations (lack
of blinding) and
imprecision
(wide confidence
intervals and low
event rates)
Brown 2017d
Insulin versus
diet
43 per 1000 32 per 1000
(18 to 57)
RR 0.74 (0.41 to
1.78)
1137
(4 RCTs)
Moderate Evidence down-
graded for study
limitations (in-
sufficient details)
Brown 2017d
Insulin regimen
A versus B
Twice daily ver-
sus four times
daily
0 per 1000 0 per 1000
(0 to 0)
RR 3.04 (0.13 to
74.07)
274
(1 RCT)
Very low Evidence down-
graded for im-
precision
(extremely wide
confidence inter-
vals; single small
study; very low
event
rates). There was
one event in the
twice daily group
and no events in
the four times
daily group
10.0 Death or serious morbidity composite (as defined in reviews)
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Table 8. GRADE Summary of findings table - Child (as neonate, child, adult) (Continued)
Brown 2017a
Metformin ver-
sus
glibenclamide
Defined as com-
posite of neona-
tal outcomes in-
cluding hypo-
glycaemia, hy-
perbilirubi-
naemia, macro-
so-
mia, respiratory
illness, birth in-
jury, still-
birth or neona-
tal death
350 per 1000 189 per 1000
(109 to 329)
RR 0.54 (0.31 to
0.94)
159
(1 RCT)
Low “Evi-
dence is based on
one small study.”
Risk of perfor-
mance
bias as partici-
pants and per-
sonnel were not
blinded
Han 2017
Ethnic specific
diet versus stan-
dard healthy diet
Defined as com-
posite of neona-
tal
outcomes that
included hypo-
gly-
caemia, neona-
tal asphyxia,
respiratory dis-
tress syndrome
(RDS)
, hyperbilirubi-
naemia and
hypocalcaemia
0 per 1000 0 per 1000
(0 to 0)
RR not
estimable
20
(1 RCT)
Very low Imprecision - ev-
i-
dence is based on
one study. Risk
of performance
bias as partici-
pants and per-
sonnel were not
blinded and se-
lective reporting
(reporting bias).
No events in ei-
ther group
Brown 2017b
Lifestyle
intervention ver-
sus usual care or
diet alone
Defined as com-
posite of death,
shoulder dysto-
cia, bone frac-
ture and nerve
palsy in one
trial and still
193 per 1000 110 per 1000
(41 to 299)
Average RR 0.57
(0.21 to 1.55)
1930
(2 RCTs)
Very low “Evidence of in-
consistency with
I2 > 70%.One of
the two trials did
not blind partic-
ipants/re-
searchers and ev-
idence of impre-
cision with wide
confidence inter-
vals crossing the
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Table 8. GRADE Summary of findings table - Child (as neonate, child, adult) (Continued)
birth, neonatal
death, hypogly-
caemia, hyper-
bilirubinaemia,
elevated cord-
blood C-pep-
tide and birth
trauma in the
other trial
line of no effect.
”
Brown 2017c
Exercise versus
control
Defined as mor-
tality and mor-
bidity compos-
ite
65 per 1000 36 per 1000
(8 to 169)
RR 0.56 (0.12 to
2.61)
169
(2 RCTs)
Moderate Imprecision -
wide confidence
intervals and low
event rates
Raman 2017
Telemedicine
versus standard
care for glucose
monitoring
Defined as com-
posite of neona-
tal intensive
care unit ad-
mission, LGA,
respiratory out-
comes (hyaline
membrane dis-
ease, transient
tachyp-
noea, need for
respiratory sup-
port); hypogly-
caemia; and hy-
perbilirubi-
naemia
560 per 1000 594 per 1000
(381 to 930)
RR 1.06 (0.68 to
1.66)
57 (1 RCT) Very low Evidence down-
graded for im-
precision (wide
confidence inter-
vals crossing the
line of no effect,
small sample size
and few events)
and study limita-
tions
Brown 2017d
Insulin versus
oral therapy
319 per 1000 329 per 1000
(268 to 402)
RR 1.03 (0.84 to
1.26)
760
(2 RCTs)
Moderate Evi-
dence was down-
graded for study
limitations (lack
of blinding)
One
trial included re-
suscitation of the
delivery room,
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Table 8. GRADE Summary of findings table - Child (as neonate, child, adult) (Continued)
preterm birth (<
37 weeks)
, neonatal in-
tensive care unit
admission, birth
injury or diag-
nosis of neona-
tal complication,
glucose infusion,
antibiotics
or phototherapy.
A second trial
included hypo-
glycaemia < 2.
6 mmol/L, RDS,
pho-
totherapy, birth
trauma, APGAR
< 7 at 5 minutes,
preterm birth <
37 weeks
Brown 2017d
Insulin regimen
A versus B
Twice daily ver-
sus four times
daily
174 per 1000 294 per 1000
(188 to 459)
RR 1.69 (1.08 to
2.64)
274
(1 RCT)
Very low Evidence down-
graded for im-
precision (Single
small study with
wide confidence
intervals and low
event rates)
11.0 Neonatal hypoglycaemia (as defined in the reviews)
Biesty 2018
Induction of
labour versus ex-
pectant manage-
ment
Not defined
38 per 1000 28 per 1000
(10 to 79)
RR 0.74 (0.26 to
2.09)
425
(1 RCT)
Very Low Evidence down-
graded for im-
preci-
sion (single study
with low events)
and study limita-
tions
Brown 2017a
Glibenclamide
versus placebo
Not defined
11 per 1000 21 per 1000
(4 to 114)
RR 1.97 (0.36 to
10.62)
375
(1 RCT)
Very low “Ev-
idence is based
on one study and
93% were His-
panic women,
results may not
be generalisable
to other popu-
lations. There is
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Table 8. GRADE Summary of findings table - Child (as neonate, child, adult) (Continued)
risk of bias, as
we did not find
a published pro-
tocol and there
were more out-
comes reported
in the published
paper than were
listed in the trial
registration doc-
ument.
Event rates were
low with 4/189
for oral antidia-
betic pharmaco-
logical
therapy (Gliben-
clamide) and 2/
186 for placebo
group with wide
confidence inter-
vals crossing the
line of no effect.
”
Brown 2017a
Metformin ver-
sus
glibenclamide
Defined as
< 2.2mmol/L (<
40mg/dL)
48 per 1000 41 per 1000
(20 to 84)
RR 0.86
(0.42 to 1.77)
554
(4 RCTs)
Low “Allocation con-
cealment
was unclear in
one study and
one other study
was open label.
Event rates were
low (< 30), 12/
281 for the Met-
formin group
and 13/273 for
the Gliben-
clamide group.”
Brown 2017a
Glibenclamide
versus acarbose
Defined as
< 2.2mmol/L (<
40 mg/dL)
53 per 1000 333 per 1000
(46 to 1000)
RR 6.33 (0.87 to
46.32)
43
(1 RCT)
Very low “There is evi-
dence of selective
reporting. Ev-
idence based on
one small study
with wide con-
fidence intervals.
Low event rates
and
sample size with
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Table 8. GRADE Summary of findings table - Child (as neonate, child, adult) (Continued)
8/24 in Gliben-
clamide group
and 1/19 in acar-
bose group.”
Brown 2016a
Myo-inositol
versus placebo2
Not defined
263 per 1000 13 per 1000
(0 to 224)
RR 0.05 (0.00 to
0.85)
73
(1 RCT)
Low “Evidence
is based on one
small study with
low event rates
- 0/35 events in
myo-inositol
group and 10/38
events
in the placebo
group.”
Han 2017
Energy- ver-
sus no energy-re-
stricted diet
Not defined
190 per 1000 201 per 1000
(91 to 441)
RR 1.06 (0.48 to
2.32)
408
(2 RCTs)
Very low “Evidence
is based on two
small studies at
unclear risk of se-
lection bias; one
study at high risk
of performance
bias and unclear
risk of detection
bias. Wide con-
fidence intervals
crossing the line
of no effect and
substantial het-
erogeneity: I² =
75% present.”
Han 2017
Low-
versus high-car-
bohydrate diet
Not defined
133 per 1000 121 per 1000
(52 to 283)
RR 0.91 (0.39 to
2.12)
149
(1 RCT)
Very low Imprecision - ev-
idence is based
on one study and
wide confidence
interval crossing
the line of no ef-
fect. Risk of per-
formance bias as
participants and
researchers were
not blinded
Han 2017
Soy- versus no
soy-protein diet
Defined as BGL
29 per 1000 88 per 1000
(10 to 806)
RR 3.00 (0.33 to
27.42)
68
(1 RCT)
Very low Imprecision - ev-
idence is based
on one study and
wide confidence
129Treatments for women with gestational diabetes mellitus: an overview of Cochrane systematic reviews (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 8. GRADE Summary of findings table - Child (as neonate, child, adult) (Continued)
< 1.7mmol/L (<
30.6 mg/dL)
interval crossing
the line of no ef-
fect. Risk of per-
formance bias as
participants and
personnel were
not blinded
Han 2017
Ethnic specific
diet versus stan-
dard healthy diet
Not defined
0 per 1000 0 per 1000
(0 to 0)
RR not
estimable
20
(1 RCT)
Very low Imprecision - ev-
i-
dence is based on
one study. Risk
of performance
bias as partici-
pants and per-
sonnel were not
blinded and se-
lective reporting
(reporting bias).
There were no
neonatal hypo-
glycaemic events
in either group
Brown 2017b
Lifestyle
intervention ver-
sus usual care or
diet alone
Not defined
75 per 1000 74 per 1000
(49 to 114)
Average RR 0.99
(0.65 to 1.52)
3000
(6 RCTs)
Moderate “Allocation
concealment was
unclear in two
trials and blind-
ing was not un-
dertaken in two
other trials.”
Brown 2017c
Exercise versus
control
Not defined
59 per 1000 118 per 1000
(12 to 1000)
RR 2.00 (0.20 to
20.04)
34
(1 RCT)
Very low “Impreci-
sion - wide con-
fidence intervals
and low event
rates. There is a
lack of clarity for
most items asso-
ciated with risk
of bias.”
Han 2012
In-
tensive manage-
ment versus rou-
tine care
Defined as:
two studies: < 1.
7mmol/L (< 30.
66 per 1000 26 per 1000
(4 to 167)
RR 0.39 (0.06 to
2.54)
426
(2 RCTs)
Very low Evidence is based
on two studies
with few events
and serious/very
serious de-
sign limitations.
Wide confidence
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Table 8. GRADE Summary of findings table - Child (as neonate, child, adult) (Continued)
6mg/dL) in any
two consecutive
measurements
one study: < 1.
94 mmol/L (<
35 mg/dL)
intervals crossing
the line of no ef-
fect and substan-
tial heterogene-
ity: I² = 62%
Raman 2017
Telemedicine
versus standard
care for glucose
monitoring
Defined as BGL
<2.6 mmol/L in
one study
82 per 100 94 per 1000
(40 to 224)
RR 1.14 (0.48 to
2.72)
198
(3 RCTs)
Very low Evidence down-
graded for im-
precision (wide
confidence inter-
vals crossing the
line of no effect,
small
sample sizes) and
study limitations
Raman 2017
Self- versus peri-
odic-glucose
monitoring
Not defined
173 per 1000 111 per 1000
(67 to 183)
RR 0.64 (0.39 to
1.06)
391
(2 RCTs)
Low Evidence down-
graded for im-
precision (wide
confidence inter-
vals crossing the
line of no effect)
and study limita-
tions
Raman 2017
Continuous-
versus self-moni-
toring blood glu-
cose
Defined as
blood glucose≤
45 mg/dL (2.5
mmol/L)
130 per 1000 103 per 1000
(46 to 232)
RR 0.79
(0.35 to 1.78)
179
(2 RCTs)
Very low Evidence down-
graded for im-
precision (wide
confidence inter-
vals crossing the
line of no effect,
small
sample sizes) and
study limitations
Raman 2017
Post- versus pre-
prandial glucose
monitoring
Defined as≤ 30
mg/dL requir-
ing glucagon or
dextrose in-
fusion for treat-
ment during the
first four days
after birth
212 per 1000 30 per 1000
(4 to 233)
RR 0.14
(0.02 to 1.10)
66
(1 RCT)
Very low Evidence down-
graded for im-
precision (wide
confidence inter-
vals crossing the
line of no effect,
single trial, small
sample sizes) and
study limitations
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Table 8. GRADE Summary of findings table - Child (as neonate, child, adult) (Continued)
Brown 2017d
Insulin versus
oral therapy
Defined as < 2.6
mmol/L
111 per 1000 126 per 1000
(94 to 1.52)
Average RR 1.14
(0.85 to 1.52)
3892
(24 RCTs)
Low Evidence down-
graded for study
limitations (lack
of blinding) and
inconsistency
Brown 2017d
Insulin type A
versus B
12 per 1000 28 per 1000
(1 to 1000)
RR 2.28 (0.06 to
82.02)
165
(3 RCTs)
Very low Evidence down-
graded for study
limitations (lack
of blinding), im-
precision (wide
confidence inter-
vals) and incon-
sistency
Brown 2017d
Insulin versus
diet
240 per 1000 211 per 1000
(82 to 583)
RR 0.88 (0.34 to
2.24)
176
(3 RCTs)
Very low Evidence down-
graded for study
limitations (lack
of blinding), im-
precision (wide
confidence inter-
vals) and incon-
sistency
Brown 2017d
Insulin versus ex-
ercise
118 per 1000 59 per 1000
(6 to 589)
RR 0.50 (0.05 to
5.01)
34
(1 RCT)
Very low Evidence down-
graded for study
lim-
itations (insuffi-
cient details) and
imprecision (sin-
gle small study,
wide confidence
intervals)
Brown 2017d
Insulin regimen
A versus B
Twice daily ver-
sus four times
daily
7 per 1000 59 per 1000
(7 to 464
RR 8.12 (1.03 to
64.03)
274
(1 RCT)
Very low Evidence down-
graded impreci-
sion (large treat-
ment effect, sin-
gle small study,
low event rates
and wide confi-
dence intervals)
12.0 Adiposity - neonate
Brown 2017b
Lifestyle
intervention ver-
sus usual care or
Mean mass:
427 g
Mean mass:
37.80 g fewer
(63.97 g fewer to
MD -37.30 g (-
63.97 to -10.63)
958
(1 RCT)
Low “Impre-
cision. Evidence
is base on a sin-
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Table 8. GRADE Summary of findings table - Child (as neonate, child, adult) (Continued)
diet alone
Defined
as: neonatal fat
mass (estimated
from skinfold
thickness)
10.63 g fewer) gle trial and there
was no blinding
of participants/
researchers.”
Brown 2017d
Insulin versus
oral therapy
Defined as per-
centage fat mass
Defined as skin-
fold sum (mm)
The mean per-
centage fat mass
was 12.8%
The mean skin-
fold sum was 16
mm
MD 1.6% lower
(3.77 % lower to
0.57% higher)
MD
0.8mm lower (0.
49 mm lower to
0.73 mm higher)
MD-1.60 (-3.77
to 0.57)
MD-0.80 (-2.33
to 0.73)
82
(1 RCT)
82
(1 RCT)
Very low Evidence
was downgraded
for imprecision
as based on one
trial
Evidence
was downgraded
for imprecision
as based on one
trial with wide
confidence inter-
vals and study
limitations (se-
lective reporting
and other bias
detected)
12.0 Adiposity -
child
Brown 2017b
Lifestyle
intervention ver-
sus usual care or
diet alone
De-
fined as: Child-
hood BMI1> 85
th percentile kg/
m²
350 per 1000 318 per 1000
(262 to 388)
RR 0.91 (0.75 to
1.11)
767
(3 RCTs)
Moderate “Al-
location conceal-
ment and ran-
domisation was
unclear in 1/3
trials and 1/3 tri-
als did not blind
participants/
researchers.”
Brown 2017b
Lifestyle
intervention ver-
sus usual care or
diet alone
Defined as:
Childhood
BMI1z score
The mean child-
hood
BMI z score was
0.49 lower
The
childhoodBMI z
score in the in-
tervention group
was 0.08 lower
(0.28 lower to
10.63 lower)
MD 0.08 (-0.28
to 0.44)
199
(1 RCT)
Very low Imprecision - ev-
idence
is based on one
study and wide
confidence inter-
val crossing the
line of no effect.
Only reports on
199 children of
the original trial
of 1000 partici-
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Table 8. GRADE Summary of findings table - Child (as neonate, child, adult) (Continued)
pants
Brown 2017d
Insulin versus
oral therapy
Defined as total
fat mass (%) up
to 2-years
The mean child-
hood total fat
mass (%) was 16.
4%
MD 0.
5% higher (0.49
% lower to 1.49
% higher)
MD 0.50 (-0.49
to 1.49)
318
(1 RCT)
Low Evidence down-
graded for study
limitations (lack
of blinding) and
imprecision as
based on a single
study
13.0 Diabetes
- - - - - - Either no data
were reported for
this outcome in
any of the in-
cludedCochrane
systematic
reviews or none
of the included
studies in the
review pre-spec-
ified this out-
come
14.0 Neurosensory disability
Brown 2017d
Insulin versus
oral therapy
Mild develop-
mental delay (18
months)
Hearing impair-
ment (18
months)
Vi-
sual impairment
(18 months)
104 per 1000
0 per 1000
21 per 1000
111 per 1000
(34 to 385)
0 per 1000
(0 to 0)
6 per 1000
(1 to 60)
RR 1.07 (0.33 to
3.44)
RR 0.31 (0.01 to
7.49)
RR 0.03 to 2.90
93 (1 RCT) Low Evidence down-
graded for im-
precision as
based on a single
study with wide
confidence inter-
vals
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and
the relative effect of the intervention (and its 95% CI).
CI: confidence interval; RCT: randomised controlled trial; RR: risk ratio
GRADE Working Group grades of evidence
High quality: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate quality:We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect,
but there is a possibility that it is substantially different
Low quality:Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the
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Table 8. GRADE Summary of findings table - Child (as neonate, child, adult) (Continued)
effect
Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the
estimate of effect
1BMI is an acronym for Body Mass Index
24 g myo-inositol + 400 µg folic acid orally per day and exercise and dietary advice versus placebo 400 µg folic acid orally per day and
exercise and dietary advice.
Table 9. GRADE Summary of findings table - Health service use
Interven-
tion and com-
parison and
outcome
As-
sumed risk with
comparator
Correspond-
ing risk with in-
tervention*
Relative effect
(95% CI)
of
participants
(studies)
Quality of the
evidence
(GRADE)
Comments
from overview
review authors
15.0 Number of antenatal visits or admissions
Han 2017
Soy- versus no
soy-protein diet
Defined as ma-
ternal hospitali-
sation
118 per 1000 88 per 1000
(21 to 365)
RR 0.75 (0.18 to
3.10)
68 (1 RCT) Very low Imprecision - ev-
idence based on
one
trial. Evidence of
risk of bias as
participants and
researchers were
not blinded.
Wide confidence
interval crossing
the line of no ef-
fect
Brown 2017b
Lifestyle
intervention ver-
sus usual care or
diet alone
Not defined
273 per 1000 289 per 1000
(237 to 352)
RR 1.06
(0.87 to 1.29)
1000
(1 RCT)
Moderate Imprecision, evi-
dence is based on
a single trial
Raman 2017
Telemedicine
versus standard
care for glucose
monitoring
De-
fined as num-
ber of hospital
or health pro-
fessional visits :
face-to-face
Mean number of
face-to-face visits
in the standard
care group was 4.
34
Mean difference
was 0.36 visits
fewer (0.92 visits
fewer to 0.20 vis-
its more)
MD -0.36 visits
(-0.92 to 0.20)
97 (1 RCT) Very low Evidence down-
graded for im-
precision (wide
confidence inter-
vals, single study,
small
sample size) and
study limitations
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Table 9. GRADE Summary of findings table - Health service use (Continued)
Raman 2017
Self- versus peri-
odic-glucose
monitoring
Defined as vis-
its with diabetes
team
Mean number of
visits in the peri-
odic monitoring
group was 5.2
Mean
difference was 0.
2 visits more (1.
09 fewer to 1.49
more)
MD 0.20 (-1.09
to 1.49)
58 (1 RCT) Very low Evidence down-
graded for im-
precision (wide
confidence inter-
vals, single study,
small
sample size) and
study limitations
Brown 2017d
Insulin versus
oral therapy
Mean number of
visits in the oral
therapy group
was 11
Mean difference
was 1 visit more
(0.
08 visits fewer to
2.08 visits more)
MD 1.00 (-0.08
to 2.08)
404 (1 RCT) Low Evidence down-
graded for im-
pre-
cision (wide con-
fidence intervals,
single study) and
study limitations
16.0 Length of postnatal stay (mother)
- - - - - - Either no data
were reported for
this outcome in
any of the in-
cludedCochrane
systematic
reviews or none
of the included
studies in the
review pre-spec-
ified this out-
come
17.0 Length of postnatal stay (baby) includingNICU1 or SCBU2
Han 2017
Diet
+ diet-related be-
havioural advice
versus diet only
Defined as > 4
days
260 per 1000 346 peer 1000
(190 to 634)
RR 1.33 (0.73 to
2.44)
99 (1 RCT) Very low Imprecision - ev-
idence based on
one small trial.
Evidence of risk
of bias as partici-
pants and
researchers were
not blinded.
Wide confidence
interval crossing
the line of no ef-
fect
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Table 9. GRADE Summary of findings table - Health service use (Continued)
Raman 2017
Contin-
uous- versus self-
monitoring
Defined
as length of stay
in NICU
Mean duration
of stay in NICU
for the self-mon-
itoring group
was 3.83 days
The mean differ-
ence for the con-
tinuous moni-
toring group was
0.83 days less (2.
35 days less to 0.
69 days more)
MD -0.83
(-2.35 to 0.69)
18 (1 RCT) Very low Evidence down-
graded for study
limitations and
imprecision (sin-
gle trial, small
sample size, wide
confidence inter-
vals)
Brown 2017d
Insulin versus
oral therapy
Duration of
stay in NICU
Mean duration
of stay in NICU
for the oral ther-
apy group was 5.
9 days
The mean differ-
ence for the in-
sulin group was
0.2 days less (1.
8 days less to 1.4
days more)
MD-0.20 (-1.79
to 1.39)
401 (3 RCTs) Very low Evidence down-
graded for study
limitations; im-
precision (wide
confidence inter-
vals) and incon-
sistency
18.0 Costs associated with the treatment
Brown 2017d
Insulin versus
oral therapy
See comment See comment See comment 197 (1 RCT) Very low Ev-
idence from one
trial suggested
that the costs of
insulins (exclud-
ing syringes) was
higher than for
glibenclamide;
metformin or for
combined met-
formin and in-
sulin. The data
were not suitable
for meta-analysis
Brown 2017b
Lifestyle
intervention ver-
sus usual care or
diet alone
See comment See comment See comment 1000
(1 RCT)
Moderate One trial in this
review included
costs associated
with the treat-
ment
for mild GDM
versus usual care
and showed costs
were higher in
the lifestyle in-
tervention group
compared to the
control group
which is mainly
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Table 9. GRADE Summary of findings table - Health service use (Continued)
due to increased
surveillance and
increased con-
tact with health
profession-
als. However, the
data were not in
a suitable for-
mat for inclusion
in a meta-analy-
sis and therefore
summarised in
Table 12
Raman 2017
Telemedicine
versus standard
care for glucose
monitoring
See comment See comment See comment 100 (1 RCT) Very low One trial
reported that “in
our study,
the telemedicine
system not only
made attention
more convenient
for the patient,
it was also less
expensive for the
health systema in
terms of the use
of health profes-
sionals time.”
Evidence down-
graded for
imprecision and
study limitations
Raman 2017
Self-monitor-
ing versus period
glucose monitor-
ing
See comment See comment See comment 347 (1 RCT) Very low One trial re-
ported costs “the
direct manage-
ment costs (me-
ter rental, equip-
ment pur-
chase, and clini-
cal reagent strip)
of the two fol-
low-ups in con-
sidering the
transfer to home
monitoring. On
aweekly basis the
expense was (US
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Table 9. GRADE Summary of findings table - Health service use (Continued)
dollars): $10.80/
woman on home
monitoring, $0.
50/woman with
a breakfast result
below7.8mmol/
L on clinic fol-
low-up, and $6.
80/woman with
a breakfast result
at or above 7.8
mmol/L
on clinic follow-
up”. Evidence
downgraded for
imprecision and
study limitations
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and
the relative effect of the intervention (and its 95% CI).
CI: confidence interval; RCT: randomised controlled trial; RR: risk ratio
GRADE Working Group grades of evidence
High quality: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate quality:We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect,
but there is a possibility that it is substantially different
Low quality:Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the
effect
Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the
estimate of effect
1NICU - Neonatal Intensive Care Unit
2SCBU - Special Care Baby Unit
Table 10. AMSTAR assessments for included reviews
Review
ID
Biesty
2018
Brown
2017a
Brown
2017b
Brown
2017c
Brown
2017d
Brown
2016a
Han
2017
Han
2012
Martis
2016a
Raman
2017
AMSTAR Domains
Answer code:
√
= Yes; X = No; ? = Unclear; NA = Not applicable
1. Was an
a pri-
ori design
provided?
√ √ √ √ √ √ √ √ √ √
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Table 10. AMSTAR assessments for included reviews (Continued)
2.
Was there
dupli-
cate study
selection
and data
extrac-
tion?
√ √ √ √ √ √ √ √ √ √
3. Was
a compre-
hensive
literature
search
per-
formed?
√ √ √ √ √ √ √ √ √ √
4. Was
the status
of publi-
cation (i.
e. grey lit-
erature)
used as an
inclusion
criterion?
√ √ √ √ √ √ √ √ √ √
5.
Was a list
of studies
(included
and
excluded)
provided?
√ √ √ √ √ √ √ √ √ √
6. Were
the char-
acteris-
tics of the
included
studies
provided?
√ √ √ √ √ √ √ √ √ √
7. Was
the scien-
tific qual-
ity of the
included
studies
√ √ √ √ √ √ √ √ √ √
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Table 10. AMSTAR assessments for included reviews (Continued)
assessed
and doc-
umented?
8. Was
the scien-
tific qual-
ity of the
included
studies
used ap-
propri-
ately in
formulat-
ing con-
clusions?
√ √ √ √ √ √ √ √ √ √
9. Were
the meth-
ods used
to com-
bine the
findings
of stud-
ies appro-
priate?
NA
√ √ √ √ √ √ √
NA
√
10. Was
the like-
lihood of
publica-
tion bias
assessed?*
X
√ √ √ √
X
√
X X
√
11. Was
the con-
flict of in-
terest in-
cluded?
√ √ √ √ √ √ √
X
√ √
To-
tal score
(out of
11):
Score in-
terpreta-
tion:
√
8 to 11 =
high
quality
9/11
High
quality
11/11
High
quality
11/11
High
quality
11/11
High
quality
11/11
High
quality
10/11
High
quality
11/11
High
quality
9/11
High
quality
9/11
High
quality
11/11
High
quality
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Table 10. AMSTAR assessments for included reviews (Continued)
4 to 7
= moder-
ate qual-
ity
≤ 3 = low
quality
*We judged publication bias assessed as a ’yes’ when a funnel plot and at least 10 studies were included in the review.
Table 11. ROBIS assessment for included reviews
Review
ID
Biesty
2018
Brown
2017a
Brown
2017b
Brown
2017c
Brown
2017d
Brown
2016a
Han
2017
Han
2012
Martis
2016a
Raman
2017
ROBIS DOMAINS
Answer code:
√
= Yes X = No ? = unclear
Domain 1: Study eligibility criteria
Did the
review
adhere
to pre-de-
fined ob-
jectives
and eligi-
bility cri-
teria?
√ √ √ √ √ √ √ √ √ √
Were the
eligibil-
ity crite-
ria appro-
priate
for the re-
view
question?
√ √ √ √ √ √ √ √ √ √
Were eli-
gibil-
ity crite-
ria unam-
biguous?
√ √ √ √ √ √ √ √ √ √
Were all
restric-
tions in
√ √ √ √ √ √ √ √ √ √
142Treatments for women with gestational diabetes mellitus: an overview of Cochrane systematic reviews (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 11. ROBIS assessment for included reviews (Continued)
eligibility
criteria
based
on study
charac-
teristics
appro-
priate (e.
g. date,
sample
size,
study
quality,
outcomes
mea-
sured)?
Were any
restric-
tions in
eligibility
criteria
based on
sources of
informa-
tion ap-
propriate
(publica-
tion sta-
tus or for-
mat, lan-
guage,
avail-
ability of
data)?
√ √ √ √ √ √ √ √ √ √
Con-
cerns re-
garding
specifi-
cation of
study eli-
gibility
criteria
LOW,
HIGH,
UN-
CLEAR
Low Low Low Low Low Low Low Low Low Low
Domain 2: Identification and selection of studies
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Table 11. ROBIS assessment for included reviews (Continued)
Did the
search
include
an ap-
propriate
range of
databases/
electronic
sources
for pub-
lished
and un-
published
reports?
√ √ √ √ √ √ √ √ √ √
Were
meth-
ods addi-
tional to
database
search-
ing used
to iden-
tify rel-
evant re-
ports?
√ √ √ √ √ √ √ √ √ √
Were
the terms
and struc-
ture of
the search
strat-
egy likely
to retrieve
as many
eligible
studies as
possible?
√ √ √ √ √ √ √ √ √ √
Were re-
strictions
based on
date,
publica-
tion for-
mat, or
language
appropri-
√ √ √ √ √ √ √ √ √ √
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Table 11. ROBIS assessment for included reviews (Continued)
ate?
Were ef-
forts
made to
min-
imise er-
ror in se-
lection of
studies?
√ √ √ √ √ √ √ √ √ √
Con-
cerns re-
garding
meth-
ods used
to iden-
tify and/
or select
studies:
LOW,
HIGH,
UN-
CLEAR
Low Low Low Low Low Low Low Low Low Low
Domain 3: Data collection and study appraisal
Were ef-
forts
made to
minimise
error in
data col-
lection?
√ √ √ √ √ √ √ √ √ √
Were suf-
ficient
study
charac-
teris-
tics avail-
able for
both re-
view au-
thors and
readers to
be able to
interpret
the
results?
√ √ √ √ √ √ √ √ √ √
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Table 11. ROBIS assessment for included reviews (Continued)
Were all
relevant
study re-
sults col-
lected for
use in the
synthesis?
√ √ √ √ √ √ √ √ √ √
Was risk
of bias (or
method-
olog-
ical qual-
ity) for-
mally as-
sessed us-
ing ap-
propriate
criteria?
√ √ √ √ √ √ √ √ √ √
Were ef-
forts
made to
min-
imise er-
ror in risk
of bias as-
sessment?
√ √ √ √ √ √ √ √ √ √
Con-
cerns re-
garding
meth-
ods used
to collect
data and
appraise
studies:
LOW,
HIGH,
UN-
CLEAR
Low Low Low Low Low Low Low Low Low Low
Domain 4: Synthesis and findings
Did the
syn-
thesis in-
clude all
√ √ √ √ √ √ √ √ √ √
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Table 11. ROBIS assessment for included reviews (Continued)
stud-
ies that it
should?
Were all
pre-
defined
analyses
reported
or depar-
tures ex-
plained?
√ √ √ √ √ √ √ √ √ √
Was the
synthe-
sis appro-
priate
given the
nature
and simi-
larity
in the re-
search
ques-
tions,
study de-
signs and
outcomes
across in-
cluded
studies?
√ √ √ √ √ √ √ √ √ √
Was
between-
study
varia-
tion (het-
erogene-
ity) mini-
mal or
addressed
in the
synthesis?
√ √ √ √ √ √ √ √ √ √
Were the
findings
robust, e.
g. as
demon-
strated
√ √ √ √ √ √ √ √ √ √
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Table 11. ROBIS assessment for included reviews (Continued)
through
funnel
plot or
sensitiv-
ity analy-
ses?
Were bi-
ases in
primary
stud-
ies mini-
mal or ad-
dressed in
the
synthesis?
√ √ √ √ √ √ √ √ √ √
Con-
cerns re-
garding
the syn-
thesis
and find-
ing:
LOW,
HIGH,
UN-
CLEAR
Low Low Low Low Low Low Low Low Low Low
Risk of bias in the review
Did the
interpre-
tation of
findings
address
all of the
concerns
identified
in
Domains
1-4?
√ √ √ √ √ √ √ √ √ √
Was the
relevance
of identi-
fied stud-
ies to the
review’s
research
√ √ √ √ √ √ √ √ √ √
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Table 11. ROBIS assessment for included reviews (Continued)
question
appropri-
ately con-
sidered?
Did the
reviewers
avoid em-
phasiz-
ing results
on the ba-
sis of their
statisti-
cal signif-
icance?
√ √ √ √ √ √ √ √ √ √
Overall
risk of
bias
according
to
Whiting
2016
Low risk Low risk Low risk Low risk Low risk Low risk Low risk Low risk Low risk Low risk
Table 12. Treament costs
Crowther 2005 Lifestyle intervention Usual care
Package of treatment for mild GDM versus usual care
Direct costs per 100 women with a single-
ton
pregnancy - including antenatal clinic
visits, specialist clinics, dietician, diabetes
educator, insulin therapy
AUD 67,432 AUD 33,681
In-patient costs - hospital costs AUD 545,125 AUD 524,891
Total direct health service costs AUD 612,557 AUD 558,572
Patient/family costs AUD 36,749 AUD 30,229
Permission granted from John Wiley & Sons, Ltd. to use this treatment costs table from Brown 2017b (table 11, p. 127)
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A P P E N D I C E S
Appendix 1. Ongoing Cochrane systematic reviews (Protocols and Title Registrations)
Protocol ID and title
and title registrations
Reference Inclusion criteria for
types of participants
Comparison interven-
tions
Overview
outcomes pre-specified
in the protocols
Rao 2017
Fetal biometry for guid-
ing the medical manage-
ment
of women with gesta-
tional diabetes mellitus
for improving maternal
and perinatal health
(Protocol)
Rao U, de Vries B, Ross
GP, Gordon A. Fetal
biometry for guiding the
medical management of
women with gestational
diabetes mellitus for im-
prov-
ing maternal and peri-
natal health. Cochrane
Database of Systematic
Reviews 2017, Issue 2.
Art. No.: CD012544.
DOI: 10.1002/
14651858.CD012544
Pregnant women with
singleton pregnancies
who have gestational di-
abetes mellitus (GDM),
as definedby the authors.
Women with multiple
pregnancy are excluded.
Data from studies in-
cluding womenwith sin-
gle and multiple preg-
nancies will only be ex-
tracted and analysed for
women with single preg-
nancy and where this is
not possible the study
will be only included if
more than 95% of the
participants have a sin-
gleton pregnancy
Comparing
the use of medical ther-
apy for GDM guided by
maternal blood glucose
values (glycaemic tar-
gets) only with medical
therapy guided by fetal
biometry on ultrasound,
MRI or other imaging
methods as well as ma-
ternal glycaemic targets.
Where diet and exercise
modifications are used,
they should be consistent
across the groups
All overview primary
outcomes for maternal
and neonatal outcomes
pre-specified,
except neurosensory dis-
ability in later childhood
(as defined in reviews)
for neonatal outcomes
pre-specified (listed as a
pre-specified secondary
outcome)
All overview secondary
outcomes for maternal,
maternal
long-term (except: de-
velopment of type 2 di-
abetes), fetal/neonatal,
later infant/childhood,
child as an adult and
health services use pre-
specified (except: length
of stay in neonatal inten-
sive care unit or special
care baby unit)
Dunn 2016 Planned
elective birth for preg-
nant women with gesta-
tional diabetes
(Title registration)
Dunne F, Biesty LM,
Egan A, Devane D,
Dempsey E, Meskell P,
Smith V
Awaiting protocol publi-
cation
Awaiting protocol publi-
cation
Awaiting protocol publi-
cation
Okesene-Gafa 2016
Probiotics for treating
women with gestational
diabetes for improving
maternal and fetal health
and well-being
(Title registration)
Okesene-Gafa KAM,
Brown J, Crowther CA,
McCowan L
Awaiting protocol publi-
cation
Awaiting protocol publi-
cation
This protocol was pub-
lished during the edit-
ing of this overview
Okesene-Gafa 2018
Wang 2016 Chi-
nese herbalmedicines for
treating gestational dia-
Wang CC, Li L, Li R,
Tam WH, Dou L
Awaiting protocol publi-
cation
Awaiting protocol publi-
cation
Awaiting protocol publi-
cation
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betes mellitus
(Title registration)
Appendix 2. Cochrane systematic reviews awaiting further classification
Review citation Overview outcomes pre-specified in re-
view with no outcome data
Main conclusion(s) of the review
Culliney KAT, Parry GK, Brown J,
Crowther CA. Regimens of fetal surveil-
lance of suspected large-for-gestational-age
fetuses for improving health outcomes.
Cochrane Database of Systematic Reviews
2016, Issue 4. Art. No.: CD011739. DOI:
10.1002/14651858.CD011739.pub2
Overview maternal primary outcomes
pre-specified include: Mode of birth (cae-
sarean section).
Overview neonatal primary outcomes
pre-specified include: Perinatal (fetal and
neonatal death) but not later infant mortal-
ity and death or serious morbidity compos-
ite (as defined in reviews, e.g. perinatal or
infant death, shoulder dystocia, bone frac-
ture or nerve palsy)
Overview secondary outcomes pre-spec-
ified for maternal include: Induction of
labour, perineal trauma, postpartumhaem-
orrhage, breastfeeding and women’s view of
care
No maternal long-term secondary out-
comes pre-specified.
Secondary pre-specified outcomes for
fetal/neonatal, later infant/childhood,
child as an adult include: gestational age
at birth, birthweight, and z-score, large-for-
gestational age, Apgar < 7, neonatal hypo-
glycaemia, birth length and HC and adi-
posity
Health services use outcomes pre-speci-
fied include: admission to neonatal special
care unit or NICU
No studies met the eligibility criteria for
inclusion. Future review up-dates may
include women with GDM.
“The majority of cases of LGA infants are
associated with maternal factors including
maternal height, weight, body mass index
(BMI), gestational weight gain, ethnicity,
parity and maternal age, as well as the pres-
ence of pre-gestational or gestational di-
abetes”. “There is no evidence from ran-
domised controlled trials to evaluate reg-
imens of fetal surveillance for suspected
large-for-gestational age (LGA) fetuses to
improve health outcomes.”
East CE, Dolan WJ, Forster DA.
Antenatal breastmilk expression bywomen
with diabetes for improving infant out-
comes. Cochrane Database of System-
atic Reviews 2014, Issue 7. Art. No.:
CD010408.
DOI: 10.1002/14651858.CD010408.
pub2
No overview primary outcomes for ma-
ternal and neonatal outcomes pre-spec-
ified. Secondary pre-specified outcomes
for maternal includes: breastfeeding at six
month.
No maternal long-term secondary out-
comes pre-specified.
Secondary pre-specified outcomes for fe-
tal/neonatal include: gestational age at
birth and neonatal hypoglycaemia.
No studies met the eligibility criteria for
inclusion. Future review up-dates may
include women with GDM.
“There were no published or unpublished
randomised controlled trials comparing an-
tenatal expressing with not expressing. One
randomised trial is currently underway.
There is no high level systematic evidence
to inform the safety and efficacy of the prac-
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No later infant/childhood, child as an
adult secondary outcomes pre-specified.
Secondary pre-specified outcomes for
health services use include: economic
costs (as defined by trial authors) which
may include some of the overview pre-spec-
ified outcomes
tice of expressing and storing breast milk
during pregnancy.”
Farrar D, Tuffnell DJ, West J, West HM.
Continuous subcutaneous insulin infu-
sion versus multiple daily injections of in-
sulin for pregnant women with diabetes.
Cochrane Database of Systematic Reviews
2016, Issue 6. Art. No.: CD005542. DOI:
10.1002/14651858.CD005542.pub3
All overview primary outcomes for ma-
ternal and neonatal outcomes pre-speci-
fied.All overview secondary outcomes for
maternal, maternal long-term, fetal/neona-
tal, later infant/childhood, child as an adult
and health services use pre-specified
None of the included trials recruited
women with GDM. Future review up-
dates may include women with GDM.
“There were no trials of appropriate
methodological quality that assessed the
use of MDI versus CSII for women with
GDM” and suggest that as “prevalence of
GDM is increasing and these women may
require insulin; this is a group of women
who should be included in future tri-
als”. “Large multi-centre randomised, ad-
equately powered trials are needed to as-
sess the effectiveness of continuous sub-
cutaneous insulin infusion compared with
multiple daily injections for women with
diabetes (GDM and pre-existing) in preg-
nancy who require insulin. It would be
beneficial if outcomes were consistent
across trials and included women’s prefer-
ences. Further trials to assess the effects
of pumps on birthweight and macrosomia
rates are needed. Future trials should un-
dertake longer-term follow-up of partici-
pants (women and their infants) as well as
assessment of associated costs.”
Jefferys AE, Siassakos D, Draycott T,
Akande VA, Fox R. Deflation of gastric
band balloon in pregnancy for improv-
ing outcomes. Cochrane Database of Sys-
tematic Reviews 2013, Issue 4. Art. No.
: CD010048. DOI: 10.1002/14651858.
CD010048.pub2
Overview maternal primary outcome
pre-specified include:Hypertensive disor-
der in pregnancy.
No overview neonatal primary outcomes
are pre-specified.
Overview secondary outcomes pre-spec-
ified for maternal include: maternal
weight gain in pregnancy, maternal hospi-
tal antenatal and postnatal admissions
No overview maternal long-term sec-
ondary outcomes are pre-specified.
Overview secondary outcomes pre-spec-
ified outcomes for fetal/neonatal in-
clude: Apgar score < 7 at 5 minutes,
preterm birth < 37 weeks and < 28 weeks,
No studies met the eligibility criteria for
inclusion. Future review up-dates may
include women with GDM and gastric
balloons. “At present, there is no guidance
on the best management of a gastric band
during pregnancy and there is variation in
care. Some clinicians advocate leaving the
balloon filled (inflated) to limit food intake
and limit weight gain during pregnancy.
This strategymight reduce the likelihoodof
maternal high blood pressure or gestational
diabetes and so improve the outcomes for
mother and baby.”
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birthweight, macrosomia, SGA, stillbirth
and early neonatal death
No overview secondary pre-specified
outcomes for later infant/childhood,
child as an adult and health services use
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